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Abstract 
 
The use of modern antidepressants has flourished over the past few decades with 
the modern attribution of affective disorders such as depression to biomedical 
causation. However, recent re-examination of clinical trials has raised questions 
regarding antidepressant drug efficacy, and issues around side effects and 
dependency are prevalent. In spite of this, as many as 10% of us may be taking 
these medications (Szabo, 2009). This study examines responses to an 
anonymous online survey about antidepressant use and withdrawal. Participants 
included 176 current users, 181 currently withdrawing, 108 ex-users, and a 
control group of 44 participants who had never used antidepressants. Participant 
groups were compared quantitatively regarding attitude towards antidepressants 
use and perceived value, effect on well-being and mood, symptoms and side 
effects, and their perceived changes in themselves on and off the drugs. 
Participants were also given the opportunity to include spontaneous comments 
at the end of the survey which were analysed thematically. Key findings include: 
1) Antidepressant users have a more positive estimation of the value of the drugs 
than those who have discontinued the drugs or who have never used them; 2) 
Scores on the WHO-5 well-being survey for all three groups with antidepressant 
experience (users, those withdrawing, and ex-users) showed poor levels of well-
being, suggesting that neither antidepressant therapy nor cessation of 
antidepressant therapy were adequate interventions to create positive well-being; 
3) Multivariate analysis of participant responses revealed a significant difference 
between the four groups on 35 of 37 physical and emotional symptoms 
associated with antidepressant use or withdrawal, with the never-used group 
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scored the lowest in all cases except one, and the withdrawing group scoring the 
highest for 27 of the symptoms; 4) Concern over antidepressant dependency and 
withdrawal was the most prevalent topic reported by all user groups in 
spontaneous comments; other key themes included frustration with side effects 
and lack of information and support from the medical profession; 5) study 
results suggest that antidepressant withdrawal may take longer and be more 
challenging than the assumed “mild”, “self-limiting” and “resolving 
spontaneously…three weeks after onset” (Haddad & Anderson, 2007); and 6) 
30% of ex-users spontaneously reported what they believed were adverse drug 
reactions, or withdrawal reactions, months or years after antidepressant use had 
ceased, a long-term iatrogenic disablement that has yet to be addressed in the 
literature. Overall, the study reveals that antidepressants are not an adequate 
intervention to create positive well-being in patients and their use comes with a 
substantial risk of unpleasant side effects, dependency, and the potential for 
residual post-drug health complications. 
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Chapter 1 
Antidepressants in Modern Society 
The pharmaceutical industry is undoubtedly the most influential actor 
in the health and mental health systems today.  
David Cohen, 2008 
 
Modern antidepressant use is not an event that occurs in isolation, nor is it 
simply the result of increasing incidence or awareness of depression in modern 
society. It is the product of an historical, scientific, cultural, social, and economic 
amalgam. To understand the prevalence and standing of antidepressants in our 
society, it is essential to look at the bigger picture. 
 The pharmaceutical industry today is enormous, with worldwide sales in 
excess of $600 billion in 2006 (Britten, 2008). Pharmaceuticals were ranked third 
in 2009 by Fortune 500, after communications and internet services, with a profit 
margin of over 19% (Fortune 500, 2009). A significant amount of this profit came 
from the sale of antidepressants, the most commonly-prescribed class of 
medication in the U.S. (Olfson & Marcus, 2009), which accounts for 15% of the 
total annual cost of medication there (Kirsch, 2010b).  
Approximately 10% of Americans reported taking antidepressants in 2005, 
twice as many as in 1996, with 80% of those prescriptions written by general 
practitioners (Szabo, 2009). This includes approximately 2.5% of U.S. children 
aged 6-17 who were prescribed antidepressants in 2005 (Olfson & Marcus, 2009) 
in spite of the U.S. Food and Drug Administration’s (FDA’s) black box warning 
against paediatric use. In Britain, antidepressant prescription rates, also around 
                                                               2
10% (Petty, House, Knapp, Raynor & Zermansky, 2006),  increased by 36% 
between 2000 and 2005, reflecting not only new prescriptions, but also long-term 
use of the drugs by many patients (Moore et al., 2009). In New Zealand, the 
number of antidepressant prescriptions nearly doubled from 1.1 million in 1997 to 
2.1 million in 2005 (Ministry of Health, 2007) with the Pharmaceutical 
Management Agency of New Zealand (PHARMAC) reporting approximately 
10% of the population being treated, including adolescents,  children and toddlers 
(Sabin, 2010).  
Yet depression is today’s fastest-rising diagnosis and third most common 
reason for consultation with a general practitioner (GP) (Currie, 2005; Mitchell & 
Coyne, 2007), and it is identified by the World Health Organisation (WHO) as the 
leading cause of poor health worldwide (Daly, 2009). According to the National 
Institute of Mental Health (NIMH, 2010), anxiety disorders frequently co-occur 
with depressive disorders, affecting over 18% of the U.S. population aged 18 and 
over. These include panic disorder, obsessive compulsive disorder (OCD), post 
traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), social 
anxiety disorder (SAD), and a variety of phobias (NIMH, 2010). Antidepressants 
are U.S. FDA approved treatments for all of these disorders, and more (see Table 
1, p. 16). 
Concurrent with the rise in antidepressant use is the rise in the number of 
individuals disabled by mental illness, reflected in a four-fold per capita increase 
of patient care episodes and a sixfold increase in people on social security 
disability insurance for mental illness in the U.S. since 1955 (Whitaker, 2005). In 
New Zealand, a 2003/2004 nationwide representative sample survey of 12,992 
reported an alarming national mental disorder prevalence, based on survey 
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responses, of 46.4% (extrapolated lifetime likelihood of mental illness diagnosis), 
with 20.7%  reporting diagnosis of a mental disorder within the past 12 months 
(Oakley Browne, Wells & Scott, 2006). In the survey, mental illness was defined 
as suffering from a mood disorder such as depression, anxiety disorder, eating 
disorder, and/or substance abuse disorder.  
It wasn’t always this way. Less than a hundred years ago, Sigmund Freud 
observed that melancholy—depression—generally resolved of itself, even without 
treatment, and suggested it plays an important role in ego development (Freud, 
1917). He argued that melancholia could be best understood and treated through 
conversation or “talk therapy”. Nearly fifty years ago, Nathan Kline2 observed 
“most depressions terminate in spontaneous remissions…regardless of what one 
does” (1964, as reported in Whitaker, 2010, p. 153). Thirty-six years ago, NIMH 
depression section head Dean Schuyler described depression as a self-limiting 
condition with complete recovery rates exceeding 50% without any intervention 
(Schuyler, 1974 as reported in Whitaker, 2010, p. 153).  Yet today, with all the 
trappings of scientific study, and modern antidepressant drugs mooted as standard 
first-line treatment for depression and anxiety, the incidence of these afflictions 
has risen to unprecedented levels, prompting the American Psychiatric 
Association (APA) to now define depression as “a highly recurrent and pernicious 
disorder,” with only 15% of patients expected to experience full remission (quoted 
in Whitaker, 2010, p. 161-162). 
It is a paradox. As antidepressant treatment rates go up, recovery rates go 
down, and chronic mental health disability increases. Correlation does not imply 
causation, of course, but is it possible that antidepressant treatment may actually 
                                                 
2
 Kline and his colleagues were the first to recognize the antidepressant properties of the MAOI 
iproniazid, and developed the TCA amitriptyline which remains the world’s most popular tricyclic 
antidepressant. See Chapter 2. 
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worsen the course of depression? In the 1960s and 1970s, some European 
physicians observed that antidepressant use appeared to shorten remission 
intervals between depressive episodes and often lead to chronic impairment 
(Whitaker, 2010, pp. 157-158). When drug-treated vs. non-treated depressive 
patients in fifteen countries were compared in a major WHO study, those who had 
not been exposed to antidepressants had significantly better outcomes at the one 
year point, prompting researchers to conclude—contrary to expectations—that 
failure to recognize or treat depression did not appear to have adverse 
consequences (Goldberg, Privett, Ustun, Simon & Linden, 1998). A Canadian 
study of employees found those on short-term disability due to depression were 
significantly more likely to become long-term disability clients if treated with 
antidepressants, a situation that was further exacerbated if the antidepressants 
were switched or augmented (Dewa, Hoch, Lin, Paterson & Goering, 2003). In 
another Canadian study, analysis of longitudinal data from two large (n = 130,880 
and n = 17,262) Canadian health surveys found that, contrary to expectation, 
patients prescribed antidepressants following a depression diagnosis reported 
more weeks of depression and a higher risk of relapse following drug treatment 
than those not prescribed antidepressants (Patten, 2004). Yet prescribing rates 
continued to climb. 
 Short-term use of antidepressants appears to produce positive outcomes, at 
least in published clinical trials, most of which averaged 6 to 8 weeks duration. 
There are, however, problems with the apparently positive antidepressant clinical 
trial results: Firstly, although trials with positive results are generally published, 
trials with negative results rarely are. In a meta-analysis of 74 antidepressant trials 
lodged with the FDA, Turner, Matthews, Linardatos, Tell and Rosenthal (2008) 
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found just 38 with positive drug efficacy results; 37 of those were published in 
journals, 11 of the trials with negative results were published in such a way as to 
convey a positive outcome, and only 3 published trials showed no drug efficacy. 
Furthermore, the FDA only requires two clinical trials with positive efficacy 
results compared to placebo for drug approval, no evidence is required that a new 
drug is superior to any existing drugs, and data from unsuccessful trials need not 
be lodged with the FDA (Medawar, Hardon, & Herzheimer, 2004). The overall 
impression conveyed to researchers, physicians, and patients, based on published 
reports, is one of positive drug efficacy. 
 How positive are those short-term results? In another meta-analysis of 
FDA-lodged antidepressant trial studies, this one focussing just on the six SSRI 
antidepressants, Kirsch et al. (2008) found an “exceptionally large” placebo 
response of over 80% and concluded that the small difference between drug and 
placebo response was only clinically significant for severely depressed patients, a 
result that was echoed more recently by Fourier et al. (2010). Kirsch also found no 
difference in drug response between drugs types—it did not matter, all drugs 
produced the same degree of improvement (Kirsch, 2010a, p. 12), echoing the 
findings of Anderson (2000) and anticipating those of Hagen, Wong-Wylie, and 
Piji-Zieber (2010). If the placebo used in a trial was active—meaning it produced 
one or more side effects—no significant difference was found between drug and 
placebo; indeed, the strongest correlation Kirsch found in the meta-analysis was 
between reported drug side effects and depression improvement (.92 for 
fluoxetine, but all extremely high) (Kirsch, 2010a, pp. 18-20). 
In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) 
study (Rush et al, 2004), which followed 4000 depressed patients treated with a 
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variety of antidepressants, 25-30% achieved remission within 12 weeks of 
treatment, about the same as the remission rate on placebo found in other studies 
(STAR*D did not have a placebo arm), but only 3% of participants showed a 
sustained remission rate following a year of continuous drug treatment (Leventhal 
& Antonuccio, 2009), suggesting that long-term efficacy results are poor, and 
echoing Fava’s 2003 literature review that revealed a “very unfavourable long-
term outcome of major depression [when] treated by pharmacologic means.” 
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Chapter 2 
A (Relatively) Brief History of Antidepressants 
 
Ancient times 
The use of a variety of ingested substances to ameliorate depression and its 
first cousin anxiety goes back to ancient times. Alcohol, a relatively simple-to-
make anxiolytic, was a very early de-stressor. The brewing of beer and fermenting 
of grapes or other fruit for wine was recorded by Egyptian and other Middle 
Eastern cultures as early as 6000 B.C, and production quickly spread throughout 
the ancient world (McGovern, 1996, p. ix; Nunn, 1996, pp. 10-13). Opium 
poppies, called “the plant of joy” by the ancient Sumerians in the 3rd millennium 
BC, yielded opium, which was a widely-traded narcotic throughout Asia, the 
Middle East and Europe in ancient times (Payk, 1994). Atropa belladona, 
extracted from deadly nightshade, and hashish were both identified in a 3rd 
millennium BC Assyrian herbal text as remediation for a variety of nervous 
disorders (Payk, 1994), and a circa 1600 BC Egyptian papyrus recommends 
extracts from henbane and thorn apple (containing the psychotropic alkaloids 
hyoscyamine and scopolamine respectively), sometimes mixed with alcohol, as a 
remedy for melancholy (Payk, 1994). 
 The word melancholia derives from the ancient Greek words melas, 
meaning black, and kholé, meaning bile3. Although the ancient Greek doctor 
Hippocates (460-377 BC) attributed the development of melancholia, or excessive 
                                                 
3
 Bile is a fluid made by the liver and stored in the gall bladder. It helps the body digest fat. An 
imbalance of its primary components cholesterol, salts, and the pigment bilirubin causes gall 
stones. Bile is usually a yellow-green colour (MedTerms, 1998a). 
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black bile, to the psychological issues of lingering shame, grief, or fear (Bennett, 
1992; Wong & Licinio, 2001), popular pharmaceutical treatments of the time—
pharmacon is the Greek word for drug—included opium, mandrake, ass’s milk, 
and barley gruel, prescribed along with a vegetarian diet, abstinence from sex, 
massage, baths, physical exercise and dance, and distraction (Payk, 1994; 
Thompson, 2007, p. 7, Wong & Licinio, 2001).  
 
The advent of psychiatry 
 The term psychiatry was created in 1808 by the German physician Johann 
Christian Reil by uniting the Greek words psyche (soul) and iatry (physician, from 
the greek iatros) (Marneros, 2008). Reil argued that mental illness could be 
treated, initially and in the most severe cases, by medical interventions including 
alcohol, drugs, pain, blistering agents, and baths (Hansen, 1998). These physical 
remedies, he believed, should be combined with sensory treatments involving 
music, art, and massage—also appropriate first-line treatments for less-disabled 
patients—and, when the patient was ready, “talk therapy” to positively influence 
ideas, imagination and judgement and enable patients to achieve a level of “full 
consciousness” (Hansen, 1998). 
A century later, another German medical doctor and psychiatrist, Sigmund 
Freud, taught that mental disease (dis-ease) was the result of unconscious 
impulses and repressions which he felt could be addressed through a process he 
called psychoanalysis. However, with the advent of psychochemistry in the 
second half of the 20th century, depression, anxiety and their derivatives were 
identified not so much as the product of responses to difficult situations, painful 
emotions, conscience-pricking behaviours, or general dissatisfaction about life in 
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general which could be treated with talk therapy, but as chemically-induced 
abnormal brain states that could be treated with a range of pharmaceuticals 
(Breggin, 1991, p 11-12; Cohen, 2008). In spite of this, there are today no 
biological tests for depression, and there is no scientific evidence to support a 
biochemical explanation for this disorder (Levanthal & Antonuccio, 2009; 
Whitaker, 2010a, pp. 78-79). 
 
Early chemical treatments for depression and anxiety  
 A variety of chemical substances deemed useful for the treatment of 
melancholia and anxiety appeared in the 19th century. Potassium bromide, a 
psychotropic sedative and hypnotic, was introduced in 1826 initially as a 
treatment for epilepsy and to lessen sexual urges; problems with dependence 
became apparent by the mid-1800’s, and it is rarely used today (Lader, 1991). 
Codeine, a derivative of opium, appeared in 1832, followed by chloral hydrate in 
1869 and paraldehyde in 1882 (Payk, 1994). 
 The first trade-marketed anxiolytic from a chemistry lab was the 
barbiturate Barbitol, synthesized by German chemists in 1903 and marketed by 
Bayer in 1904 under the trade name “Veronal”. This was followed by 
phenobarbital (“Luminal”) in 1912 and amobarbital in 1923 (Lader, 1991). Well 
over a thousand barbiturate compounds were synthesized, and about 50 were 
brought to the market, but significant issues with toxicity and dependence made 
the need for safer sedative formulations apparent (Lader, 1991). 
 In 1929, Gordon Alles, a biochemist working on decongestants, developed 
a new compound, beta-phenyl-isopropylamine, which came to be known as 
amphetamine. A base form of the compound was patented by the pharmaceutical 
                                                               10
firm Smith, Kline and French (SKF) in 1933 and the inhaler form was sold over-
the-counter for the next 15 years4 (Rasmussen, 2008). SKF soon found other uses 
for the new drug, however, and in 1937 received the American Medical 
Association (AMA) seal of approval for a tablet-form of amphetamine called 
Benzedrine Sulfate for treatment of narcolepsy, Parkinsonism, and minor 
depression (Rasmussen, 2008).  
According to Rasmussen, SKF recruited a champion for the product in 
Harvard neurologist and psychiatrist Abraham Myerson, author of the then-
popular book When Life Loses Its Zest, who reasoned that since depression is 
expressed by a lack of energy, enthusiasm and focus—in other words, 
anhedonia5—the adrenergic stimulation of amphetamine would be a perfect 
antidote and mood elevator. SKF used Myerson’s reputation, medical backing and 
logical reasoning to launch an advertising campaign for the new drug aimed at 
general practitioners (GPs).  
Full page SKF advertisements for Benzedrine Sulfate appeared in medical 
journals during the 1940’s promised “a non-narcotic drug capable of alleviating 
depression”, patients feeling “better than well” and “immediate results: favourable, 
in some instances spectacular.” Sales of Benzedrine Sulfate tablets grew steadily 
(Rasmussen, 2006).   
In the late 1950’s, after their patent for Benzedrine Sulphate ran out, SKF 
introduced a new antidepressant, Dexamyl, which was composed of 
                                                 
4
 In 1938 the U.S. Congress initiated regulation requiring drugs be tested for safety, but it wasn’t 
until 1951, after the passing of the Durham-Humphrey Amendment, that potentially dangerous 
formulations required a doctor’s prescription rather than patients being allowed unrestricted access, 
a move which gave physicians a very privileged place in society (Whitaker, 2010, pp. 55-56) 
 
5
 Myerson revived and reinterpreted this obscure nineteenth-century term meaning literally “lack 
of pleasure”, rescuing it from obscurity, and broadened the previously more narrow definition of 
depression from the formerly used “neurasthenia”, or neurotic disorder, and paving the way for 
increased sales to a broadening market. (Rasmussen, 2006) 
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dextroamphetamine and the barbiturate amobarbital. It was promoted as a product 
to quell anxiety without drowsiness, and also as a remedy for weight loss which 
would not only lessen the appetite but also treat the emotional causes of 
overeating. The amphetamine market continued to expand, reaching a peak in the 
1960’s when it was guesstimated that over 6% of the US and UK populations had 
used an amphetamine product within a given six month period (Rasmussen, 2008). 
 Meanwhile, meprobamate, developed by Frank Berger in the 1950’s as a 
muscle relaxant for laboratory animals, became an exciting new product for 
anxiety, one that offered a sense of relaxation without the sedation engendered by 
the barbiturates. Berger coined a new term for the drug: tranquilizer. It was 
marketed under the trade names “Miltown” and “Equanil” by Carter Products, and 
became the first blockbuster psychotropic drug in American history (Healy 2004). 
In spite of its alarming dependence potential, it continues to remain popular in 
some countries because of cost effectiveness (Lader, 1991). 
The development of the benzodiazepines, the modern tranquilizers, began 
with Leo Sternbach, a molecular chemist working for Hoffmann-La Roche, a 
chemical research company. One of the compounds he synthesized, 
chlordiazepoxide, was found to have clinically significant hypnotic and sedative 
effects. In spite of dubious safety results with initial (albeit limited) trials, it was 
brought to the market in 1960, and that release was followed by the still-popular 
diazepam (Valium) in 1963 (Lader, 1991). A bevy of other “benzos” soon flooded 
the market as patents for barbiturate products lapsed, launching what came to be 
known as the 20th century “Age of Anxiety” (Lader, 1991). Heavily promoted 
with direct-to-consumer advertising in popular women’s magazines such as The 
Ladies Home Journal and Cosmopolitan and feature articles in news magazines 
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such as Time, Newsweek, and Science Digest  as a panacea for the suburban 
frustration of modern housewifery, benzodiazepines became known as “Mother’s 
Little Helpers”6 (Metzl, 2003). Freudian psychoanalysis, still tremendously 
popular in the 1950s7, might help identify problems, but Valium promised to fix 
them. Reports of “improved sleep”, “frigid women…responding more readily to 
their husbands’ advances” and “calm in frantic lives” saw sales soar, signifying 
the beginning of the “biological revolution” in psychiatry (Metzl, 2003).   
In 1951, two new compounds, iproniazid and isoniazid, were synthesized by 
the pharmaceutical company Hoffman-La Roche from leftover WW II stockpiles 
of hydrazine, a key component in German rocket fuel, and tested on tubercular 
patients with gratifying results. By Easter 19528, headlines proclaimed iproniazid 
(in particular) a “TB wonder drug” (Sandler, 1990).  
One unexpected side effect of iproniazid treatment was a sense of euphoria 
or hypomania that developed in some treated patients. Recognizing the potential 
of the new drug as a possible treatment for depression, psychiatrist Nathan Kline 
and his colleagues trialled it with 20 long-term institutionalized  “probably 
schizophrenic” patients and found it effective (Loomer, Saunders, & Kline, 1958, 
as reported by Sandler, 1990). Iproniazid was the first monoamine oxidase 
inhibitor (MAOI). In spite of their propensity to cause liver damage and what 
became known as “the cheese reaction,” whereby co-consumption with fermented 
                                                 
6
 The Rolling Stones song “Mother’s Little Helper”, written by Mick Jagger and Keith Richards, 
was recorded in 1965. They sang:  
“Kids are different today, I hear ev'ry mother say 
Mother needs something today to calm her down 
And though she's not really ill, there's a little yellow pill 
She goes running for the shelter of a mother's little helper 
And it helps her on her way, gets her through her busy day” 
 
7
 The biography Sigmund Freud: Life and Work by Ernest Jones made the US bestseller lists in 
1955 (Metzl, 2003). 
 
8
 This was before clinical trials were required. 
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foods such as cheese or wine resulted in a sudden and potentially-fatal episode of 
hypertension (Thase, Trivedi, & Rush, 1995), MAOIs were widely prescribed for 
depression during the 1950s and 1960s. Their use declined with the advent of 
safer drugs and more frequent outpatient care for depression, and they are rarely 
prescribed today (Thase, Trivedi & Rush, 1995). 
 
Modern antidepressants 
 The neologism “antidepressant” first appeared in 1959 in the New York 
Times (Whitaker, 2010a, p. 60), about the same time as the first tricyclic 
antidepressants (TCAs) came on the market. Imipramine, a histamine-type drug 
with a 3-ring chemical structure (hence “tricyclic”), was developed by psychiatrist 
Roland Kuhn for the Swiss pharmaceutical firm Geigy; positive results from his 
trial with 40 depressed patients were published in 1957 (Kuhn, 1970).  In 
retrospect, according to Moncrieff (2008), it seems possible that the 
“improvement”, the agitation and euphoria experienced by Kuhn’s patients that he 
identified as proof of depression remission, may have been due, at least in part, to 
the sudden withdrawal of the chlorpromazine they had previously been taking, but 
the idea that a drug such as imipramine could reverse a depressive episode leant 
support to the budding concept of depression as a biological disease and laid the 
groundwork for the development of the modern antidepressant market (Moncrieff, 
2008).  
Geigy, unable to recognize a significant market for an anti-depressive 
product at that time, saw little reason to actively promote imipramine (Healy, 
2004) but a year later, the chemical company Merck approached Frank Ayd, 
Nathan Kline (the developer of iproniazid), and several of their colleagues and 
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asked them to examine amitriptyline, another chemical compound based on a 
tricyclic chemical structure, for possible treatment of schizophrenia or depression 
(Healy, 1997, pp 74-75). When the depression trials proved positive, Merck filed a 
patent for amitriptyline specifically as a treatment for depression in 1961 (Healy, 
1997, p 75). Meanwhile, Frank Ayd wrote a book titled Recognizing the 
Depressed Patient, and Merck commissioned fifty thousand copies for distribution 
to psychiatrists and physicians in areas where the new drug was being actively 
promoted.  Amitriptyline quickly became the best-selling antidepressant (Healy, 
2004), and it remains the best-selling TCA today. TCAs like imipramine and 
amitriptyline are sometimes referred to as “first-generation antidepressants;”9 
(Julien, 2001). 
To discover how to make better antidepressants, researchers needed to 
understand why existing ones seemed to work. What was it the pills were 
changing? The identification of neurotransmitters, chemicals that transmit 
information between brain cell synapses, prompted the amine theories of 
depression. In the 1960’s American Joseph Schildkraut introduced the 
catecholamine10 hypothesis which proposed that depression was correlated with a 
deficit of monoamines, most specifically norepinephrine, based on observations 
that drugs such as reserpine, which depletes or deactivates production of 
norepinephrine11, produces sedation and depression12, whereas drugs such as 
                                                 
9
 During the TCA-dominated era, the term “second generation antidepressants” referred to a 
second wave of TCAs (after imipramine and amitriptyline) The more modern definition of “second 
generation antidepressants” refers to the atypical antidepressants referred to later in this chapter, 
sometimes including the SSRIs in that category (Gartlehner, et al., 2008). 
10
 Catecholamines function both as hormones and as neurotransmitters. The most common 
catecholamines in humans are epinephrine (adrenalin), norepinephrine (noradrenalin) and 
dopamine (Catecholamine, 2010). 
11
 Both reserpine and imapramine were identified as norepinephrine reuptake inhibitors in papers 
at the time (e.g., Hertting, Axelrod & Whitby, 1961), but Shildkraut indicated no awareness of this.  
 
                                                               15
imapramine and the MAOIs increased brain levels of norepinephrine and in doing 
so stimulated activity and uplifted mood (Schildkraut & Kety, 1967).  
Around the same time in the UK, George Ashcroft found lowered levels of 
brain serotonin in the spinal fluid of depressed patients and cadavers of suicides in 
1960 and hypothesized that depression might be caused by low levels of the 
neurotransmitter serotonin, a theory he rescinded following further studies in 1970 
(Ashcroft & Healy, 2000).  
 Either hypothesis was a boon to the pharmaceutical industry because it 
suggested that depression could be approached as a medical condition or illness 
with a biological cause, and therefore medication could be developed to treat it. If 
depression was caused by low levels of key amines such as norepinephrine or 
serotonin, and new antidepressants could be shown to target this low level, the 
prospects for marketing would be enormous. Forty years on, the chemical 
imbalance theory of depression, and the suggestion that depression results from 
deficiencies of any monoamine neurotransmitters remains widely reported but 
unsupported by any scientific evidence (Leventhal & Antonuccio, 2009; Watters, 
2010, pp. 234-235).  
The TCAs dominated the antidepressant drug market until the mid-1980s 
when the first Selective Serotonin Reuptake Inhibitors (SSRIs) were developed. 
Table 1 shows the most commonly prescribed antidepressants in the US in 2007. 
 
 
 
                                                                                                                                      
12
 Interestingly, in 1955, in the first modern clinical drug trial, Michael Shepherd compared 
reserpine to placebo in a group of depressive patients and demonstrated an antidepressant action 
superior to any drug available at that time, but drug company Ciba did not recognize a market for 
such a product and chose to market the drug as a neuroleptic instead (Healy, 2004). It seems 
unlikely that Schildkraut was unaware of this study. Subsequent studies have shown  that only 
around 6% of patients given reserpine develop depression (Irving, 2010a, p. 88) 
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Table 1. Most commonly prescribed antidepressant drugs based on number of 
prescriptions in the US, 2007 (Drug Topics, 2008) and their US FDA approved 
indications. Approved indications for each drug in the USA is based on information from 
www.FDA.gov; each drug has its own prescribing information pages. Indications may vary 
in other countries. Plasma half-life figures from Nierenberg et al., 2008 and FDA 
prescribing information pages. 
 
Drug Brand 
Names 
Class 2007 US 
Prescriptions  
FDA Approved 
Indications 
Plasma 
Elimination 
Half Life 
(approx.)  
 
Sertraline Zoloft SSRI 29,652,000 MDD, OCD, Panic 
Disorder, PTSD, PMDD, 
SAD 
 
26 hours 
Escitalopram Lexapro, 
Cipralex 
SSRI 27,023,000 MDD, GAD 27-32 hours 
 
 
Fluoxetine Prozac, 
Serafem 
SSRI 22,266,000 MDD, OCD, Bulimia 
Nervosa, Panic Disorder. 
Also in combination with 
the antipsychotic 
olanzapine for bipolar I 
and treatment-resistant 
depression. Sarafem for 
PMDD. 
 
4-6 days 
Bupropion Wellbutrin, 
Budeprion, 
Zyban 
NDRI 20,625,000 MDD, Seasonal Affective 
Disorder, Zyban for 
smoking cessation. 
 
21 hours 
Paroxetine Paxil, 
Seroxat, 
Aropax, 
Loxamine, 
Pexeva 
 
SSRI 18,141,000 MDD, OCD, Panic 
Disorder, SAD, GAD, 
PTSD 
21 hours 
Venlafaxine Effexor SNRI 17,200,000 MDD, SAD, GAD, Panic 
Disorder 
 
5 hours 
Citalopram Celexa, 
Cipramil 
 
SSRI 16,246,000 Depression 35 hours 
Trazodone Desyrel TeCA 15,473,000 Depression 3-6 hours 
 
Amitriptyline Elavil TCA 13,462,000 Depression 10-50 hours 
(average 15) 
 
Duloxetine Cymbalta SNRI 12,551,000 MDD, GAD, pain 
management from 
fibromyalgia 
 
12 hours 
Mirtazapine Remeron TeCA   5,129,000 Depression 20-40 hours 
 
Nortriptyline Pamelor TCA   3,105,000 Depression 1-4 days 
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Doxepin Adapine, 
Deptran, 
Sinequan 
 
TCA   2,072,000 Depression, Anxiety 8-24 hours 
Imipramine Tofranil TCA   1,524,000 Depression 9-20 hours 
 
MDD-Major Depressive Disorder; OCD-Obsessive Compulsive Disorder; PTSD-Post-traumatic Stress 
Disorder, PMDD-Premenstrual Dysphoric Disorder, SAD-Social Anxiety Disorder, GAD-Generalized 
Anxiety Disorder 
SSRI-Selective Serotonin Reuptake Inhibitor; NDRI-Norepinephrine Dopamine Reuptake Inhibitor; 
SNRI-Serotonin Norepinephrine Reuptake Inhibitior; TCA-Tricyclic Antidepressant; TeCA-Tetracylic 
Antidepressant 
 
Whereas the TCAs and MAOIs were discovered more or less by accident, 
the SSRIs were deliberate creations. Schildkraut’s 1965 catecholamine theory 
pointed to inhibition of norepinephrine as the essential modus operandi of 
antidepressant drug function, but Swedish researcher Arvid Carlsson proposed 
that antidepressant compounds that would act selectively on the serotonin system 
might be as effective as the TCAs and have fewer side effects (Healy, 2004). In 
1978, he trialled two new compounds, zimelidine and citalopram, identified as 
“selective 5-HT13 reuptake inhibitors,” in rats (Carlsson & Lindqvist, 1978), and 
human trials soon followed. Zimelidine was launched onto the European market 
as Zelmid in 1982, becoming the world’s first commercially available SSRI, but 
was removed shortly thereafter following reports linking it to development of the 
paralyzing neurological disease Guillain Barré syndrome, liver damage, and 
suicidal ideation (Healy, 2004, pp 18-19; Shorter, 2009, pp 173-174). Citalopram 
was not made commercially available until 1989 in Europe and 1998 in the U.S. 
(Shorter, 2009, p. 174).  
In Let Them Eat Prozac, David Healy (2004, pp 30-39) tells the story of the 
development of the first SSRI blockbuster drug, Prozac (fluoxetine), summarized 
here. Adapted from the antihistamine diphenhydramine (trade name Benadryl) by 
                                                 
13
 5-HT, or 5-hydroxytryptamine is serotonin (MedTerms, 2003a) 
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researchers in the Eli Lilly laboratories in the 1970s, the new product did not 
block the sedative action of reserpine as other antidepressants did, but it did 
stimulate aggression in rats, which suggested it had some “activating” properties. 
Lilly was keen to develop a new antidepressant to replace their best-selling TCA 
nortriptyline, marketed under the trade name Pamelor, but the new drug did not 
show efficacy for use with severe depression, causing distress and agitation in 
patients, nor did it work for schizophrenia, pain relief, hypertension or obesity. 
Finally, adjuncted with benzodiazepines to quell subjects’ ensuing agitation, it 
was trialled with a group of five mildly depressed individuals (Breggin, 2008, pp 
247-248). All five responded positively14. It was a small success, but enough to 
initiate the launch of the next blockbuster drug (Healy, 2004).  
Prozac underwent numerous clinical trials over the next few years, enough 
of which yielded results adequate (but just barely) for FDA approval15 in 1987. 
The marketing team launched the drug with much fanfare onto the American 
market in 1988 under a one-pill-a-day-fits-everyone banner in an attempt to 
expand beyond the psychiatric prescribing market into the much larger sales arena 
of general practitioners. Promoted as “a breakthrough drug in the treatment of 
depression”, Prozac made the cover of Newsweek in 1990 (Wong, Bymaster & 
Engleman, 1995). Ironically, it took six more years for the drug to pass German 
regulators for use there, one regulator noting “Considering the benefit and the risk, 
we think this preparation totally unsuitable for the treatment of depression.” 
                                                 
14
 They likely were responding, at least in part, to the benzodiazepine (Healy, 2004, p 44). 
 
15
 The US FDA requires lodgement of two trials demonstrating superiority to placebo; data from 
unsuccessful trials need not be lodged (Medawar, Hardon, & Herzheimer, 2004). Of Lilly’s three 
submitted placebo-controlled trials for fluoxetine, one showed no effect, one showed a very small 
superiority over placebo but inferiority to the TCA imipramine, and the third showed efficacy but 
had only 11 completers of the 4-week trial (Healy, 2004, p. 35). Furthermore, Lilly trial subjects 
who experienced drug-induced agitation were co-prescribed benzodiazapines during the trials, 
although this was not reported in published results (Breggin, 2008, pp. 247-248). 
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(internal Eli Lilly communication reported in Healy, 2004, p. 39). Nevertheless, 
Prozac proved enormously popular, with sales for that one drug alone accounting 
for 30% of Eli Lilly’s company profits (McLean, 2001). Although the patent for 
the drug expired in 2001, generic fluoxetine remains a popular antidepressant drug 
choice for many today.  
Five other SSRIs have joined fluoxetine on the US market: fluvoxamine, 
citalopram, paroxetine, sertraline, and escitalopram oxalate (Table 1, p. 16). 
Touted as safer than the TCAs because of lower cardio-toxic reactions in overdose, 
and safer than the MAOIs with their liver toxicity and “cheese reaction”, easy for 
general practitioners to prescribe, and applicable to an ever-growing list of 
applications, both on- and off-label, SSRIs have dominated the antidepressant 
market for two decades. 
 The TCAs, MAOIs, and SSRIs all work in different ways, but provide 
similar antidepressant actions (Leventhal & Antonuccio, 2009). Clearly, no one 
theory or chemical structure has proved fundamental for an understanding of how 
antidepressants work, although all of these products appear to cause an alteration 
of the neurotransmitter system to achieve effect. Several other drugs with slightly 
different mechanisms, known collectively as atypical antidepressants, are also 
currently prescribed. 
Modern dual-action drugs that affect the reuptake of both serotonin and 
norepinephrine (SNRIs) include duloxetine, nefazodone, trazodone, venlafaxine 
and desvenlafaxine.  SNRIs are thought to be effective because of serotonin’s 
moderating effect on mood and norepinephrine’s positive effect on drive and 
energy levels (Hindmarch, 2001). Eli Lilly brought duloxetine to the market under 
the brand name Cymbalta in 2004 after agreeing to FDA requirements to indicate 
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clearly on the label the drug’s propensity for liver damage (Eisenberg, 2005). 
Liver damage is also an issue for nefazodone, first marketed by Bristol-Meyers 
Squibb in 1994 under the trade name Serzone; various generic versions are now 
available (Galson, 2004). Nefazodone inhibits reuptake of serotonin and 
norepinephrine and selectively blocks the 5-HT2A receptor; it is considered 
particularly useful where insomnia is comorbid with depression (Julien, 2001, p 
301; Papacostas & Fava, 2007;). Venlafaxine, introduced by Wyeth in 1993 under 
the trade names Efexor and Effexor, inhibits the reuptake of dopamine to some 
extent as well as serotonin and norepinephrine (Hindmarch, 2001; Julien, 2001, pp 
294-295). Wyeth added desvenlafaxine, synthesized from the active metabolite in 
venlafaxine, to their product line in 2008 under the brand name Pristiq for 
treatment of major depressive disorder (MDD) and menopausal symptoms 
(Medinews.direct, 2008). Clomipramine, first developed by Giegy in the 1960s 
and marketed as Anafranil, is structurally a TCA, but functions as an SNRI; it is 
used primarily for treatment of obsessive compulsive disorder (OCD) but also 
depression and phobic disorders (Julien, 2001, p 294). 
The tetracyclic mirtazapine was brought to the market in 1994 by Organon 
International under the trade name Remeron. Now out of patent, there are many 
generic version of the drug. It does not act as a reuptake inhibitor like the SSRIs 
or TCAs but instead works as an antagonist of norepinephrine and serotonin 
autoreceptors and blocker of histamine receptors (Julien, 2001, pp 301-302).  
Trazodone (trade name Desyrel), also a tetracyclic, does not significantly 
block the reuptake of serotonin or norepinephrine, but appears to down-regulate 
some of the serotonin receptors (Julien, 2001, p. 293). It was approved for 
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treatment of depression by the FDA in 1981, and an extended-release formula was 
approved in 2010 (Waknine, 2010). 
Bupropion, patented by GlaxoSmith Kline, was approved for use as an 
antidepressant by the FDA in 1985 under the trade name Wellbutrin, and as a 
tablet for smoking cessation and nicotine addition in 1997 under the brand name 
Zyban (FDA, 2009a). Now available in generic form, it selectively inhibits 
dopamine and norepinephrine reuptake and is a nicotinic antagonist, but does not 
appear to affect serotonin (Julien, 2001, pp 293-294; Slemmer, Martin, & Damaj, 
2000). 
Quetiapine (trade name Seroquel), is an antipsychotic primarily used for 
treatment of schizophrenia and bipolar disorder. It has recently been approved by 
the US FDA as an adjunctive medication for use with patients diagnosed with 
major depressive disorder who are already taking another antidepressant 
(AstraZenica, 2010). Lithium, a mood-stabilizer approved by the US FDA in 1970 
for treatment of mania and bipolar disorders, is also sometimes co-prescribed with 
antidepressants for treatment-resistant patients (Bauer & Döpfmer, 1999). 
Several other drugs have come and gone, overtaken by market conditions or 
safety concerns. What does seem clear is that although many antidepressants 
interact with the serotonin (or cholinergic) system, a point pharmaceutical 
companies often reiterate, there are no studies that show depression caused by any 
sort of deficiency or malfunction in those systems (Lacross & Leo, 2005). In spite 
of the inability to induce depression via serotonin depletion, or to alleviate 
depression through increased serotonin, the low-serotonin-causes-depression 
concept has become such an integral cornerstone of product marketing for modern 
                                                               22
antidepressants (Lacrosse & Leo, 2005) that it seems almost sacrilegious to 
question it (Kresser, 2009). 
Given that every drug and drug combination has the same, relatively small 
general effect as any other, with no stand-out performers (Leventhal & 
Antonuccio, 2009), Kirsch (2010a) hypothesized that any positive anti-depressive 
action perceived as a result of these various chemical agents is simply a product of 
their role as active placebos.  
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Chapter 3 
Antidepressant Side Effects, Long-term Use, Off-label Use,  
Compliance, and Dependency   
When you make a medicine, you are trying to disrupt the fundamental 
biological process. That’s a pretty profound change. You can’t do that 
without producing some unwanted effects. 
Patrick Vallance, Head of Drug Discovery, GSK (2010) 
 
 If antidepressants were merely placebos with no negative effect, and if 
people found they worked to alleviate depression and anxiety, there would not be 
a problem with their use. Unfortunately, antidepressants often produce a range of 
unpleasant side effects and, for some users, the risk of drug dependency. 
 
Side Effects 
 Up to 70% of patients discontinue their antidepressant before their 
prescribing physician believes they should, 28% within the first month. The most 
common reason given for premature discontinuation is bothersome side effects 
(Khawam, Laurencic, & Malone, 2006). In clinical trials, dropout rates varied 
between 7% and 44% for the TCAs, and 7% and 23% for the SSRIs (Khawam et 
al., 2006).  
The TCAs were originally tested as neuroleptics, and share some of the 
same side effects due to suppression of the cholinergic system (Breggin, 1991). 
According to Breggin (1991) and Khawam et al. (2006), common side effects 
reported by patients prescribed TCAs include blurred vision, dry mouth, urinary 
retention, constipation, sleep disturbances, weight gain, lowered blood pressure, 
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impaired cardiac function and cardiac arrhythmias, sedation, lethargy, anxiety, 
sexual side effects and emotional blunting. Because of their cardiac effect, the 
TCAs are particularly dangerous when taken in overdose, or when combined with 
other drugs that suppress the central nervous system such as sleeping pills, 
tranquillizers, some analgesics, and alcohol (Breggin, 1991). It is this cardiac 
danger and somewhat greater side effect profile that have made the TCAs, which 
demonstrate otherwise similar levels of efficacy to the SSRIs (Anderson, 2000), 
less attractive prescribing options.  
According to Khawam et al. (2006), the SSRIs selectively block serotonin 
reuptake, at least in theory, with citalopram and excitalopram demonstrating the 
most selective effect. Paroxetine, like the TCAs, is also anticholinergic, while 
fluoxetine and sertraline also inhibit norepinephrine reuptake, and sertraline 
weakly inhibits dopamine reuptake. All of the SSRIs are metabolized in the liver, 
where they inhibit the hepatic enzymes that break down other drugs, leading to a 
possibly toxic increase in a variety of co-prescribed drugs (Khawam et al., 2006). 
SSRIs should not be combined with other serotonin-enhancing drugs, including 
most other antidepressants, or blood thinners such as warfarin or aspirin (Khawam 
et al, 2006). Itemized drug reactions can be found on manufacturer-supplied 
patient leaflet sheets for specific drugs, most of which are available on the internet. 
Eighty-six percent of SSRI patients reported at least one troublesome side 
effect in telephone interviews conducted 75-105 days after initiation of an SSRI 
prescription, a figure significantly underestimated by physicians surveyed (Hu et 
al, 2004). Zimmerman et al. (2010) found patients reported 20 times more side 
effects when responding to a checklist than what their dispensing psychiatrists had 
noted in their records. The most commonly reported side effect of the SSRIs is 
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sexual dysfunction, which presents as delayed ejaculation, anorgasmia, and 
decreased libido in as many as 60-73% of patients according to Khawam et al 
(2006) and Bahrick & Harris (2009). They report this can impact negatively on 
patient recovery and well-being by increasing anxiety and destabilizing intimate 
relationships, yet prescribers often neglect to discuss these issues with their 
patients. Furthermore, the sexual dysfunction often lingers long after treatment has 
ceased, a point extolled by the pharmaceutical industry who advocate [off-label] 
SSRI treatment for premature ejaculation as having “a lasting post-treatment 
effect” (Bahrick & Harris, 2009). Antonuccio (2008) raised a subsidiary issue 
regarding the prescribing of SSRIs and SNRIs to children and adolescents, voicing 
a concern that the drugs may alter pubertal development.  
Nausea and diarrohea are also common side effects. The anorexia as a 
result of nausea and appetite suppression that can occur early in treatment lead 
early clinical trial evaluators to speculate on the value of SSRIs for weight loss; 
with time, however, weight gain becomes a common side effect of SSRI treatment, 
possibly due to desensitization of serotonin receptors responsible for appetite 
control (Khawam et al., 2006). Long-term use of antidepressants with subsequent 
weight gain is associated with an increased risk of diabetes (Andersohn, Schade, 
Suissa, & Garbe, 2009).  
SSRIs also negatively impact the central nervous system, resulting in 
increased anxiety, insomnia, nightmares, and sedation for about 25% of users 
(Khawam et al., 2006), hence Eli Lilly’s decision to co-prescribe Prozac with 
benzodiazapines in clinical trials. Akathisia, a sort of inner agitation that can range 
from uncomfortable to torturous, affects up to 25% of fluoxetine users, with lesser 
rates for the other SSRIs (Breggin,2003/2004) and can result in irritability, 
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violence and suicidality (Healy, Herxheimer & Menkes, 2006). SSRIs also inhibit 
blood platelet function which can cause prolonged bleeding and gastrointestinal 
bleeding (Khawam et al, 2006). Serotonin plays a significant role in lens 
transparency, and recent studies have linked SSRI use to the development of 
cataracts, with fluvoxamine, venlafaxine, and paroxetine demonstrating the 
highest risk (Etminan, Mikelberg, & Brophy, 2010). Although some research has 
suggested SSRIs might be useful for treating alcoholism (Swift, 1999), or the 
depression that is often concurrent with alcoholism (Pettinati, 2004), anecdotal 
reports from forum websites such as www.paxilprogress.org support Breggin’s 
(2008, p. 112) claim that antidepressants can drive some people to increase their 
alcohol consumption as a method of calming drug-induced anxiety and over-
stimulation. 
Not all side effects are physical. In a qualitative study utilizing interviews 
and examination of internet postings, Price, Cole and Goodwin (2009) identified 
eight key emotional themes reported by SSRI users:  1) general reduction of 
emotional intensity; 2) reduced intensity and frequency of positive emotions; 3) 
reduced intensity of negative emotions; 4) emotional disconnection with people 
and events; 5) general feelings of indifference towards things and people that used 
to matter; 6) altered personality, which persisted even after medication was 
discontinued; 7) short-term positive but long-term negative impact on everyday 
life in terms of responsibilities, relationships, creativity, and decision-making; and 
8) emotions affected by dose and adherence: a sense that who you are becomes 
controlled by a pill. 
Regarding the atypical antidepressants Khawam et al. (2006) report the 
most common side effects for venlafaxine are nausea, dizziness, insomnia, 
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somnolence, dry mouth, sexual dysfunction, and hypertension. Mirtazapine causes 
sedation and weight gain, and may affect the liver. Dizziness, dry mouth, 
constipation, and disturbing dreams have also been reported. Bupropion can cause 
increased irritability and agitation as well as insomnia, headache, tremors, and 
nausea, and carries a small risk of seizure. It is not recommended for patients who 
are heavy users of alcohol, who have liver or kidney disease, or who have a 
history of seizures. Duloxetine is associated with nausea, dry mouth, constipation, 
fatigue, sweating, and increased blood pressure. Sexual dysfunction is less 
common with duloxetine than with the SSRIs. 
Many countries have a body which records reports—usually from 
physicians—of adverse drug reactions. In the US, it is MedWatch, a branch of the 
FDA; in the UK it is the Medicines and Healthcare products Regulatory Agency 
(MHRA); in New Zealand, it is the Centre for Adverse Reactions Monitoring 
(CARM), a branch of MedSafe. In spite of having what the World Health 
Organization describes as “the highest number of [adverse reaction] reports 
submitted per capita” which are “of the highest quality”, it is estimated that only 
10% of adverse reactions are reported in New Zealand (MedSafe, 2009). 
In 1999, Spigset analyzed the 1861 SSRI adverse reactions reported to the 
Swedish Adverse Reactions Advisory Committee. The most commonly reported 
adverse symptoms were neurological (22.4%), including paraesthesias (a burning 
or prickling skin sensation), headache, dizziness, tremor and seizures. There are 
only slightly more commonly reported than psychiatric symptoms (19.5%) which 
included anxiety, confusion, hallucinations, and disturbed sleep. Gastrointestinal 
symptoms accounted for 18% of reports, consisting primarily of nausea, vomiting 
and abdominal pain. Elevated liver enzyme levels were reported in 25 cases after 
                                                               28
long-term use. Dermatological reactions such as rashes accounted for 11.4% of 
reports, most made within a few weeks of the beginning of treatment. Fatigue and 
weight gain were also commonly reported. Spigset observed that the majority of 
reported adverse reactions were in response to standard doses. 
 
Off-label prescribing and contraindications 
Antidepressants are sometimes prescribed “off label”, meaning they are 
prescribed for indications for which they have not been approved or licensed, 
prescribed to patients who have not been approved to receive them, or prescribed 
at dosage levels beyond approved levels. According to Evans (2009), 
pharmaceutical companies actively promote off-label prescribing, although doing 
so is illegal, tossing off the court fines as part of the cost of doing business. Pfizer, 
for example, has paid US$2.75 billion in fines for off-label drug promoting since 
2004, just over 1% of the company’s revenue. Because of cross-over advertising, 
many doctors are unaware of which indications are tested and approved for a drug, 
and which are not (Evans, 2009). In the U.S., it is not illegal for a doctor to 
prescribe medication off-label, nor is it compulsory that the patient be informed 
that a prescribed drug is not approved for a particular use, but the issue creates 
ethical and liability conundrums (Wilkies & Johns, 2008). In New Zealand, the 
Medicines Act 1981 does require doctors to inform patients if a medicine is being 
prescribed for an unapproved use, and s/he is obligated to discuss the potential 
risks and benefits of the medication with the patient (MedSafe, 1998).  
Examples of off-label prescribing of antidepressants for non-approved 
conditions are the tricyclic amitriptyline for pain relief or as a sleep aid (Mayhew, 
2009), paroxetine and other SSRIs for premature ejaculation (Waldinger, 2007), 
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and a variety of antidepressants for anxiety, back pain, migraine headaches, 
bulimia, anorexia nervosa, fibromyalgia, irritable bowel syndrome, chronic fatigue 
and attention deficit disorder (ADD) (Pomerantz et al., 2004; Leydon & Raine, 
2006). It is also common for dose increases to go beyond recommended 
guidelines in the case of treatment-resistant conditions, a strategy which may be 
helpful with TCAs16 and venlafaxine (Adli, Baethge, Heinz, Langlitz, & Bauer, 
2005) but which has proved ineffective and likely to cause significantly increased 
side effects with the SSRIs (Adli et al, 2005; Ruhé et al., 2006).  
The most common type of off-label prescribing occurs with paediatric 
patients, elderly patients, pregnant patients, and patients with contraindicated 
disorders or medications. Although most clinical trials of antidepressants have 
been conducted with adults, these medications are often prescribed for children 
and adolescents who are experiencing depression, OCD and other disorders 
(Baldwin & Kosky, 2007). Twelve of the 15 SSRI paediatric trials submitted for 
FDA approval failed to adequate show efficacy (Whitaker, 2010, p. 230). Only Eli 
Lilly’s results from two short-term paediatric trials on Prozac with participants 
aged over 8 years old demonstrated adequate efficacy over placebo to the FDA 
(Lilly, 2006), making fluoxetine the only antidepressant approved for paediatric 
treatment of depression and OCD in the US, although many critics suggest this is 
more a tribute to clinical trial manipulation than to a superior product17. No SSRI 
                                                 
16
 In contrast to Adli et al.’s findings, in a meta-analysis of 41 TCA trials that evaluated dose levels, 
Furukawa, McGuire, and Barbui (2002), found TCAs in general more effective at treating 
depression and less likely to cause significant side effects when prescribed at levels below 
recommended doses. 
 
17
 Earlier fluoxetine trials failed to show efficacy in paediatric groups. The two “successful” 
studies involved extensive screening of participants prior to the trial for placebo response, and  
exclusion of data from those who responded adversely during the trial from the final reported 
results (Healy, 2006). 
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antidepressants are approved for use with children or adolescents in New Zealand 
(Jessamine, 2008). 
Although antidepressants are prescribed to children as young as one year 
old (Leslie, Newman, Chesney & Perrin, 2005), almost nothing is known about 
the long-term impact of antidepressant use on children’s motor, cognitive, 
emotional, social, or sexual development (Wohlfarth et al., 2009). Children and 
adolescents are involuntary patients dependant upon wise decision-making from 
their parents and medical practitioners who must weigh up the values of short 
term efficacy with potential side effects and safety issues when prescribing 
antidepressants. In the TADS study of 439 depressed adolescents, March et al., 
(2004) compared placebo with fluoxetine alone, cognitive behavioral therapy 
(CBT) alone, and fluoxetine plus CBT. At 12 weeks, the combination treatment 
was found most effective for depression; however by 36 weeks, all three 
treatments (excluding placebo) showed similar results (Kennard et al., 2009). The 
authors acknowledged the study “was designed to minimize the placebo 
response,” and data on the placebo group was not taken after 12 weeks. Twenty-
four (5%) of the participants experienced a “suicide-related adverse event” in the 
first 12 weeks, although participants had been pre-screened for suicidality. When 
considering the safety of the four treatment conditions, Antonuccio (2008) 
concluded CBT the best treatment choice, followed by placebo. 
Fluoxetine is the only antidepressant drug approved for use with patients 
over 65 years of age (Ables & Baughman, 2003).  The elderly may be as 
vulnerable as the pediatric population to antidepressant side effects, given their 
decreased blood-brain barrier protection, lower metabolism, and decreased renal 
clearance of chemical agents (Crumpacker, 2008). Nevertheless, many patients 
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over 65 take antidepressants. The daily use of SSRIs within the elderly population 
is correlated with lower bone mineral density and a 2-fold increased incidence of 
falls resulting in fractures over non-SSRI users (Richards et al., 2007), while 
TCAs can aggravate glaucoma, prostatic hyperplasia, and coronary diseases 
(McLeod, Ruang, Tamblyn & Gayton, 1997; Zellwegar et al., 2004). Because the 
elderly are more likely to have concurrent health issues, co-prescription of drugs 
which are contraindicated by antidepressants is also a risk.  
Although no antidepressants are approved for use during pregnancy or for 
breast-feeding mothers, it is not uncommon for women who are taking 
antidepressants to become pregnant. A 20% increased risk of pre-term births and 
subsequent low birth weight is associated with both depression and maternal 
antidepressant use (Wisner et al., 2009), and Einarson, Choi, Einerson, and Koren 
(2009) found a 3-fold increased risk of miscarriage (spontaneous abortion) among 
antidepressant-using mothers, yet the risk of increased or returning depressive 
symptoms with drug discontinuation during pregnancy is also significant (Cohen 
et al. 2006). Transfer of SSRIs and SNRIs across the placenta is “substantial” 
(Rampono et al, 2009) and a neonatal withdrawal syndrome has been associated 
with maternal SSRI use, especially of paroxetine (Sanz, De-las-Cuevas, Kiuru, 
Bate, & Edwards, 2005). 
 
Long-term use 
 There is some controversy regarding the value of long-term maintenance 
on antidepressants. Psychiatric practice guidelines recommend long-term 
maintenance for patients with recurrent depressive disorder (Holma, Holma, 
Melartin & Isometsä, 2008) but primary physician guidelines for antidepressants, 
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as reported in Petty et al. (2006), recommend withdrawal of antidepressant 
treatment following six months of remission. In practice, many patients remain on 
antidepressant treatment for much longer, an average of 5.7 years (Petty et al., 
2006). Although intractable long-term distress may demand long-term treatment, 
Petty et al. found patient use of antidepressants poorly monitored by many health 
practitioners, with patients without regular documented reviews of their 
medication use tending to have the longest treatment times. In a literature review, 
Fava and Offidani (2010) identified numerous studies linking long-term use of 
antidepressants with increased drug tolerance, more frequent depressive episodes, 
worsened long-term outcomes and exacerbated manic symptoms in bipolar 
patients. Petty et al. (2006) and Fava and Offidani (2010) found long-term 
antidepressant use as maintenance therapy both ineffective and inappropriate. 
 
Antidepressants, suicide, and violence 
Suicidal ideation is not an adverse effect.  
(Heiligenstein, a Lilly psychiatrist, 
 as quoted in Healy, 2004, p. 151, 
 from the Wesbecker deposition) 
 
The use of antidepressants has been linked with incidences of suicide and 
violence. According to Khawam et al. (2006) and Stone et al. (2009), following 
the 2004 analysis of all FDA lodged short-term placebo-controlled antidepressant 
trials which revealed a two-fold increase in reported suicidal thoughts and 
behaviors in treatment groups over placebo in trial participants under 25, no 
significant difference in patients aged 26-65, and a minor decrease in suicidal 
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behaviors in those over 65,18 the FDA mandated a black box warning on all 
antidepressants sold in the US advising patients and doctors of the increased risk 
of suicidal thoughts and behaviors, especially when starting or stopping treatment 
or changing dose levels. Although children and adolescents were specifically 
mentioned in the 2004 warning, and young adults under 26 were added to the 
warning in 2006, the black box currently states  
“Patients of all ages who are started on antidepressant therapy 
should be monitored appropriately and observed closely for clinical 
worsening, suicidality, or unusual changes in behavior. Families and 
caregivers should be advised of the need for close observation and 
communication with the prescriber.” (FDA, 2009b). 
 
Since 1990, numerous case reports of patients developing “intense suicidal 
preoccupation” and violent fantasies following administration of antidepressants, 
especially SSRIs, have been recorded in the literature (Breggin, 2003/2004; 
Breggin, 2008; Healy & Whitaker, 2003; Liebert & Gavey, 2008). Over 3,500 
cases of suicide and/or violence involving SSRIs are documented online at 
www.ssristories.com with links to relevant media reports. In court testimony, 
Glenmullen (2007) accused pharmaceutical manufacturer GlaxoSmithKline of 
deliberately concealing the 8-fold increase in suicidal acts that occurred with 
paroxetine over placebo revealed in clinical trials19, and confidential Eli Lilly files 
                                                 
18
 Clinical trials were testing drugs primarily for efficacy, and none were designed to test for 
suicidality. Potentially suicidal participants were screened out. Nevertheless, suicidality rates of 
4% on treatment versus 2% on placebo were evident from trials (Khawam et al., 2006). This high 
placebo rate is due, at least in part, to trial patients “on placebo” actually being in a “washout” 
phase after drug use (Healy, 2004, pp. 238-241). Even higher suicidality rates were “hidden” by 
researchers who recoded “suicidal ideation” as “depression” or “no response” or who removed the 
suicidal participant from the study, a fact revealed in pharmaceutical litigation (Breggin, 2004; 
Whitaker, 2010, p. 286). 
 
19
 In an examination of 1989 clinical trial data for paroxetine obtained from GlaxoSmithKline 
under subpoena in 2007, Glenmullen found 7 completed suicides, 5 of which occurred during drug 
treatment or washout (withdrawal), and 40 attempted suicides among treatment groups. He 
accused GSK of hiding the suicide risk by allocating suicides and attempted suicides that occurred 
during drug washout periods (withdrawal) to “placebo” in the trial results supplied to the US FDA. 
Glenmullen’s report was made publicly available in January 2008. GSK has paid out an average $2 
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revealed a 1.6% incidence of hostility and 0.8% incidence of self-injury in 
fluoxetine clinical trials, figures first exposed during the much touted Joseph 
Wesbecker murder/suicide trial20 (Watkins, 2005). Although numerous analyses 
of larger data groups (post-clinical trials) have failed to definitively establish 
antidepressant causation, given the inherent risk of suicidality in untreated 
depression21 (Gunnell, Saperia, & Ashby, 2005), Healy and Whitaker (2003) 
regard it impossible to sustain a null hypothesis given the data.  
Jick, Kaye and Jick (2004) examined medical records of 159,810 
antidepressant users prescribed variously amitriptyline (TCA), fluoxetine (SSRI), 
paroxetine (SSRI) and dothiepin (TCA) and found no significant difference in risk 
of suicidal behaviors between the four drugs, although there was a non-significant 
higher rate for paroxetine; their study did not incorporate a comparative placebo 
group. They identified non-fatal suicidal behavior as 4 times more likely in the 
first 9 days after the initial prescription, and 3 times more likely in the first month 
than it was 90 days after the initiation of treatment. They also reported a higher 
risk for patients who had previously demonstrated suicidal behavior and those 
who had been prescribed one or more antidepressants at a previous time, an 
observation that was echoed by Tiihonen et al. (2006).  
Tiihonen et al.’s Finnish study of death records and hospital registers 
examined data from 15,390 patients admitted to hospital following suicide 
                                                                                                                                      
million per settlement in around 150 suicide cases, and $300,000 per settlement in around 300 
attempted suicide cases (Feeley & Kelley, 2010). 
 
20
 Wesbecker killed eight people and then himself following a brief course of Prozac; in the civil 
suit brought against Eli Lilly, the prosecution claimed that the drug company was negligent in not 
warning doctors and patients of the drug’s propensity to induce violent and suicidal acts. The drug 
company settled just prior to the jury verdict for “an astonishing sum of money”. (Healy, 2004).  
 
21
 The risk of suicide with depression is often quoted as a lifetime risk of 15%, a potentially 
misleading figure based on data from hospitalized patients diagnosed with melancholic depression 
in the 1970s, not those being treated as outpatients by primary care physicians as are most users of 
modern antidepressants (Healy & Whitaker, 2003; Simon et al., 2006; Healy, 2004, p. 98). 
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attempts and found a significantly increased risk of a severe suicide attempt 
among antidepressant users compared to non-users, but a lower overall completed 
suicide rate. A lower overall mortality rate for SSRI users was attributed primarily 
to a decrease in cardiovascular-related deaths in that group. In their study, no 
significant difference in suicide risk was observed between drug classes (e.g, 
TCAs, SSRIs, atypicals), but the specific drugs venlafaxine and paroxetine were 
associated with the highest mortality rates and unusual levels of violence. 
In a similar study, Simon, Savarino, Operskalski, & Wang (2006) 
examined computerized medical records of 65,103 patients treated with 
antidepressants and found 31 completed suicides and 76 serious suicide attempts 
during the first six months of treatment within that patient group, yielding an 
overall risk rate of roughly one in 3000 for completed suicide and one in 1000 for 
serious attempt. The group at highest risk of suicide and suicide attempt was less 
than 18 years of age, showing a risk level four times as high as that seen in adults 
in the sample. The highest risk period for suicide in the group, however, was 
during the month preceding initiation of treatment, probably because a serious 
suicide attempt is likely to prompt drug treatment. They did not find any 
difference in suicide risk between prescribed drugs. 
Studies examining general population suicide statistics with population 
antidepressant use often find that as antidepressant use goes up, overall suicide 
rates go down. In a summary of international suicide rates and antidepressant use, 
Gibbons, Hur, Bhaumik, and Mann (2005) reported a decrease in suicide rates 
with increased antidepressant use in the U.S., most of Europe, Australia, and 
Scandinavia, but the opposite effect in Japan and Iceland. Their analysis of US 
health statistics revealed a decrease in completed suicides with SSRI and atypical 
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prescriptions, but TCAs were associated with an increased suicide rate. In a later 
study, Gibbons et al. (2007) analyzed data from 226,866 veterans diagnosed with 
depression and compared suicide attempt rates between those treated with SSRIs, 
TCAs, atypicals and those who received no treatment at all and found lower 
suicide attempt rates among veterans treated with antidepressants in general, and a 
significant protective factor with SSRI use in all adult age groups with 346 suicide 
attempts per 100,000 with SSRIs compared to 1057 per 100,000 for those not 
treated with SSRIs.  
In contrast, in a sample of 57,361 New Zealand patients who received 
prescriptions for antidepressants,  Didham, McConnell, Blair and Reith (2005) 
found “significantly increased incidence rates for self harm with SSRIs as a group 
compared with TCAs”, and little difference between the SSRIs, but oddly 
concluded that self-harm and suicidal ideation were greater risk factors for suicide 
than antidepressant use. 
  In summary, it appears that SSRI use seems to lower the risk of 
completed suicide in large sample populations, but during the first few weeks or 
months of a new SSRI prescription, the risk of suicidal ideation, self harm, and 
serious suicide attempts is significant (Hall & Lucke, 2006). TCAs may or may 
not increase suicide risk, but do not seem to lessen it.  
 
Compliance 
In spite of this cornucopia of drug-induced side effects and complications, 
concerns about compliance are pervasive among prescribers (e.g., Aikens, Nease, 
& Klinkman, 2008; Akerblad, Bengtsson, Holgersson, Knorring, & Ekselius, 2008; 
Malpass et al., 2009). Liebert (2006, pp 61-68) interviewed several health 
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professionals in New Zealand who expressed concerns about antidepressant 
compliance. They explained how they modified their language and delivery of 
information to patients to deliberately play down antidepressant side effects and 
risks and enhance possible benefits, stating that patient awareness of risks created 
a barrier to treatment. Many highlighted the risks of not taking antidepressant 
medication: “Look, depression’s a terminal illness”. In her analysis, she found 
some who utilized their position of trusted authority to induce compliance while 
others saw compliance as a control issue. While iterating the importance of 
compliance, Malpass et al. (2009) acknowledge that “compliance with medication 
is not a meaningful concept from the patient’s perspective.” Although analysis of 
American healthcare insurance claims showed a significant correlation between 
antidepressant compliance and higher medication costs, no significant difference 
on other healthcare costs between compliant and non-compliant depressed patients 
was shown (Birnbaum et al., 2009), suggesting that antidepressant-compliant 
patients are not significantly healthier (or sicker) than non-compliant patients, but 
they—or their insurance companies—may be more out of pocket.  
  
Antidepressant withdrawal and drug dependency 
 Antidepressant withdrawal symptoms were first reported with the TCA 
imapramine more than fifty years ago, and are common with all antidepressants 
(Haddad, 2005). Up to 80% of patients taking amitriptyline (TCA) report 
withdrawal symptoms, and 100% report withdrawal symptoms with imapramine 
(TCA) (Haddad, 2005; Haddad & Anderson, 2007). The SSRIs are somewhat less 
likely to generate withdrawal symptoms upon discontinuation (Haddad, 2005).  
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A gradual reduction in antidepressant dose is recommended to reduce 
symptom severity (Glenmullen, 2005; Shatzberg et al., 2006). In most cases, 
withdrawal symptoms are mild and self-resolving, peaking 7-10 days after a dose 
drop and disappearing within 2-3 weeks (Glenmullen, 2005, p. 41; Haddad & 
Anderson, 2007; Fava & Offidani, 2010). If a severe reaction occurs, experts 
advise the previous dose be resumed, which quickly mitigates symptoms, and a 
more gradual taper be undertaken (Schatzberg et al., 2006). Some doctors switch 
patients from short plasma-life agents to long-life fluoxetine to create a more 
gradual withdrawal experience, although success rates utilizing this technique are 
unknown (Haddad & Anderson, 2007).  
Common TCA withdrawal symptoms include abdominal pain, diarrhoea, 
nausea, vomiting, headache, fatigue, weakness, and a general sense of malaise 
(Rosenbaum, Fava, Hoog, Ascroft, & Krebs, 1998). In a randomized clinical trial 
sponsored by Eli Lilly which employed a 5-8 day double blind placebo 
substitution in patients’ maintenance SSRI therapy, Rosenbaum et al. (1998) 
found 60% of sertraline patients (n=63) reported withdrawal symptoms on a 
Discontinuation Emergent Signs and Symptoms (DESS) checklist, as did 66% of 
paroxetine patients (n =59). In contrast, only 14% of patients on fluoxetine22 (n = 
63) reported symptoms, a result which the authors suggest may reflect fluoxetine’s 
long plasma half life of up to 6 days, as compared to sertraline (26 hours) and 
paroxetine (10-21 hours) (Rosenbaum et al., 1998). Fava, Mulroy, Alpert, 
Nierenberg and Rosenbaum (1997) reported a 78% incidence of reported 
withdrawal symptoms three days following the discontinuation of the SNRI 
                                                 
22
 This was a positive marketing result for Eli Lilly, who could use the trial as promotional 
evidence of Prozac’s unusually low withdrawal effects profile. 
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venlafaxine, which has an even shorter half-life (5-7 hours). (See Table 1, p. 16, 
for a list of drug plasma half lives). 
Withdrawal symptoms reported in Rosenbaum’s SSRI study, in order of 
report frequency, were worsened mood, irritability, agitation, dizziness, confusion, 
headache, nervousness, crying, fatigue, emotional lability23, trouble sleeping, 
abnormal dreams, anger, nausea, amnesia, sweating, depersonalization, muscle 
aches, unsteady gait, panic attacks, sore eyes, diarrhoea, shaking, muscle tension, 
and chills. A third of paroxetine and sertraline patients experienced depressive 
symptoms at a level of a major depressive episode during the placebo period. 
Three of the paroxetine patients pulled out of the study during the placebo period 
due to severity of withdrawal effects.  
 In a similar study (double blind placebo interruption of SSRI maintenance 
therapy), Michelson et al. (2000) revealed the most commonly reported 
withdrawal symptom across all drug agents was dizziness or vertigo, and the most 
severe withdrawal symptom response was associated with paroxetine: paroxetine 
patients experiencing statistically significant worsened severity of nausea, 
disturbing dreams, fatigue, irritability, unstable moods, difficulty concentrating, 
muscle aches, sleep disorders, agitation, and diarrhoea; they also experienced a 
statistically significant increase in standing heart rate during the placebo period. In 
addition, paroxetine patients reported significant deterioration in social and 
workplace interactions, while some sertraline patients reported minor deterioration 
in social function, and fluoxetine patients reported no change in social function 
during the placebo portion of the trial. Supporting Rosenbaum et al. (1998), the 
authors found a statistically significant correlation between plasma half of the 
                                                 
23
 Emotional lability refers to extreme and often unmanageable emotions or dramatic swings of 
emotion. In some clinical trials, suicidality was coded as emotional lability (Healy, 2006). 
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drug agent and severity of withdrawal response, but observed that plasma half life 
did not correlate with any particular symptoms, and further observed that plasma 
concentration of the drug may not accurately reflect brain exposure, a reminder 
that psychotropic drugs affect the whole organism. 
 Glenmullen (2005, p. 205) created a withdrawal symptom checklist for 
patients which included several items not assessed with the DESS such as 
hallucinations, self-harm, suicidal thoughts, suicide attempts, homicidal urges, 
tinnitus, electric “zap” like brain sensations, changes in appetite, abnormal sense 
of taste or smell, vomiting, stomach bloating, chest pain, tremor, restless legs, 
elevated mood (feeling high), and manic behaviours. Many of these symptoms are 
also noted by Haddad and Anderson (2007) who add to the list rare reports of 
mania, Parkinsonian symptoms, dystonia (involuntary repetitive movements) and 
akathisia. Sexual dysfunction, including anorgasmia, erectile dysfunction, and 
diminished libido are common during antidepressant use and sometimes linger 
long after discontinuation (Csoka & Shipko, 2006).  
 Although it is not clear why antidepressant withdrawal symptoms occur, 
studies suggest that sustained blockade of receptors may result in receptor 
desensitization, which in the event of withdrawal could lead to an acute 
hyposerotonergic (or other receptor) state which may also affect the 
norepinephrine and dopamine systems (Schatzberg et al., 2006). The severity of 
the paroxetine withdrawal experience is often attributed to cholinergic and well as 
serotonergic rebound (Rosenbaum et al., 1998).  
 There are numerous case reports of antidepressant withdrawal syndrome 
sometimes severe enough to discourage or prevent discontinuation of the drug. 
Fava, Bernardi, Tomba and Rafanelli (2007) reported three out of twenty 
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outpatients who discontinued their antidepressant and were still experiencing 
worsened mood, fatigue, emotional lability and sleep problems more than a month 
after discontinuation of paroxetine; one resumed the drug within a year, resolving 
symptoms. Tonks (2002) noted GlaxoSmith Kline’s acknowledgement that 
paroxetine “can cause intolerable withdrawal symptoms” and quoted Haddad 
regarding a minority of patients experiencing severe withdrawal symptoms 
“treatable only by restarting the drug.”  
An analysis of calls to a national (UK) medication helpline between 1997 
and 2005 revealed 7.8% of all calls were regarding antidepressant withdrawal, of 
which 40% were in reference to paroxetine, and 14% were in reference to 
venlafaxine (SNRI) (Taylor, Stewart, & Connolly, 2005). Websites like 
www.paxilprogress.com, a forum site for individuals withdrawing from 
paroxetine and other antidepressants, offer numerous first-hand accounts of severe 
and prolonged withdrawal experiences.  
 In semi-structured interviews with 17 patients regarding antidepressant 
withdrawal, Leydon, Rodgers, and Kendrick (2007) identified three key themes: 
concern about the benefit of continuation, fear of withdrawal symptoms and 
relapse, and the importance of the GPs role in cessation of medication. For some, 
the risks of discontinuation were identified as greater than the unknown risks of 
long-term use. 
The current Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV-TR) (APA, 2000) identifies 11 classes of substances that cause dependence: 
alcohol, amphetamines, sedatives and anxiolytics, cannabis, cocaine, 
hallucinogens, inhalants, nicotine, opioids, and phencyclidine, but not 
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antidepressants. To qualify as a dependency-causing substance, according to the 
DSM-IV-TR, the substance must elicit three or more of the following symptoms:  
• tolerance, defined as a need for increased amounts of the substance to 
achieve the desired effect;  
• withdrawal symptoms which cause psychological or physical changes that 
remits when the drug is reinstated;  
• the substance is taken for longer than was intended;  
• there is a desire to reduce or quit taking the drug but efforts to do so are 
unsuccessful; 
• time is spent obtaining the drug or recovering from its effects;  
• use of the drug affects social, occupational and/or recreational activities;  
• use of the substance is continued in spite of precipitating physical or 
psychological problems. 
Glenmullen (2005, pp 17-27) observed that antidepressant users may 
encounter any or all of these symptoms when they attempt to withdraw from the 
drug, and he observes that antidepressants clearly cause dependence in some 
patients. He believes the terms “dependence” and “addiction” in this context be 
used interchangeably. 
The concept that prescribed drugs can cause dependence at therapeutic 
doses has been controversial. The benzodiazepines demonstrated signs of 
tolerance and physical dependency upon withdrawal from high doses in numerous 
studies and case reports in the 1960s and early 1970s but the general belief among 
physicians was that patients on lower doses could continue to take the drugs safely 
and indefinitely (Lader, 1991). However, several seminal studies in the mid 1970s 
demonstrated up to 25% of long-term users of benzodiazepines showed signs of 
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physical dependency, and that withdrawal symptoms were identical regardless of 
dose size; furthermore, studies suggested withdrawal could be prolonged or 
associated with major depressive disorder (Lader, 1991). As a consequence, both 
doctors and patients became more wary of benzodiazapines. UK guidelines now 
recommend the prescribing of benzodiazepines for short-term use only (Lader, 
1991). 
The situation with antidepressants remains more controversial. Most 
pharmaceutical companies have chosen to market antidepressants as non-addictive, 
pointing out that antidepressants do not cause drug cravings in the same way that 
alcohol, nicotine, or opioids do.  Haddad & Anderson (2007), both consultants for 
pharmaceutical companies, defended the corporate claim, arguing that the 
existence of a withdrawal syndrome is not indicative of drug dependence. 
However, in response to a huge public outcry following two BBC documentaries 
on GlaxoSmithKline’s SSRI Seroxat (paroxetine) in the UK in 2002 and 2003, the 
company agreed to remove all references to non-addictiveness of the drug in their 
advertising and literature, acknowledging the claim “causes confusion” 
(Glenmullen, 2005, pp 23-27). Other pharmaceutical companies continue to hedge 
the issue. 
It seems likely that the new DSM-V, due out in 2013, will address the 
antidepressant dependency issue in some way. In a private correspondence, 
Charles O’Brian, a member of the DSM-V task force, wrote, “For DSM-V, we are 
discussing a section on neuroadaptation and discontinuation syndromes from 
prescribed medication such as opioid analgesics, SSRIs, tricyclics, 
benzodiazepines and beta blockers,” (O’Brian, 2009).  
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Chapter 4 
The Power of the Internet 
The internet has been more than a bit-player in the development of the 
antidepressant story. By the late 1990s, the internet had become a forum and 
opportunity for antidepressant users to begin to compare notes, share experiences, 
support one another, and exchange information about the mental conditions and 
drugs that had come to impact upon their lives (Cohen, 2008; Houston, Cooper & 
Ford, 2002; Medawar & Hardon, 2004). A patient-empowering tool, the internet 
also provided opportunities for patients to do their own research about conditions 
and the drugs used to treat those conditions.  
For pharmaceutical companies, mental health providers and other related 
industries and government bodies, the internet provides opportunities for access to 
potential patients, clients and customers in a way that appears direct and personal, 
but which can be handled as a mass-market, low-cost, easily-managed promotion. 
When Graber and Wedkmann (2002) examined website information given by nine 
pharmaceutical companies, they found most of the companies came up on the first 
page (first ten links) of internet searches and all company websites contained 
information that was advertorial and emotive. None of the company websites 
mentioned drug costs, only one offered efficacy statistics, adverse effects were 
minimized, and other drugs or types of therapy received minimal mention, making 
it difficult for consumers or doctors to compare drugs or make educated treatment 
choices based on company website information. Many modern drug companies 
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now include web links to government-body-authorized data sheets about the drugs 
they market. 
Not all advertorial material appears on obvious company websites, 
however. In an analysis of 50 depression websites, Wattignar and Read (2009) 
found those backed by pharmaceutical company funding—22 of the 50 
examined—were more likely to covertly espouse biomedical causes and 
treatments for depression while minimizing the possibility of psycho-social causes, 
even if specific products were not promoted; similar results were obtained in an 
analysis of PTSD sites (Mansell & Read, 2010). Examples of innocuous-sounding 
sites financially backed by drug companies include depression.com, 
mentalhelp.net, psychcentral.com, webmd.com, healthcentral.com, 
depression.com.au, and everybody.co.nz  (Wattignar & Read, 2009).  
The internet also provides access to patient groups and information for 
researchers on a variety of medical and social topics. In a one-year cohort study of 
internet depression support group use by depressed patients, Houston, Cooper and 
Ford (2002) found the median age of participants was 40 years, 42% were 
unemployed, 79% were female, 73% had at least some tertiary education, 86% 
had been treated with counselling, 96% had been treated with antidepressants, and 
23% were dissatisfied with their depression care. Sixty-two percent of participants 
had been influenced enough by their internet forum participation to query their 
doctor about their care and medication, resulting in a medication change for 26% 
of patients—proof of the power of internet group participation to influence 
medical and prescribing decisions. Although a causal relationship could not be 
drawn from their data, individuals who had more frequent contact with an internet 
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depression support group were more likely to resolve their depression symptoms 
over the year than those who had lesser contact. 
In a qualitative analysis of postings on internet message boards, Pestello 
and Davis-Berman (2008) found an interesting paradox: although prescription of 
an antidepressant implied a mental illness which led posters to refer to themselves 
as unhealthy, defective, or damaged, it also empowered posters to share their 
experiences and offer first-hand advice to others, demonstrating a good deal of 
experiential knowledge. Many posters challenged diagnoses and treatments, not 
only their own but those of other posters, and many expressed criticism of their 
physicians, claiming that their doctors often behaved with profession arrogance, 
dismissing patient concerns, experiences, and opinions. Many posters reported 
years of struggle with antidepressant medications and their symptoms, belying the 
PhRMA tenant that psychiatric medication is a reliable solution to alleviate mental 
anguish. 
Although their study focussed on antipsychotics rather than 
antidepressants, Moncrieff, Cohen and Mason (2009) utilized subjective, self-
reported comments from 439 users posted at www.askapatient.com regarding 
older antipsychotics, risperidone, and olanzapine. Quantitative and qualitative 
analyses of symptoms and comments posted on the site indicated considerable 
concern regarding sedative effects, impaired cognition, emotional flattening, 
increased anxiety and depression, akathisia and resultant suicidality, sexual 
impairment, and weight gain with all of these drugs, side effects that are likewise 
reported by some antidepressant users during treatment or during a withdrawal 
period. The authors addressed the issue of skewed results that could occur given 
self-selected reporting and possible motivation due to unusually negative 
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experiences by comparing their results to those obtained in studies based on 
questionnaire responses. They found only slightly higher rates of subjective 
adverse reporting in conventional prevalence studies than in the spontaneous 
internet reports and concluded any difference to be negligible.  
In 2008, I undertook an analysis of postings from www.paxilprogress.org 
of 24 individuals who had been off SSRI antidepressants for over six months and 
were still reporting (spontaneously on this internet forum) significant after-effects 
that they attributed to withdrawal from their antidepressant (Thrasher, 2008). Four 
of the posters had been on an antidepressant for six weeks or less; nine had taken 
antidepressants for more than nine years. Most participants had been on low or 
average doses and none had been on unusually high doses, although several had 
taken more than one psychoactive medication. Seven of the participants had been 
drug-free for more than two years. The majority had been taking paroxetine, but 
given the website name paxilprogress--Paxil is the trade name for paroxetine in 
the US--that may reflect a site bias, although paroxetine is generally considered 
the most notorious SSRI for withdrawal difficulties (Haddad, 2005). More than 
half of these posters reported increased anxiety, worsened mood or depression, 
mood swings (emotional lability), disturbing thoughts, poor stress tolerance, 
fatigue, impaired ability to concentrate and memory lapses. Fewer than 50%, but 
more than 17% reported tremor or twitching, headaches or head pain, obsessive 
thoughts, suicidal thoughts, low energy, appetite changes, panic attacks, 
agoraphobia, and impaired sexual function. None of these posters attributed 
symptoms to a return of pre-medication conditions, and most stated that symptoms 
first occurred during drug administration or upon cessation of medication. All 
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expressed surprise and concern that their symptoms of withdrawal continued to 
linger for months or years. 
The internet also provides researchers a platform for data collection, as is 
done in this study, by way of an on-line survey. 
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Chapter 5 
  
 
The Research Questions 
 
More research needs to be done which looks at the patient’s 
experience of taking psychiatric medication to further examine side 
effects and the impact of these drugs on the sense of self. Although this 
work is beginning, the complexity of taking psychiatric medications 
needs more exploration... 
(Pestello & Davis-Berman, 2008) 
 
  The aim of this study is to understand the patient’s subjective experience 
of antidepressant drug-taking and withdrawal and the role of antidepressants in 
general patient perception of health and well-being. Several recent meta-analyses 
compared results from the many clinical trials on antidepressants (Kirsch et al, 
2008; Stone et al, 2009; Fourier et al., 2010), challenging the validity of positive 
trial result perceptions and raising significant questions regarding the efficacy and 
safety of modern antidepressants. Anecdotal reports from antidepressant users on 
web forums (e.g., www.paxilprogress.org, www.drugs-forum.com, and 
www.depressionforums.org) suggest that our understanding and appreciation of 
drug side effects and withdrawal issues based on trial studies and physician-
provided adverse reaction reports may not accurately reflect what happens in “real 
life” where patients are not regularly monitored and other factors such as life 
stressors, diet, and concurrent drug intake—all part of normal living—are 
prevalent. It is likely that minor annoyances caused by the drugs routinely go 
unreported to adverse reaction bodies, and that some relatively major side effects, 
even if reported—and keeping in mind that at least 90% go unreported (MedSafe, 
2009)--may not be recognized as attributable to an antidepressant drug reaction. 
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Life, after all, is complicated.  Although it is commonly assumed that 
antidepressants enhance the lives of those individuals who take them, and that a 
potential antidepressant withdrawal syndrome at some point in the future should 
not be regarded as a detrimental factor when assessing the appropriateness of a 
prescription (Leder, 2007), these assumptions have yet to be adequately proved. 
Indeed, in discussions and interviews with 49 GPs and 15 mental health 
practitioners, Leydon and Raine (2006) found prescribers cited the implied need to 
do something that would be perceived as helpful, the limited availability of other 
treatments, and the ability to take action within the constraints of a brief 
consultation period as the primary motivations for antidepressant prescription, 
rather than any perceived belief in the effectiveness or safety of the medication. 
Many had not considered any potential harm that could be caused: “I hadn’t 
actually thought…about the side effects,” reported one mental health worker, and 
a GP commented, “I deal them out like Smarties” (Leydon & Raine, 2006). 
There have been a few studies where antidepressant users were asked 
directly about their experience with the medication. Bogner, Cahill, Frauenhoffer, 
and Barg (2009) performed a thematic study on interviews with adults over 65 
regarding their antidepressant medication and identified six major themes: 1) the 
importance of adherence to the prescription; 2) antidepressants are beneficial, but 
3) medication is just a partial fix; 4) finding the right medication is a trial-and-
error process rather than an exact science; 5) elderly patients are more vulnerable 
than younger adults; and 6) concern over the addictive nature of antidepressants. 
In another study utilising interviews, Grime and Pollock (2004) found most 
patients using antidepressants reported frustration with side effects, disconcertion 
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over the appearance of a “new self” as opposed to the “normal self” that existed 
before using antidepressants, and anxiety about difficulties in stopping the drug.  
In 2002, Vanderkooy, Kennedy and Bagby developed the Toronto Side 
Effect Scale (TSES), a frequency and severity scale of 32 symptoms associated 
with antidepressant use, and trialled it on 193 depressed patients receiving 
antidepressant treatment. Although they found individual side effect differences 
between various antidepressants (e.g., sertraline produced the most tremor and 
sweating, bupropion caused the most nervousness, paroxetine caused delayed 
ejaculation) there was no significant difference found between types of 
antidepressants regarding the total burden of side effects. Lack of a placebo group 
in their study limited any conclusion about prevalence of these side effects as a 
result of antidepressant use, but the authors advised using the TSES to increase 
antidepressant side-effect evaluation and reporting. 
Medication side effects provide the most commonly reported reason for 
antidepressant discontinuation (Zimmerman et al., 2010), a point of frustration for 
many physicians who, seeking treatment compliance (Aikens et al., 2008; 
Akerblad et al., 2008), significantly underestimate the frequency and bothersome 
nature of these side effects (Hu et al., 2004). When Zimmerman et al. (2010) 
compared the TSES results from 300 depressed psychiatric patients being treated 
with antidepressants with their medical records, they found patient reports of side 
effects on the TSES to be 20 times higher than the number of side effects noted by 
the treating psychiatrists in their records. Each of the 31 items on the TSES were 
reported by more than 10% of patients in the study, with number of symptoms 
reported M = 7.7, SD = 6.1. A quarter of those side effects were reported by 
patients as occurring often or daily. The psychiatrists in the study all reported 
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using an open-ended general question when asking patients about side effects. The 
authors suggested that use of a checklist heightens patient awareness and concerns 
about their antidepressant use and could lead to greater levels of discontinuation, 
but use of such a checklist also allows doctors to treat patients more effectively 
because they are more cognisant of problems. 
Some patients have chosen to quit taking their antidepressant medication, 
perhaps because they are feeling better, because their circumstances have changed, 
or because the side effects are too onerous—there are a variety of reasons. While 
some patients have not found that difficult, most have found quitting their 
antidepressant a short-term minor challenge, and some have found it very difficult 
indeed (Glenmullen, 2005).  For a few, getting off the drugs has become a 
handicap and goal that can dominate lives and families for many months, and 
sometimes years.24 A better understanding and appreciation of the challenges 
faced by patients unable to easily quit taking a drug, and the impact that this can 
have on families and associates, might make it easier to help those who choose to 
go through the withdrawal process in the future. 
In spite of these issues and concerns, studies assessing the role of these 
drugs and how they affect the ordinary lives of outpatient individuals who are the 
majority of antidepressant-users, are rare. In a previous unpublished study 
(Thrasher, 2008), I examined the internet postings of 24 adults who were 
experiencing prolonged withdrawal symptoms following an SSRI discontinuation 
(more than six months post-drug), but this is not a representative group of 
antidepressant users (or ex-users in this case) either. 
                                                 
24
 See www.paxilprogress.org for a sample of forum postings by just such a group. 
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 The purpose of this study was to learn more about the antidepressant 
experience by soliciting subjective responses from ordinary users, addressing a 
number of key questions: Do antidepressant users find the drugs helpful? Are side 
effects a problem? Does use of the drugs enhance or undermine quality of life for 
users? Is iatrogenic suicidality an issue? Is withdrawal a significant issue for users? 
What is the likely occurrence of severe or prolonged withdrawal symptoms? Do 
ex-users experience a long-term post-withdrawal impact? Does use of 
antidepressants alter the perception of value and effectiveness of the drugs? Given 
an opportunity to comment on their antidepressant use experience, what issues and 
themes are raised by users and ex-users? 
On one hand, this study was exploratory, and in that sense qualitative and 
bottom-up. Never-the-less, the survey itself was designed to address several 
hypotheses: 1) There is a difference in mood, symptoms, behaviours, and attitudes 
reported between groups of antidepressant users, non-users, ex-users, and those 
currently withdrawing from an antidepressant. It is anticipated that those actively 
withdrawing from a drug will experience the most—and most extreme—
alterations from health and normality, and that those who have never taken an 
antidepressant will experience the least. 2) Current antidepressant users are not 
likely to report a significant reduction in anxiety, stress, or depression, and will 
report some side effects. Nevertheless, current users may feel the drugs are helpful. 
(If they didn’t, one surmises, they wouldn’t still be taking them.) 3) Some of the 
participants who used antidepressants in the past will report experiencing long-
term negative effects from their drug use. 4) Responses to some individual items 
will be of particular note such as feeling suicidal, weight changes, and emotional 
flattening.  
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Chapter 6 
Method  
 Study Design 
 According to Johnson and Onwuegbuzie (2004), quantitative research is 
based on deduction, hypothesis testing, prediction, data collection, and statistical 
analysis—the epitome of the scientific paradigm—to reach a numbers-based 
conclusion that can be generalized to the wider case. Qualitative research, on the 
other hand, utilises induction, discovery, hypothesis generation, and qualitative 
analysis for a more open and in-depth study of a complex phenomena. Both 
paradigms used together, often called a mixed-methods study, can provide insight 
into broader research questions through convergence and collaboration of findings 
(Johnson & Onwuegbuzie, 2004).  
This is a mixed-methods study, combining statistical data and subjective 
reports from antidepressant users and ex-users, along with a “baseline” group of 
participants who have never used antidepressants. The study endeavoured to 
explore antidepressant use and withdrawal through the reported experiences of 
four different groups of participants: those who are currently using antidepressants, 
those who are currently withdrawing from an antidepressant, those who used to 
take an antidepressant but who no longer do so, and a “control group” of 
individuals who have never taken an antidepressant or other prescription 
psychotropic drug. 
All participants completed a survey about their own antidepressant use 
with most responses reported on 5- or 6-step Likert scales (ultimately, a subjective 
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quantification of a qualitative measure [Jick, 1979]), followed by an open-ended 
opportunity to add additional comments, providing an opportunity to explore a 
single issue through two different types of data from the same group of 
participants. Participation was completely anonymous. 
Based on side effects and withdrawal symptoms noted in previous studies 
and symptom checklists like the DESS (Rosenbaum et al., 1998), TSES 
(Vanderkooy et al., 2002) and Glenmullen’s antidepressant withdrawal checklist 
(Glenmullen 2005, p. 205) and withdrawal symptoms reported in Thrasher 
(2008)25, an anonymous on-line survey was designed to test participant well-being, 
symptomology, and perceived changes between medicated and un-medicated 
states, and giving them an opportunity to add additional comments. This 
combination of quantifiable and qualitative data provided the basis for a mixed-
methods analysis to elicit insight into the experience of antidepressant users 
within a naturalistic, “real-life” setting. 
Following a first reading of the comments to get a feel for the general 
trends of thought and identify any potential problems with the quantitative survey 
data that might become apparent from the comments, a quantitative analysis of the 
survey data was undertaken. This was followed by a thematic analysis of the 
comments. 
                  
Survey Design 
All participation was voluntary and anonymous; no information was 
collected that could be linked back to a specific participant.  
                                                 
25
 Items identified in Thrasher (2008) and not included on the TSES, DESS, or Glenmullen’s 
checklist but included in this survey were an increased need for sleep, emotional flattening, body 
pain, head or facial pain (not headache), food and/or chemical sensitivity, impaired judgement, and 
bladder or urinary problems. 
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The initial section of the survey gathered demographic data (sex, age 
group, country of origin, medication and dosage[s] as applicable, reason for 
prescription, length of time on drug and [where applicable] time since withdrawal, 
and co-prescribed drugs), and also a likert-type question to establish the 
participant’s overall attitude towards antidepressants. This section was followed 
by 21 6-point likert-type questions regarding mood to evaluate the level of 
depression experienced by the participant at the time of filling out the survey. This 
section incorporated all five questions from the WHO-5 well-being index 
(Newnham, Hooke, & Page, 2010) and some questions from the Major ICD-10 
Depression Inventory (MDI) (Bech, Rasmussen, Olsen, Noerholm, & Abildgaard,  
2001); the remainder of the MDI questions were placed elsewhere in the survey 
such as those asking about increased or decreased appetite and sleep issues (put 
under symptoms). Several additional questions were incorporated into this mood 
section such as “I have felt like I wanted to harm someone else” and “I have had 
mood swings” which were based on previous literature as possibly linked to 
antidepressant use. Because there were more negatively-worded questions than 
positively-worded questions, some statements were reversed to create a balanced 
range of statements. Typical questions were “I have felt calm and relaxed” (from 
the WHO-5) and “I have had difficulty concentrating”26 (from the MDI).  
The WHO-5 well-being index is recommended by the World Health 
Organisation as a quick initial screen for depression, and compares well with other 
depression screening instruments (Löwe et al., 2004; Newnham et al., 2010). It 
consists of 5 6-point Likert questions like “I have felt cheerful and in good spirits” 
assessed on a 25-point scale (“at no time” counts as zero). Scores are added up, 
                                                 
26
  The actual initial wording in the MDI is “Have you…” suggesting the questions are being asked 
by someone else. Since this survey is a self-report, MDI questions were reworded with an initial  
“I”. 
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and a score below 13 is considered indicative of depression risk (Psychiatric 
Research Unit, ND). The MDI functions as a simple, widely-accepted, brief self-
rating 6-point Likert-scale instrument for diagnosis of depression that when 
compared with the DSM-IV and the WHO’s Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) criteria, gives a 0.90 sensitivity score sufficient for 
evaluating levels of depression (Bech et al., 2001).  
The next section of the survey consisted of a list of 37 antidepressant side 
effect and withdrawal symptoms based on those reported and assessed by 
Rosenbaum et al. (1998), Vanderkooy et al. (2002), and Glenmullen (2005) as 
well as additional items highlighted by Thrasher (2008). Using the format of the 
TSES (Vanderkooy et al., 2002), participants rated frequency of each symptom 
during the past two weeks on a 5-point Likert scale from “never” to “all the time”. 
If a symptom had been experienced, participants were asked to rate the severity of 
the symptom on a 5-point Likert scale from “very minor” to “very severe”. 
Examples of symptoms included nausea, chest pain, dizziness, fatigue, and 
insomnia. Participants were also asked about weight gain or loss. 
 The fourth section on emotion and behaviour asked participants to 
compare their current likelihood of feeling or behaving in a certain way to how 
they would have done so in the past (e.g., on medication now compared to before 
being on medication). Items were rated on a 5-point Likert scale from “much more 
likely to” to “much less likely to”. Typical items included “act impulsively,” 
“worry about things,” and “show affection,” and were based on anecdotal reports 
(e.g., Breggin, 2008), loosely-related research papers (e.g., Goodman, Murphy & 
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Storch, 2007, Harmer, 2008)27 and on-line forums. This author is not aware of any 
studies which have examined self-reported behavioural or emotional changes 
among antidepressant users. 
A final section gave participants the opportunity to add any additional 
information about the survey, their experience, or their thoughts on 
antidepressants. None of the questions in the survey were compulsory. 
Following approval by the Victoria University of Wellington School of 
Psychology Human Ethics Committee (SoPHEC) the survey (Appendix A) was 
posted on www.surveymonkey.com, a web-based survey tool.  
 
Participants 
Participants were recruited over a 5-month period through a variety of 
methods including local posters inviting participation, local residential letterbox 
drops, invitations to participate on internet forums28, and email notifications to 
friends and colleagues who might be willing to participate or pass on the link to 
someone who would. Clearly, this is much more of a shotgun snowball approach 
than random sampling, but the difficulties of recruiting participants through more 
“official” channels such as doctors or public mental health providers, given patient 
confidentiality policies, are not insignificant (Pestello & Davis-Berman, 2008). 
Extrapolating results from this study to the general population must be done with 
the caveat in mind that a bias towards greater reporting of adverse reactions could 
                                                 
27
 The former paper examines concerns over the activation of aggressive and suicidal tendencies in 
1-3% of youths prescribed antidepressants, and the second  speculates on  alterations in emotional 
processing caused by serotonin enhancers. 
 
28
 This proved more difficult than anticipated with most forum administrators refusing to allow a 
link to the survey. Links were posted at www.drugs-forum.com, www.beyondblue.org.au, 
www.paxilprogress.org, and www.quitpaxil.info, although the latter link was not posted on line 
until a week before the final download of data from the survey. 
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exist given self-selective participation and the use of a survey in the form of a 
checklist (Moncrieff et al., 2009; Zimmerman et al, 2010). Participants received 
no payment or reward for participation, but were invited to send email details for 
notification of study results at the completion of the project if interested. Fifty 
participants requested such notification. 
 
Analytic Strategy 
The analytic strategy for this study was to integrate both hypothesis testing 
and hypothesis generation. Initially, demographic data was assessed and 
categorized.  This was followed by an initial reading of comments in response to 
the final survey prompt: “If there is anything else you would like to add about 
your antidepressant experience, or about this survey, please share your comments 
in the box below.”  An initial quantitative analysis was then undertaken to 
compare groups on the mood data, frequency and severity of symptoms, and 
examine participant perception of drug effects reflected in their perceived 
behaviour and mood changes between “then” and “now.”  SPSS 16.0 was used for 
all of the statistical data analysis in this research. Finally, comments at the end of 
the survey were coded and a thematic analysis was undertaken to identify 
recurring issues. 
Two issues were raised by the comments regarding the quantitative 
analysis. It became clear that many of the “current users” had, in fact, changed 
their prescription or dose recently, suggesting that this group lacked uniformity. 
Although treated as a single group in the initial analysis, the group was also split 
into “stable” and “unstable” users based on the survey question “Have you 
changed your antidepressant or dose in the past three months?” to identify any 
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significant differences within that subgroup. It also became clear from the 
comments that many of those in the “ex-user” group continued to suffer from 
what they perceived as withdrawal more than 2 months following complete drug 
cessation. Because no specific question allowed an easy split of this group into 
“stable” and “unstable” factions, following the initial general group comparison 
analysis, comments were assessed to identify those ex-user participants who chose 
to report ongoing health issues they ascribed to antidepressant drug use or 
withdrawal. Although not an ideal method for splitting the group, it was felt that 
an assessment of any statistically significant differences between these two sub- 
groups would increase understanding and expand the relatively meagre existing 
literature regarding the prolonged antidepressant withdrawal experience and help 
to illustrate the kinds of effects that might be residual in those individuals 
sensitive to a prolonged withdrawal syndrome.  
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Chapter 7 
Results I 
The Quantitative Analysis 
The survey was completed by 509 participants. No questions were 
compulsory, and data from participants who did not complete more than half of 
the survey were not included in the analysis. Missing data for individual questions 
throughout this study were excluded analysis by analysis, such that a missing 
response to one item did not preclude analysis of that participant’s responses to 
other items. 
 
Demographics 
Sex, age, information about drug types taken and duration of medication 
time within each group (current users, actively withdrawing from antidepressants, 
ex-users, and never used) are presented in Table 2.  
Depression was the most common self-reported diagnosis or reason 
reported for the antidepressant prescription (212 participants), and anxiety came a 
fairly close second (176), plus another 10 participants specifically reported GAD. 
Panic disorder (53) was also commonly reported, along with OCD (19), social 
phobia/anxiety (16), PTSD (12), insomnia (12), stress (11), and post-natal 
depression (10). As noted in Chapter 2, antidepressants are approved treatment for 
a variety of anxiety disorders as well as depression. Many participants reported 
more than one cause for the prescription (e.g., “depression, anxiety and mild 
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OCD”), and 20 offered reasons or qualifiers (e.g., “going through a stressful life 
period” and “situational depression due to family death”). 
Table 2. Participant group profiles showing number of participants in each category. 
Several participants reported taking more than one antidepressant. Non-antidepressant 
medication included contraceptives, gastric reflux medication (two most commonly reported) 
as well as mood-altering drugs including sleeping medications, benzodiazepines, Lamictal, 
Depakote, lithium, quetiapine, buspirone and dextroamphetamine29. 
 
 Current 
users  
(n = 176) 
Withdrawing  
(n = 181) 
Ex-users  
(n = 108) 
Never 
used  
(n = 44) 
 
Sex 
   Male 
   Female 
 
Age 
   <20 
   20-39 
   40-60 
   >60 
 
Time on antidepressants 
   <3 months 
   3-12 months 
   1-3 years 
   3-8 years 
   >8 years 
 
Drug type taken 
SSRI (eg. paroxetine, fluoxetine) 
 
48 (27%) 
128 (73%) 
 
 
10 (6%) 
105 (60%) 
47 (27%) 
13 (7%) 
 
 
13 (7%) 
28 (16%) 
30 (17%) 
43 (25%) 
62 (35%) 
 
 
139 (79%) 
 
45 (25%) 
136 (75%) 
 
 
6 (3%) 
99 (55%) 
64 (35%) 
12 (7%) 
 
 
6 (3%) 
35 (19%) 
34 (19%) 
49 (27%) 
57 (32%) 
 
 
174 (96%) 
 
29 (27%) 
79 (73%) 
 
 
4 (4%) 
59 (55%) 
39 (36%) 
5 (5%) 
 
 
11 (10%) 
30 (28%) 
28 (26%) 
17 (16%) 
21 (20%) 
 
 
89 (82%) 
 
16 (36%) 
28 (64%) 
 
 
1 (3%) 
27 (61%) 
12 (27%) 
4 (9%) 
SNRI (eg. venlafaxine) 20 (11%) 6 (3%) 16 (15%)  
NDRI (e.g. bupropion) 16 (9%) 3 (2%) 1 (1%)  
TCA (e.g. imipramine) 6 (3%) (0%) 3 (3%)  
Other (e.g. mirtazapine, 
trazodone) 
9 (5%) 3 (2%) 24 (22%)  
Taking more than one AD 13 (7%) 10 (6%) 16 (15%)  
Concurrent non-AD medication 91 (52%) 24 (13%) 36 (33%) 15 (34%) 
 
 
Other reasons given for antidepressant prescriptions included suicidal 
ideation (8), bipolar (7), low mood or sadness (7), PMS/PMDD (5), pain relief (4), 
                                                 
29
 Both lithium and quetiapine are approved by the US FDA as antidepressant augmentation for 
drug-resistant depression, and benzodiazepines were used in some SSRI clinical trials to quell 
iatrogenic agitation as noted earlier in this thesis. Lamictal (lamotrigine) and Depakote (valproic 
acid) are anti-seizure medications sometimes used for treating the manic phase within a bipolar 
disorder; buspirone is an anti-anxiety drug; dextroamphetamine is used for treatment of ADHD. 
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irritable bowel syndrome (4), and anger management (4). A few participants said 
their antidepressant prescription was to help them deal with the side effects of 
other drugs, e.g., “for insomnia caused by other medications”. Diagnoses 
including Seasonal Affective Disorder, menopausal symptoms, anorexia nervosa, 
ADHD, chronic fatigue syndrome, and fibromyalgia were cited by fewer than 3 
participants. Seven participants stated that they did not know why they had been 
prescribed antidepressants. 
Some interesting things to note in general about participants in this study 
(Table 2): Although varying in size, the groups are roughly comparable in terms 
of sex and age: when a chi-square analysis for sex was conducted, no significant 
difference was found between groups, and results of an ANOVA for age likewise 
revealed no significant difference between groups. Almost three-quarters of 
respondents were women, which is not unrealistic given women are twice as 
likely to be prescribed psychotropic drugs as men (Currie, 2005; Ussher, 2010). 
The most common age-range in all four groups was 20-39. The majority of 
antidepressants used by participants in this study were SSRIs, not surprising given 
the dominance of SSRIs in the modern pharmaceutical market (Table 1, p. 16). 
More than a quarter of participants, not including the never-used group, had taken 
antidepressants for more than eight years.  
Of the 108 participants who used to take antidepressants, four could not 
remember what drug(s) they had taken. The majority of this group (67%) reported 
no prescription drug use now, but of those that did, 14% reported regular or 
occasional use of a benzodiazepine. Thirty percent of this group had been off their 
antidepressant for less than a year (but more than 2 months), 37% had been off for 
1-3 years; 20% had been off the medication for 3-5 years, and 13% had been off 
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antidepressants for over five years. Regarding the use of other mood-altering 
medications such as benzodiazepines co-prescribed with antidepressants, some 
participants commented that these drugs helped them cope with antidepressant 
side-effects or withdrawal symptoms. 
Forty-four percent of participants withdrawing from their antidepressant 
reported 2-5 attempts to stop taking it, and 10% reported more than 5 attempts to 
do so. Current users were not asked this question, but many reported in their 
comments at the end of the survey about unsuccessful attempts to withdraw from 
the drug. Of those currently withdrawing and ex-users, 42% reported an abrupt 
stopping (cold turkey), 30% reported taking less than 3 months to taper the drug, 
14% reported taking 3-5 months, 6% took 6-12 months, and 8% reported spending 
over a year tapering off their antidepressant.  
 
Perceived helpfulness of antidepressants 
Participants were asked how helpful they believed antidepressants to 
be in general, with a Likert score of 6 being “very helpful” and a score of 1 
being “very harmful”.   Results of a one-way ANOVA between participant 
groups are shown in Table 3. A significant difference was found between 
groups, except between those withdrawing and the never-used groups 
regarding antidepressants “in general”, based on Tukey-Kramer post hoc 
tests. Current users expressed the most positive attitude towards 
antidepressants in general and personally, with the highest mean group 
scores, while ex-users expressed the least positive attitude with the lowest 
mean group scores. In all three user groups, the evaluation of personal 
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Table 3. Attitude towards antidepressants: Mean based on a Likert scale where 6 = “very helpful” and 1 = “very harmful”. 3.5 is the neutral point. 
ANOVA results show a significant difference between groups; a Tukey-Kramer post hoc analysis supports a significant difference between all groups 
except between participants withdrawing and those who have never taken antidepressants on the “in general” question.  
 
 
Attitude towards ADs  Current users  AD withdrawal  Ex-users  Never used  F  
    N = 176   N = 179   N = 108   N = 42 
 
    M SD  M SD  M SD  M SD 
 
I believe that antidepressants 
In general are…   4.77 0.97  4.27 1.42  3.14 1.80  3.76 1.27  F(3, 501) = 33.44*** 
 
For me, the antidepressant(s) 
I am taking is/are  4.73 1.15  3.99 1.65  3.07 1.86     F(2, 458) =38.71***
  
*** significant at p < .001     
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antidepressant experience was lower (less helpful) than the belief of 
antidepressant value in general. 
 
Mental health and mood 
Following the demographic data, the survey fell into three data 
segments followed by the opportunity to leave comments. The first data 
segment contained 21 statements about mood.  
 
WHO-5 well-being survey. 
The five items that comprise the WHO-5 well-being questionnaire 
were extracted from the mood data and, following establishment of normal 
distribution between groups, a between-subject groups ANOVA was 
conducted on the scores. Results are reported in Table 4.  
A significant difference was found between groups, although a 
Tukey-Kramer post hoc test established no significant difference between 
group means for current users and ex-users. The means for all three 
antidepressant-experienced groups, however, fell below 13. The WHO 
advises that a raw score below 13 is indicative of poor well-being and 
indicative of possible depression. Participants in the currently-withdrawing 
group reported the lowest mean. Although one cannot attribute use of 
antidepressants as a cause of low WHO-5 scores, these results suggest that 
neither use of antidepressants, nor withdrawal from them, are adequate 
interventions to establish a normal state of well-being. 
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Table 4. WHO-5 Well-being assessment. The WHO advises that a raw score below 13 indicates a poor level of well-being and possible depression. 
ANOVA results demonstrated a significant difference between groups. A Tukey-Kramer post hoc test found no significant difference between current 
users and ex-users, but all other group differences were significant. 
  
 
    Current users  AD withdrawal  Ex-users  Never used  F  
    N = 176   N = 179   N = 108   N = 42 
 
    M SD  M SD  M SD  M SD 
 
WHO-5 survey results  11.05 4.54  9.76 4.18  11.38 5.21  15.34 3.63  F(3, 493) = 18.47*** 
 
  
*** significant at p < .001     
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The US FDA warns that clinical worsening and suicidality may 
occur at times of dose changes, either increases or decreases, as well as 
during early treatment (FDA, 2009b). To test this, the current user group 
participants were asked if they had altered their dose up or down, or 
changed their medication within the past two months. 42% had done so. To 
test if dose stability was reflected in WHO-5 results, an independent 
samples t-test was run comparing those antidepressant users on stable doses 
with those who had recently changed their dose. No significant effect was 
found between these two subgroups. 
 
Complete set of mood items. 
In the interests of data management and to provide a usable summary of 
the complete mood data set, an exploratory principal components analysis of the 
21 mood items in the survey was undertaken. A KMO of .94 and small residuals 
indicated a strong level of factorability. Initial analysis yielded four factors with 
eigenvalues greater than 1, explaining 43.2%, 10.7%, 6.4%, and 4.8% of the 
variance respectively; three or four principle components were evident from the 
scree plot. A reasonably high factor correlation between the second and third 
component of .45 suggested an Oblimin rotation would be more appropriate than 
Varimax, which assumes factors to be uncorrelated (Pallant, 2005, p. 185). A 
three-component solution was chosen as more succinct, with factors of “positive 
energy”, “agitation”, and “aggressive depressive” all showing a number of strong 
loadings. Results are shown in Table 5. All component loadings over .30 are 
shown in bold. Cross-loadings occur for “feeling calm” for positive energy and 
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agitation, and for “sad” for positive energy and life sucks; “agoraphobia” loads at 
a similar level in all three categories. Percent of variance attributable to each 
factor cannot be calculated if components are correlated.  
Table 5. Summary of exploratory components extraction analysis for mood 
question—pattern matrix, Oblimin rotation converged in 13 iterations. (N = 509).   
 
 
       Factor Loadings 
 
Item    Positive Energy  Agitation Aggressive/ 
         Depressive 
 
Feeling Energetic   -.89  -.01  .07 
Feeling Vigorous   -.83  .08  .04 
Feeling Fantastic   -.78  -.10  -.10 
Wake feeling refreshed   -.73  -.20  .17 
Feel self-confident   -.69  .07  -.04 
Feel interested in life   -.65  .09  -.28 
Feel cheerful    -.64  -.08  -.31 
Feel subdued    .38  .30  .06 
Mind is racing    -.25  .88  -.25 
Feeling restless    -.09  .76  .04 
Feeling agitated    .10  .73  .10 
Experiencing mood swings  .03  .72  .06 
Feeling anxious    .17  .67  .07 
Having difficulty concentrating  .30  .61  -.05 
Feeling calm    -.44  -.50  -.00 
Feeling angry    .09  .43  .31 
Agoraphobia (fear of going out)  .31  .32  .28 
Suicidal or self-harm feelings  .02  .00  .83 
Feeling homicidal (harm others)  -.19  .07  .76 
Feel like life is not worth living  .23  .03  .72 
Feel sad    .32  .17  .51 
 
Cronbach’s Alpha for component .90  .89  .80 
          
Note: Factor loadings over .31 appear in bold.  
 
Regression factor scores generated by SPSS were used to undertake a one-
way multivariate analysis (MANOVA) between subject groups to examine the 
effect of drug use and/or withdrawal/history on mood. A significant effect 
between groups was observed (Wilks’ λ = .83, F(3, 455) = 9.46, p < .001) for the 
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first two components:  “positive energy,” F(3, 455) = 15.89, p < .001 and 
“agitation,” F(3, 455) = 18.43, p < .001. Post hoc comparisons using the Tukey-
Kramer test for “positive energy” indicated that the mean score for participants 
who had never taken antidepressants (M = -.93, SD = .74) was significantly 
different (p < .001) from the other three groups, but those groups were not 
significantly different from each other (current users, M  = -.02, SD = .93; 
currently withdrawing, M = .23, SD = .93; ex-users, M = -.02, SD = 1.12). Post 
hoc comparisons using the Tukey-Kramer30 test for “agitation” indicated that the 
mean scores for current users (M = -.14, SD = .93) and ex-users (M = -.28, SD 
= .96) were not significantly different, but participants currently withdrawing (M 
= .37, SD = 1.00) scored significantly higher on this factor than the other three 
groups (p < .001), and those who had never taken antidepressants (M = -.65, SD 
= .62) scored significantly lower than those withdrawing (p < .001) and current 
users (p <.05). No significant difference was found between groups on the 
aggressive/depressive factor. 
In summary, those who have never used antidepressants appear to have 
significantly more positive moods than the three antidepressant-experienced 
groups, and participants withdrawing from their antidepressants have a 
significantly greater degree of anxiety and agitation than the other groups.  
 Results from a multivariate ANOVA comparing stable-dose and unstable-
dose user subgroups found a significant effect between groups, F (1, 166) = 2.76, 
p < .05, Wilks’ λ = .95 with a significant difference between the subgroups on the 
aggressive/depressive component, F(1, 166) = 7.48, p < .01 with the unstable 
subgroup (M = .19, SD = 1.09) scoring significantly higher on this component 
                                                 
30
 All calculations were done on SPSS which automatically converts the Tukey HSD post hoc test 
to the more conservative Tukey-Kramer in the event of uneven group sizes (Newsom, 2006) 
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than the stable subgroup (M = -24, SD = .89), suggesting antidepressant users who 
have recently increased or decreased their dose, or changed to a different 
antidepressant, are significantly more likely to harbour aggressive and depressive 
(including suicidal and/or homicidal) feelings than their counterparts on more 
stable doses. This supports the FDA warning regarding increased risk of 
suicidality, aggressiveness and hostility that may occur during dose adjustment 
(FDA, 2009b). No difference was found between these two subgroups on the other 
two mood components. 
 
Symptoms 
The terms “side effects” and “symptoms” have been used somewhat 
interchangeably within this thesis. MedTerms (2000) defines “side effects” 
as “problems that occur in addition to the desired therapeutic effect,” while 
symptom is defined as “subjective evidence of disease” (MedTerms, 2003b). 
When describing withdrawal effects, most researchers refer to them as 
symptoms (e.g., Vanderkooy et al, 2002; Rosenbaum et al 1998; Glenmullen, 
2005) even though they are essentially the side effects of a therapy 
manipulation. Complicating the issue with antidepressants is the overlap 
between disease symptoms such as anxiety, insomnia, fatigue, and changes 
in appetite which are common markers of depression (APA, 2000), 
recognized side effects of the drugs (see Chapter 3), and symptoms of 
withdrawal (Chapter 3). Taking a semantic approach with “disease” defined 
as “illness or sickness often characterized by patient problems (symptoms)” 
(Medterms, 1998b), and following the lead of other researchers examining 
withdrawal, I have chosen to use the word “symptoms” whether referring to 
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primary symptoms of illness, patient problems caused by drug side effects, 
and patient problems caused by therapy manipulation such as drug 
withdrawal. The purpose of the symptom analysis in this study is to identify 
any significant difference in frequency and intensity of experienced 
symptoms and types of symptoms between antidepressant users, those in the 
throes of drug withdrawal, and those who have been off antidepressant 
medication for at least two months, and to compare those results with survey 
participants who have never taken antidepressants.  
In the survey, participants were asked to identify the frequency 
during the past fortnight, if any, of 37 different symptoms that have been 
associated with antidepressant use or withdrawal, and to evaluate the 
severity of any experienced symptoms. Symptom frequency was rated on a 
scale of 1 (have not experienced this symptom within the past two weeks) to 
5 (have experienced this symptom constantly within the past two weeks), 
and severity on a scale from 1 (very minor) to 5 (very severe) where 3 is 
“impacts upon daily routine”.   
An assessment of the raw data revealed some issues which were 
corrected prior to analysis. In cases where a participant recorded no “1’s” 
for frequency (didn’t experience) for some symptoms but had filled in 
scores of 2-5 for other symptoms, frequency blanks were re-coded with “1” 
(didn’t experience) as a default value. Several participants did not enter a 
severity value for any items. In all cases where frequency was coded as 1 
(didn’t experience), severity was coded as 0 (no severity). If a frequency 
other than “1” (didn’t experience) was indicated, the item group mean was 
used for the severity value. Following these data adjustments, the score for 
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frequency was added to the score for severity, yielding a combined score 
range of 1-10. This means, of course, that a participant who experienced a 
very mild symptom often might score 5 overall, the same as a participant 
who experienced a severe symptom briefly.  
An exploratory principle component analysis of symptoms was 
attempted which yielded 9 components showing eigenvalues greater than 1, 
but 8 of those components each accounted for less than 5% of variance, and 
35 of the 37 symptoms showed a principle loading on the first component31.   
A general picture of the overall symptom experience between groups was 
examined briefly by performing a one way between subjects ANOVA on the 
single extracted factor, which showed a significant difference between 
groups, F(3, 449) = 24.75, p < .001. Although a Tukey-Kramer post hoc 
examination showed no significant difference in overall symptom loading 
between antidepressant users (M = -.07, SD = .84) and ex-users (M = -.04, 
SD = 1.17), a significantly higher frequency/severity of symptoms was 
found for the withdrawal group (M = .39, SD = .92) compared to the other 
three groups, and a significantly lower frequency/severity of symptoms for 
the untreated group (M = -1.00, SD = .44).  
To explore in greater detail the role of individual symptoms and 
identify symptom experience changes that might occur as participants 
journey from users through withdrawal to ex-users, and to compare those 
results with the experience of never-used participants, a one-way 
multivariate analysis (MANOVA) between subject groups was employed on 
the frequency plus severity for all of the symptoms, and a significant effect 
                                                 
31
 The two exceptions were increased appetite and increased libido.  
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between groups was observed, F(3, 450) = 3.21, p < .001, Wilks’ λ = .469, 
partial eta squared = .223.  Only 2 of the 37 symptoms, “rash” and “suicidal 
ideation,” did not reveal a significant difference between groups. Results of 
this analysis are reported in Table 6.  Post hoc comparisons of symptom 
results between groups using the Tukey-Kramer test are also reported in 
Table 6. The lack of any identifiably significant difference between any two 
groups for body pain, based on post hoc results, is attributed to 
compensation for the uneven group sizes through use of the relatively 
conservative Tukey-Kramer post hoc test. 
With all symptoms except “increased libido”, the control group 
(having never used antidepressants or other prescribed psychoactive drugs) 
reported the lowest mean score (lowest frequency plus severity), and those 
actively withdrawing from antidepressants reported the highest mean scores 
for the majority of symptoms; however, the current user group recorded the 
highest mean scores for constipation, increased appetite, and decreased 
libido, and the ex-users group reported the highest mean scores for chest 
pain, food and chemical sensitivity, and tinnitus.  
All groups recorded their highest symptom frequency/severity score 
for fatigue. Current users and those in withdrawal both rated an increased 
need for sleep as second, while ex-users and those who had never used 
antidepressants rated nervousness as the second most onerous symptom they 
experienced. Decreased libido ranked third for both current users and ex-
users, while those in withdrawal put nervousness in third place and those 
who had never used antidepressants put insomnia third.
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Table 6. Group mean, standard deviation and MANOVA results for symptoms demonstrating a significant effect between groups. Scores reflect 
symptom frequency range between 1 (haven’t experience this symptom in the past two weeks) to 5 (experience this symptom constantly) PLUS severity 
range between 1 (very minor) to 5 (very severe), with 3 defined as “moderate, impacts upon daily routine”. If F = 1, then S = 0. Subscripts indicate Tukey-
Kramer post hoc comparisons, p < .05: a—significantly different from current user group; b—significantly different from currently withdrawing group; c—
significantly different from ex-user group; d—significantly different from never used group. Items are listed by highest reported mean in any group (bold). 
 
Symptom   Current users  AD withdrawal  Ex-users  Never used  F  
    n = 158   n = 158   n = 99   n = 38 
 
    M SD  M SD  M SD  M SD 
 
Fatigue    5.40d 2.19  5.75cd 2.32  4.85bd 2.54  3.10abc 1.65  F(3, 450) = 14.96*** 
Increased need for sleep 5.06cd 2.62  5.09cd 2.61  3.72ab 2.53  2.66ab 1.96  F(3, 450) = 14.82*** 
Decreased libido  4.85d 1.10  4.25d 3.08  4.27d 3.10  1.65abc 1.46  F(3, 450) = 11.29*** 
Nervousness   4.08bd 2.14  4.84ad 2.06  4.40d 2.15  2.97abc 1.57  F(3, 450) = 9.40*** 
Dizziness, vertigo  3.19bd 1.94  4.82acd 2.44  2.83b 2.15  2.00ab 1.25  F(3, 450) = 30.61*** 
Agitation   3.70bd 1.95  4.70acd 2.13  3.85cd 2.19  2.71abc 1.58  F(3, 450) = 12.68*** 
Disturbing dreams  3.48bd 2.32  4.52acd 2.82  3.06b 2.18  1.89ab 1.25  F(3, 450) = 15.84*** 
Headache   3.61bd 2.02  4.49ad 2.36  3.83d 2.35  2.37abc 1.68  F(3, 450) = 10.89*** 
Insomnia   4.08d 2.47  4.43d 2.66  4.25d 2.73  2.79abc 1.89  F(3, 450) = 4.33** 
Excessive sweating  3.60cd 2.48  4.06cd 2.37  2.48ab 1.94  1.53ab 1.10  F(3, 450) = 19.18*** 
Weakness   3.25bd 2.09  4.04acd 2.42  3.26bd 2.56  1.66abc 1.19  F(3, 450) = 12.09*** 
Nausea    2.67bd 2.05  3.85acd 2.41  2.38b 2.04  1.63ab 1.20  F(3, 450) = 18.64*** 
Emotional flattening  3.46d 2.50  3.55d 2.39  3.80d 2.93  1.84abc 1.42  F(3, 450) = 5.99** 
Excessive thirst   3.58d 2.36  3.77cd 2.23  2.86b 2.17  2.45ab 1.74  F(3, 450) = 6.05*** 
Body pain   3.17 2.28  3.69 2.42  3.56 2.28  2.68 1.69  F(3, 450) = 2.76* 
 
* Significant at p < .05; ** significant at p < .01; *** significant at p < .001     
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Symptom   Current users  AD withdrawal  Ex-users  Never used  F  
    N = 158   N = 158   N = 99   N = 38 
 
    M SD  M SD  M SD  M SD 
 
 
Brain zaps   2.22b 2.06  3.66acd 2.89  1.84b 1.72  1.32b 1.12  F(3, 450) = 20.79*** 
Panic attacks   3.05d 2.36  3.47d 2.34  2.84d 2.26  1.16abc 0.71  F(3, 450) = 11.06*** 
Increased appetite  3.41cd 2.36  2.84 2.15  2.58 1.87a  2.21d 1.63  F(3, 450) = 5.18** 
Diarrhoea   2.59b 1.91  3.41acd 2.30  2.62b 1.98  1.82b 1.43  F(3, 450) = 8.42** 
Reduced appetite  2.75d 2.30  3.32d 2.29  2.63 2.25  1.66ab 1.15  F(3, 450) = 6.43*** 
Dry mouth   2.91d 2.02  3.18d 2.25  2.66 2.31  1.79ab 1.34  F(3, 450) = 4.78** 
Vision abnormalities  2.19b 1.79  3.10ad 2.22  2.75d 2.38  1.29bc 0.87  F(3, 450) = 10.64*** 
Food or chemical sensitivity 2.25c 2.15  2.53 2.45  3.04ad 2.86  1.74c 1.43  F(3, 450) = 3.58* 
Tinnitus    2.18bc 2.01  2.96ad 2.34  3.01ad 2.40  1.87bc 1.53  F(3, 450) = 5.93** 
Abdominal pain   2.70d 2.05  2.96d 2.16  2.85d 2.26  1.63abc 1.96  F(3, 450) = 4.27** 
Head or facial pain  1.90b 1.52  2.94ad 2.23  2.52d 2.18  1.52bc 1.43  F(3, 450) = 10.36*** 
Impaired judgement  2.04bc  1.66  2.89ad 2.14  2.78ad 2.36  1.40bc 0.94  F(3, 450) = 9.44*** 
Constipation   2.68d 2.26  2.49d 1.95  2.45d 1.97  1.39abc 1.03  F(3, 450) = 4.22** 
Restless legs   2.65d 2.08  2.67d 2.11  2.49d 2.02  1.44abc 0.97  F(3, 450) = 4.15** 
Twitching   1.80c 1.53  2.08d 1.55  2.43ad 2.00  1.21bc 0.62  F(3, 450) = 6.49*** 
Chest pain   2.09 1.83  2.18d 1.68  2.43d 1.88  1.31bc 0.84  F(3, 450) = 3.89** 
Increased libido   1.41b 1.10  2.22a 1.93  1.91 1.65  1.95 1.68  F(3, 450) = 6.76*** 
Bladder or urinary problems 1.96 1.98  2.20d 2.22  2.09 2.09  1.18b 0.65  F(3, 450) = 2.67* 
Tremor    1.88d 1.74  2.20d 1.84  1.96d 1.67  1.05abc 0.32  F(3, 450) = 4.83** 
Vomiting   1.35 1.08  1.62d 1.46  1.28 0.83  1.08b 0.49  F(3, 450) = 3.49** 
 
* Significant at p < .05; ** significant at p < .01; *** significant at p < .001   
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There is a great deal of data here regarding symptoms commonly 
associated with antidepressant use and withdrawal, and the reader is invited 
to explore individual symptoms through a close examination of the tables. 
For example, the reported frequency/severity increase in many symptoms 
such as nausea, vertigo, and agitation experienced by participants 
withdrawing from antidepressants appears to abate with time (ex-users), 
although other symptoms such as tinnitus and food or chemical sensitivity 
appear to increase as participants move from user though withdrawal to the 
ex-user stage. 
Lastly in the “symptoms” section of the survey, participants were 
asked about weight gain and loss. A one-way ANOVA between subject 
groups was run examining weight gain since the onset of the antidepressant 
prescription (first three groups) or within the last year (never-used group), 
although the latter is not necessarily comparable32. A significant difference 
between groups was found, F(3,451) = 11.16, p < .001. Participants currently 
taking antidepressants reported a mean weight gain just over 10 pounds (4.5 
kg) (M = 3.22, SD = 1.58, where “3” is defined on the survey as “less than 
10 pounds [4.5 kg]”), as did participants withdrawing (M = 3.09,  SD = 1.59), 
and ex-users just a bit below that (M = 2.95, SD = 1.71). The “never used” 
group, however, reported a mean of 1.65 ± 0.89 where “1” = no weight gain 
and 2 = ”less than 5 lbs./2.3 kg”.  A Tukey-Kramer post hoc test revealed a 
significant difference between the never-used group and each of the user 
groups (p < .001), but no significant difference between the user groups 
                                                 
32
 The latter group is referring to a one-year period; the other three groups are “since the onset of 
prescription” which could mean a few months or ten years. Results, therefore, are inconclusive at 
best. However comments regarding iatrogenic weight gain were common (see Chapter 8). 
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themselves. There was no significant difference found between groups for 
weight loss.  
 The results of a multivariate analysis of stable and unstable user 
subgroups over the total combined symptoms revealed no significant 
difference between groups, F(1, 156) = .93. p > .05, Wilks’ Lambda = .78, 
partial eta squared - .22, suggesting that the symptom profile is not 
significantly different between these two subgroups. 
 
Subjectively perceived changes: That was then, this is now. 
For the final segment of statistical data collected, participants were 
asked to compare their moods and behaviours between their present state 
and a previous one. Participants currently taking antidepressants were asked 
to compare being on antidepressants with how they felt or behaved before 
going on antidepressants. A one-sample t-test was employed to examine 
self-perceived change on 23 emotional and behavioural elements where a 
value of “3” indicates a no-change response. Significant results are shown in 
Table 7. Items where feelings or behaviours are perceived to have increased 
are shown in bold. Because of the risk of a type-one error with this many  
items in the analysis, a Bonferroni correction was utilised and a statistical 
significance level of less than .001 was set.  
On the basis of these self-perceived changes, the antidepressant users 
in this study felt positive overall, experiencing fewer negative emotions and 
displaying fewer negative behaviours than prior to taking medication, and 
experienced more positive emotions and behaviours (except, perhaps, “crave 
junk food”) since taking antidepressants. 
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Table 7.  Current users comparing “now” (on antidepressants) with “then” 
(before antidepressant use). Significant responses to the prompt “Since being on 
antidepressants, I have been more/less likely to…”  “3” indicates no change based 
on a 5-point likert rating scale, with means over 3 indicating increased likelihood, and 
those less than 3 a decreased likelihood. 
 
Behaviour or mood   M SD  t    
 
Find the positive in a negative event 3.42 .90  t(153) = 5.83*** 
Feel happy    3.42 .91  t(153) = 5.65*** 
Feel good about myself  3.43 1.06  t(154) = 4.99*** 
Enjoy social events   3.42 1.06  t(153) = 4.95*** 
Crave “junk” food   3.36 .94  t(153) = 4.79*** 
Feel empathy for others  3.26 .83  t(154) = 3.88*** 
Lose temper    2.69 1.01  t(153) = -3.77*** 
Remember things   2.63 .91  t(154) = -5.02*** 
Worry about things   2.56 .88  t(153) = -6.24*** 
Gamble     2.52 .92  t(149) = -6.44***  
Cry     2.39 .99  t(152) = -7.61*** 
Feel depressed    2.34 1.04  t(153) = -7.80*** 
 
***significant at p < .001 
 
Participants currently withdrawing from antidepressants were asked 
to compare how they felt and behaved while withdrawing from  
antidepressants with how they felt or behaved when taking antidepressants. 
As with current users, a one-sample t-test was employed to examine the self-
perceived change on a variety of emotional and behavioural elements. 
Significant results are shown in Table 8. Items where feelings or behaviours 
are perceived to have increased are shown in bold. Again, because of the risk 
of type-one error with this type of analysis, a statistical significance level of 
less than .001 was set. Overall, while withdrawing from their antidepressant, 
participants reported increased negative emotions and behaviours and a 
decrease in social activity participation and mental agility.  
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Table 8.  Participants currently withdrawing from antidepressants comparing 
“now” (in withdrawal) with “then” (when taking antidepressants). Significant 
responses to the prompt “Now that I am withdrawing, I have been more/less likely 
to…”  “3” indicates no change based on a 5-point likert rating scale, with means over 
3 indicating increased likelihood, and those less than 3 a decreased likelihood. 
 
Behaviour or mood   M SD     t     
 
Cry     3.80 .96  t(147) = 10.20*** 
Feel depressed   3.62 .92  t(146) = 8.12*** 
Lose temper    3.66 1.02  t(148) = 7.88*** 
Worry about things   3.52 1.00  t(149) = 6.36*** 
Drink alcohol    2.67 1.10  t(143) = -3.58*** 
Enjoy social events   2.66 .97  t(148) = -4.30*** 
Think clearly    2.59 1.03  t(148) = -4.87*** 
Remember things   2.59 .91  t(147) = -5.42*** 
Gamble     2.43 .92  t(139) = -7.39***  
 
 
***significant at p < .001 
  
Participants who had not taken an antidepressant for at least two 
months were asked to compare their feelings and behaviours post-AD with 
how they were feeling and behaving on antidepressants, and also how their 
current state compared with how they felt and behaved before taking any 
antidepressants. As with current users, a one-sample t-test was employed to 
examine self-perceived change on the same emotional and behavioural items 
as was examined in the user group and withdrawing group. Significant 
results comparing how they felt now with how they felt on antidepressants 
are shown in Table 9. Items where feelings or behaviours are perceived to 
have increased are shown in bold. Again, because of the risk of type-one 
error with this type of analysis, a statistical significance level of less 
than .001 was set (Bonferroni correction). Items where feelings or 
behaviours are perceived to have significantly increased are shown in bold. 
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The ex-user participants report significant positive improvements in 
feeling and behaviour over how they felt and behaved while on 
antidepressants. There appears to be a slight shift in the kinds of significant 
positive feelings and behaviours reported in this group compared to the 
antidepressant users, however, with a greater focus among ex-users on 
caring about others, spending time with family (as opposed to users’ “enjoy 
social events”), and showing affection.  
 
Table 9.  Ex-users comparing “now” with when they were taking 
antidepressants. Significant responses to the prompt “Compared to when I was 
taking antidepressants, now I am more/less likely to…”  “3” indicates no change 
based on a 5-point likert rating scale, with means over 3 indicating increased 
likelihood, and those less than 3 a decreased likelihood. 
 
Behaviour or mood   M SD     t     
 
Care about others   3.53 1.11  t(84) = 4.40*** 
Find the positive in a negative event 3.51 1.10  t(83) = 4.25*** 
Laugh     3.47 1.14  t(84) = 3.81*** 
Show affection    3.50 1.21  t(83) = 3.80*** 
Gamble     2.49 .91  t(83) = -5.15***  
 
 
***significant at p < .001 
 
 Interestingly, results of a one-sample test on ex-users asked to 
compare how they feel and behave now with how they felt and behaved 
prior to taking antidepressants revealed no items showing a significant 
differences between then and now at the p < .001 level, suggesting that 
group participants felt—as a group—that they had returned to pre-drug 
levels on all items.  This is a curious paradox: although users reported 
feeling better than before they took antidepressants, and ex-users report 
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feeling better than while they were on antidepressants, ex-users did not 
report feeling better than they did before the antidepressant prescription. 
 
A problem with the ex-users group—the prolonged withdrawal factor 
 At the end of the survey, participants were invited to leave comments 
about their antidepressant use or withdrawal experience, or about the survey. 
Although the survey was designed around the assumption that antidepressant 
withdrawal symptoms would more-or-less be resolved two months following 
a 0 gram dose (Haddad & Anderson, 2007; Fava & Offidani, 2010), 23 (21%) 
of participants in the ex-users category commented on their ongoing issues 
with protracted withdrawal33. It is possible that some of the other 
participants within that group also suffered from protracted withdrawal but 
did not comment to that effect, and this figure does not include those who 
wrote of having experienced a protracted withdrawal experience that they 
reported eventually resolved itself.  
This is an important issue because it compromises the integrity of the 
ex-user group to some extent, especially when used in comparison with the 
group of participants who are currently withdrawing. Since this research is 
exploratory as well as hypothesis-driven, and gaining a better understanding 
of the antidepressant withdrawal experience is one of the stated goals of the 
study, a closer examination of the two ex-user subgroups was undertaken. It 
is also important because the existence of a prolonged withdrawal 
experience with antidepressants is generally perceived as rare—see Chapter 
3—but this current study suggests a prolonged withdrawal experience might 
                                                 
33
 The next chapter of this thesis covers a thematic analysis of participant comments. Participant 
reports of withdrawal and the prolonged withdrawal experience are addressed there.  
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be more prevalent, and last longer for some individuals (see Chapter 8), than 
previously supposed. 
 As was done with the group of antidepressant users—in that case it 
was between those with stable and destabilized antidepressant dosage—the 
ex-users group was split into two subgroups, one of participants who 
spontaneously self-identified themselves as currently suffering from a 
prolonged withdrawal syndrome (PWD) in their comments and the other of 
participants who did not do so (NoPWD). Participant comments like “I am 
still not out of the woods from withdrawal and it has been 1.5 years,”, “at 
nearly five years off Paxil, I feel like my central nervous system has still not 
fully recovered,” and “I am still experiencing some withdrawal symptoms” 
are typical of comments used to identify ex-users reporting ongoing drug or 
withdrawal symptoms (PWD) from within the ex-user group. Anyone who 
did not make a specific reference in a comment to currently experiencing 
symptoms they attributed to withdrawal were considered NoPWD. In 
retrospect, a specific question in the survey would have sorted these ex-user 
sub-groups much more precisely, but lacking that, it was felt that this 
method of division would at least allow a preliminary exploration into the 
prolonged withdrawal experience. All results reported regarding these two 
subgroups must be assessed with the caveat of subgroup division limitations 
in mind. 
A multivariate analysis comparing PWD and NoPWD ex-user 
subgroups on the three mood factors “positive energy”, “agitation” and 
“aggressive/depressive” found a significant effect between groups F (1, 70) 
= 5.92, p < .01, Wilks’ λ = .80. When the dependent variables were 
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considered separately, a significant difference was found between these two 
subgroups on all three mood components (Table 10).  
 
Table 10. Mood components showing a significant difference between ex-users 
who reported prolonged withdrawal symptoms (PWD) in their comments and 
ex-users who did not (NoPWD).  
 
   PWD  NoPWD     F 
Mood Component n = 23  n = 53 
   M SD M SD 
 
Positive Energy  .68 1.10 -.36 1.09 F(1, 75) = 13.49, p < .001 
Agitation   .25 1.04 -.44 0.85 F(1, 75) = 7.17, p < .005 
Aggressive/Depressive .52 1.01 -.18 0.77 F(1, 75) = 10.42, p < .005 
 
 These results suggested that ex-users who are still suffering a 
prolonged drug withdrawal reaction more than two months after they ceased 
taking the medication are more likely to feel substantial mood volatility 
characterized by greater levels of positive energy, agitation, and 
aggressive/depressive feelings than more stable participants who are no 
longer feeling the results of drug withdrawal.  
An independent samples t-test was also run on the WHO-5 well-
being questions, and a significant difference was found between the PWD 
ex-user subgroup (M = 8.36, SD = 4.91) and the NoPWD ex-user subgroup 
(M = 13.21, SD = 4.91), t(79) = -4.21, p < .001. The WHO advises that a 
raw score below 13 is indicative of poor well-being and a signal of possible 
depression (Psychiatric Research Unit, ND), suggesting that participants 
undergoing a prolonged withdrawal experience are experiencing a poor level 
of well-being indicative of significant depression risk. Ex-users not currently 
experiencing a prolonged withdrawal response are not showing a depression 
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risk based on the WHO-5. Together, these results suggest a lack of 
homogeneity within the ex-user group. 
A multivariate ANOVA comparing PWD and NoPWD ex-user 
subgroups on the 37 symptoms was performed and a significant effect 
between groups was found, F (1, 82) = 2.30, p < .005, Wilks’ λ = .35. When 
the dependent variables were considered separately, a significant difference 
was found between these two subgroups on 27 of the 37 symptoms (Table 
11).  
There was no significant difference found between these two 
subgroups on digestive symptoms (nausea, vomiting, diarrohea, constipation, 
increased or decreased appetite), nor on non-dream sleep issues (insomnia, 
need for more sleep). There was also no significant difference found for the 
symptoms of excessive sweating and increased libido. In all cases, the ex-
user sub-group experiencing prolonged withdrawal recorded a higher mean 
symptom response than the ex-user subgroup not experiencing a prolonged 
withdrawal reaction. An examination of individual symptoms with high 
group means suggest that even more than two months post-drug, many 
onerous symptoms remain for some users: reported as particularly 
bothersome were fatigue, decreased libido, and nervousness. This is an 
important observation not only for antidepressant users and their doctors, but 
also for clinical trial researchers who assume a drug washout period of a 
week or two adequate when testing new drug or placebo results. 
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Table 11. Symptoms (frequency plus severity) showing a significant difference 
between ex-users who reported prolonged withdrawal symptoms (PWD) in 
their comments, and ex-users who did not (NoPW. All ex-users reported being 
antidepressant-free for at least 2 months. Mean scores reflect a symptom frequency 
range between 1 (haven’t experience this symptom in the past two weeks) and 5 
(experience this symptom constantly) PLUS severity range between 1 (very minor) 
and 5 (very severe), with 3 defined as “moderate, impacts upon daily routine”. If F = 
1, then S = 0. Symptoms are listed in order of highest mean. 
 
 
Symptom  PWD  NoPWD 
   n = 23  n = 61 
M  SD M  SD F 
 
Fatigue   6.43 2.59 4.36 2.29 F(1, 83) = 12.76** 
Decreased libido 5.96 3.10 3.80 2.95 F(1, 83) = 8.64** 
Nervousness  5.91 1.98 3.87 1.94 F(1, 83) = 18.42*** 
Emotional flattening 5.61 3.13 3.23 2.62 F(1, 83) = 12.34** 
Food/chemical sensitive 5.48 3.00 2.18 2.13 F(1, 83) = 31.78*** 
Body pain  5.26 2.45 2.97 1.91 F(1, 83) = 20.57*** 
Weakness  5.13 2.77 2.57 2.06 F(1. 83) = 21.14*** 
Headaches  5.04 1.97 3.46 2.17 F(1, 83) = 9.34** 
Agitation  4.78 2.43 3.61 2.03 F(1, 83) = 5.03*  
Tinnitus   4.61 2.55 2.33 1.91 F(1, 83) = 19.63*** 
Vision abnormalities 4.48 2.64 2.10 1.80 F(1, 83) = 22.35*** 
Impaired judgement 4.48 2.78 2.16 1.79 F(1, 83) = 20.26*** 
Disturbing dreams 4.43 2.19 2.49 1.95 F(1, 83) = 15.53*** 
Panic attacks  4.30 2.44 2.20 1.93 F(1. 83) = 17.16*** 
Twitching  4.00 2.35 1.95 1.55 F(1, 83) = 21.55*** 
Dizziness/vertigo 4.00 2.35 2.44 2.06 F(1, 83) = 9.63** 
Thirst   3.96 2.48 2.36 1.80 F(1, 83) = 10.61** 
Head or facial pain 3.91 2.50 2.00 1.74 F(1, 83) = 15.67*** 
Dry mouth  3.91 2.64 2.11 1.94 F(1, 83) = 11.66** 
Abdominal pain  3.91 2.47 2.48 2.13 F(1, 83) = 6.99* 
Suicidality  3.70 2.36 1.87 1.55 F(1, 83) = 17.07*** 
Restless legs  3.61 2.23 2.00 1.74 F(1, 83) = 12.06** 
Chest pain  3.43 1.80 2.03 1.85 F(1, 83) = 9.70** 
Bladder/urinary problem 3.09 2.81 1.70 1.67 F(1, 83) = 7.68** 
Tremor   3.04 2.18 1.62 1.25 F(1, 83) = 13.87*** 
Brain zaps  2.83 2.29 1.51 1.30 F(1, 83) = 10.99**  
Rash   2.52 2.17 1.39 1.23 F(1, 83) = 8.97** 
 
*Significant at p < .05; ** significant at p < .01; *** significant at p < .001 
 
 A significant difference between PWD and noPWD on suicidality is 
of some note since no difference was found on this symptom between the 
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four intact groups. Although an increased risk of suicidality is linked with 
both antidepressant use and withdrawal (see Chapter 3), this author is not 
aware of any studies examining the possibility of an increased suicide risk 
post-withdrawal for some patients.  
 It is possible, of course, that those patients reporting ongoing 
withdrawal issues more than two months after their terminal antidepressant 
dose are simply responding to a return to their original illness, but their 
comments indicate that they do not believe this to be the case, and many 
made the point in their comments of feeling “WAY better off before taking 
any meds” (ex-user).
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Chapter 8 
Results II 
An Examination of Comment Themes 
Qualitative health research is research with a focus on the social 
world, not the world of nature. ...When researching the natural world 
the phenomena can be treated as objects or things, and from careful 
observation, natural laws may be generated. But in the social world, 
we are dealing with subjective experiences, and understanding of 
reality can change over time and in different social contexts. 
--Kevin Dew, 2007 
 
Although including a comment was optional, 65% of participants included 
personal comments at the end of the survey where invited to do so34; those who 
were withdrawing from antidepressants were the most likely to respond with a 
76% return rate, while participants without antidepressant experience showed the 
lowest response to this invitation at just 22%. The longest response was 959 words; 
the shortest 3 words, and the median response length was 72 words.  
All quotes from participants used as examples in this chapter are as written, 
including the use of capital letters for emphasis. Obvious typographical errors 
have been corrected (e.g., remember instead of rememeber), and punctuation has 
been amended for clarity (e.g., commas to separate items in a series). An ellipsis 
(…) is used to indicate portions of the comment that have been omitted for brevity. 
A thematic analysis was conducted of the comments using Braun and 
Clarke (2006) as a guide. The data set was read through several times to identify 
repeated patterns of meaning. Notes were made in the margins and text passages 
                                                 
34
 Actual invitation: “If there is anything else you would like to add about your antidepressant 
experience, or about this survey, please share your comments in the box below.” 
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highlighted with different colours to facilitate the coding process. A series of 
thematic maps were generated and items clustered and consolidated. A general 
trend differentiating the three user groups was observed, and six key themes that 
occurred across all three user groups were identified along with three subsidiary 
issues that were raised indirectly by the comments. This trend, the key themes, and 
the subsidiary issues are discussed below. Comments from the never-used group 
were different in tone to those made by the antidepressant-experienced groups and 
are addressed briefly near the end of this chapter. 
The antidepressant experience as a whole can be seen as a sort of journey, 
moving from a perceived need for a pharmaceutical intervention, through the user 
experience, through the withdrawal experience, and arriving eventually at an ex-
user endpoint. The majority of participants in this study were exploring this 
journey, and their responses were, understandably, coloured by their current stage 
and progress in that journey. None of the participants focussed primarily on the 
pre-prescription stage, although several commented in passing on their diagnosis: 
My depression is a manifestation of my PTSD which was triggered 
due to a number of social and work stressors. (Current user) 
 
They are supposed to clear my head and make it easier for me to be 
motivated towards positive change. In reality, I’m not sure that has 
happened. (Current user) 
 
Of those participants with antidepressant experience, an overall impression 
is that those who currently take the drugs were generally the most positive about 
antidepressant use, those withdrawing less so, and ex-users were the most negative. 
Each group tended to focus on issues peculiar to their stage in the journey. Typical 
examples: 
All the antidepressants I’ve taken have helped me get through daily 
life, but I’ve become more numb to life itself. (Current user) 
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Don’t take them if your issues aren’t severe. The process of getting off 
them is painful and terrible. (Currently withdrawing) 
 
I thought Paxil was a wonder drug for the first 12 years I was on it. 
However, after hitting “poop out”, my entire last 3 years has been the 
most difficult experience I have ever faced. I am left with severe nerve 
pain after a 2½-year taper. (Ex-user) 
 
Although almost all of the comments were about individual antidepressant 
experiences, a variety of issues were explored by respondents under this general 
umbrella. For this analysis, six themes were identified: 1) the effects of 
antidepressants; 2) antidepressant withdrawal; 3) issues with medical authorities; 4) 
regret; 5) the role of the internet; and 6) comments on the survey itself. Some of 
these themes incorporated several sub-themes. 
 
The effects of antidepressants  
Most of the comments dealt with some aspect of antidepressant effectiveness 
or problems perceived as a result of antidepressant use. 16 participants (5%)35 
commented on the helpfulness of their antidepressant in an unqualified way: 
They did make a vital difference when the walls were essentially 
closing in on me and I was severely clinically depressed. (Ex-user) 
 
I used to stress about this but now take things in my stride. I feel able 
to continue working and enjoy my work. (Current user) 
 
My thinking is steady and the previous cloud has lifted. It doesn’t 
make life easier…but I am able to handle the feelings and emotions… 
If it weren’t for my pills I don’t know where I would be now. (Current 
user) 
 
However, the majority of participants who reported positively about their 
antidepressant use also included a significant “but”: 
Paroxetine increases confidence and feeling of contentment. Decreases 
creativity, motivation and general energy level. Emotions are blunted, 
                                                 
35
 Of participants who left a comment; all percentages given in this chapter are of those who left 
comments, not of the survey group as a whole. 
 91
unable to feel excited or passionate about anything. (Currently 
withdrawing) 
 
Antidepressants certainly stopped my panic attacks and depression, but 
this came at a cost. Weight gain, emotional blunting, and fatigue. 
Functioning well, but feeling nothing. Trying to get off has been a 
nightmare. (Currently withdrawing) 
 
I was able to be more social at first and landed my husband at 25 (I’d 
probably still be a virgin if not) but it was almost as bad as doing a real 
drug substance. I lost my academic and career goals, my artistic 
talents… (Current user) 
 
I felt like my depression and mood was getting better whilst taking 
antidepressants, and it was. However, it became very hard to show 
empathy. I severed relationships…became more selfish… (Currently 
withdrawing) 
 
Many participants went on to itemize a variety of difficulties and unpleasant 
symptoms they experienced as a result of antidepressant use, both short-term 
and long-term: 
Citalopram has made me very anxious and restless, cannot concentrate, 
have developed insomnia, caused me to fall quite behind in uni work. 
(Current user) 
 
I was not too bad in the beginning but it pooped out. Was so ill, plus 
think it was poisoning me. Liver gave out, eyesight went, stomach 
bleed, cysts of ovaries, Parkinsonism. I became a different person for 
the 18 years I was on them…. (Ex-user) 
 
While I was on Paxil for 4 months, I gained 50 pounds and I haven’t 
been able to loose this weight even though I switched medications. 
(Current user) 
 
Four participants (1%) recounted details of severe adverse reactions after 
brief exposure, treated by increased doses or additional drugs. 
I was WAY better off before taking any meds. One dose of an SSRI 
caused SEVERE, INTRACTABLE, CHRONIC insomnia, horrific 
electric-shocks in my head and heart, nightmares, a complete loss of 
thirst and appetite, shaking and tremors. On multiple doctors’ advice, 
was poly-drugged with more ADs, benzos, and anti-psychs which 
created non-stop anxiety, massive weight loss, and a host of other 
symptoms like severe allergies, hypersensitivities and suicidal ideation. 
(Ex-user) 
 
 92
Several participants reported experience with a variety of 
antidepressants and identified how their responses changed with subsequent 
prescriptions, how they reacted differently to different drugs, and reported 
that generic versions of a drug do not necessarily elicit the same response as 
a brand-name drug. The use of sequential or multiple drugs was a fairly 
common sub-theme with two predictable outcomes: either acceptable 
medication was found by this trial and error method, or nothing seemed to 
provide satisfaction.  
Although my most recent antidepressant prescription was for 
bupropion, I was previously placed on various serotonergic 
antidepressants. These included mirtazepine, trazodone, nortriptyline, 
sertraline, fluvoxamine and fluoxetine. The SSRIs all induced a semi-
psychotic state (paranoia, delusions, auditory hallucinations) while the 
other antidepressants had a “distant/dissociative” sort of feel to them, 
which caused me to drop every single one immediately after the effects 
set in. (Currently withdrawing) 
 
I have been on antidepressants since I was 18 years old. Hated the 
tricyclics for somnolence and weight gain, Prozac for the tremor, 
citalopram stopped working; so far venlafaxine is very good. (Current 
user) 
 
“Since Aropax [paroxetine] isn’t funded anymore, I tried the generic 
brand Loxamine but found it gave me headaches. (Current user) 
 
An unsuccessful sequence of drugs prompted one responder to query the 
fundamental assumption of biomedical causation and belief that a chemical 
cure can be found if one only tries hard enough:  
I have been on almost every medication over a 22 year period, 
including Prozac, Welbutrin, Celexa, Buspar, Paxil, Lexapro, Zoloft, 
Cymbalta and many others. I was told I had been prescribed all 
available medication. Yet I still was depressed… EXACTLY what is 
MEDICALLY wrong with me if NO DRUGS are working? (Currently 
withdrawing) 
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 These examples also highlight one of the subsidiary issues—by that I mean 
issues not directly addressed by participants in the comments but revealed by them:  
long-term use of antidepressants and the use of sequential medication.  
An overall impression is that these are factors that influence participants’ 
understanding of the antidepressant use process, affecting attitudes and decisions, 
and resulting in particular physical responses to the drugs. For example, reference 
to “poop out”—the drugs ceasing to work without increased dosage as in the 
extract above—implies a long-term use effect which may lead to a decision to 
increase the dose, withdraw from a now-not-working drug, or try a different drug. 
Behind this is a fundamental belief that depression will be cured (resolved) if the 
right medicine can be found. Although recent studies suggest that long-term use is 
more likely to be detrimental than helpful (see Chapter 3), little awareness of this 
is revealed in comments, except in a vague way. 
I was told that I would have to take Paxil for the rest of my life and 
after almost 10 years have had enough. Quit cold turkey and suffering 
the side effects is worth it. (Currently withdrawing) 
 
Antidepressant withdrawal  
Although many issues were raised in the comments, withdrawal was the 
most commonly-addressed topic in all experienced groups, with 43% of current 
users’ comments about attempts to withdraw or concerns about quitting, 73% of 
comments from those withdrawing adding additional information about their 
personal withdrawal experience, and 59% of ex-users’ comments addressing 
withdrawal issues in their responses. Although my initial instinct was to 
incorporate this theme under the theme “effects of antidepressants”, I decided to 
give it a classification in its own right, given it is a particular focus area of this 
study and a primary focus of so many participant responses. 
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  It is difficult to clearly identify and count participants for whom the 
withdrawal experience has been minor because many participants understandably 
did not elaborate in their comments about what they did not experience. A few, 
however, did comment: 
My withdrawals were not as extreme as I thought they were going to 
be. I researched a lot before I stopped taking them. I was prepared for 
the worst and sailed through VERY slowly with only minor effects! 
(Currently withdrawing) 
 
A change of circumstances changed the withdrawal experience dramatically 
for one participant: 
Withdrawal was horrible. No warning. First time CT’d and lasted a 
week before the horror came on suddenly. Second time I made sure I 
was overseas staying with good friends and doing new stuff that made 
me happy and it was a doddle. (Ex-user) 
 
The rest ranged from brief summaries: 
 
Coming off venlafaxine sucks (Current user) 
 
To itemized lists of withdrawal symptoms: 
 
Cold chills at times, difficulty concentrating, social discomfort, numb 
hands at times, internal vibrations, sleep apnoea… (Ex-user)  
 
It was 8 weeks of vomiting, crying, headaches and the worst 
nightmares imaginable. I thought I would never survive it. (Ex-user) 
 
As I was on a “considered low dose”, the physician said I could just 
stop the Zoloft. Within 48 to 72 hours, I had severe abdominal 
symptoms (pain, nausea, and vomiting), became very dehydrated, and 
ended up in hospital for 24 hours for pain control… Abdominal scans 
were negative.  (Ex-user) 
 
Those initial three weeks…were, by a large margin, the worse days of 
my life… I considered suicide every day and for a large part of the day. 
I was extremely depressed. I could barely eat anything. I had severe 
acid reflux, hallucinations (both visual and auditory), akathisia, 
horrendous mental fog (I would often forget mid-sentence what I was 
talking about), I was exceptionally sensitive to stimuli, light, perfumes. 
I couldn’t even watch television due to rapid movements. I had 
dizziness, extreme balance issues, I couldn’t walk up a flight of 
stairs… (Ex-user) 
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In their responses, many participants gave reasons for discontinuing their 
antidepressant, which included problems with side effects, lack of efficacy, 
pregnancy, and seeking an un-medicated self: 
After 40 pounds, lack of emotion, and absolutely no libido, I am 
looking forward to see who I am again after so much time (Currently 
withdrawing) 
 
In no time over the past 10-12 years while I’ve been switched from 
one so called anti-depressant to the next have I made any tangible 
progress in my inner battle …not only have they not helped in any 
meaningful way but also contributed to worsening symptoms. 
(Currently withdrawing) 
 
I am 6 weeks pregnant... Now that my hubby and I are having another 
there was no way I would go through pregnancy taking that sort of 
medication. The health of our baby is more important.  (Currently 
withdrawing) 
 
Four current users expressed a general fear of quitting, either because of fear 
of withdrawal effects or fear of a return of pre-drug symptoms (a common theme 
according to Leydon, Rodgers, and Kendrick [2007]),  
I am frightened to stop (Current user) 
Would like to stop taking Paxil, but also concerned that this might 
result in recurrences of the anxiety that led me to take it in the first 
place. (Current user) 
 
but 35 (30% of current users) commented specifically on unsuccessful attempts to 
quit taking the drugs in the past or on unpleasant and concerning withdrawal 
symptoms when medication was inadvertently stopped: 
I want to stop. I will go a few days without taking the drug, but it is 
hard for me to control the withdrawals so I get back on it every time. 
(Current user) 
 
I have attempted to come off paroxetine several times without success. 
The last time I tried was 5 years ago and I was hospitalised… (Current 
user) 
 
A recent hospital visit landed me with an extremely inexperienced 
hospitalist who cancelled my Paxil without me knowing it and I 
immediately felt the side effects. (Current user) 
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Many of those currently withdrawing had also made previous attempts to quit 
 
I have attempted to quit antidepressants more than 10 times in the past 
22 years, unsuccessfully. …The physical symptoms are painful and the 
mental and emotional symptoms are terrifying. The withdrawal caused 
me to believe that “this is my REAL behaviour…” I quickly went back 
on them for fear of what might happen. (Currently withdrawing) 
 
Also disturbing is the number of ex-users (29, 42% of those who left a 
comment36) reporting severe withdrawal symptoms months or years after 
discontinuing their antidepressant.  
After almost six years off antidepressants, I still have lots of 
withdrawal problems, mainly neurological in the form of rapidly 
shifting muscle tone problems (from spasms and stiffness throughout 
the body to extreme weakness) plus the so often reported so-called 
brain zaps. These symptoms are still severe and very disabling and 
refuse to go away. Improving by about 5-10 percent per year only. I’d 
like to mention that I didn’t have any of these problems before taking 
SSRIs. Before the ADs I never had any kind of physical symptoms. 
(Ex-user) 
 
It’s been 19.5 months and I’m STILL experiencing some pretty bad 
withdrawal symptoms like tinnitus, tremor, anxiety, akathisia/agitation, 
occasional depersonalization/derealization, rage, bran zaps, tingling, 
depression, sensitivity to light and noise, and INTENSE brain fog. It 
used to actually be worse. (Ex-user) 
 
Participants experiencing long-term withdrawal problems filled out the 
survey as “ex-users” since “currently withdrawing” was confined to those 
currently dropping doses or within the two months following drug cessation. It 
became apparent from comments such as these that the “ex-user” group was 
hardly a drug-symptom free group and that many participants experienced 
withdrawal symptoms for much longer than two months following dose cessation, 
although not all participants in the group reported experiencing long-term 
lingering effects when taking the survey: 
I am now off 11 months and feel pretty stable. (Ex-user) 
                                                 
36
 This is 34% of total ex-users including those who did not leave a comment 
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It took a long time for the withdrawal symptoms to fade. Once off the 
medication, I believe it was close to a year before I felt none of these 
effects anymore. (Ex-user) 
 
Issues with medical authorities.  
A third theme raised by respondents regarded issues with medical 
authorities37. Many participants wrote of anger and frustration with their doctors 
and the medical profession in general, citing lack of sufficient or appropriate 
information about their antidepressant medication prior to being given the 
prescription: 
I was not told much about the side effects, and I don’t think I was told 
anything about the withdrawal. It took me years to figure out that I 
needed to take it at the same time every day.  (Currently withdrawing) 
 
I am very angry that I wasn’t told that this drug is addictive. (Currently 
withdrawing) 
 
Others decried the lack of support—indeed, sometimes of belief—when distressed 
by side effects or withdrawal, and expressed a sense of betrayal that professional  
advice and ongoing prescribing had led to unanticipated and unwanted long-term 
problems. Some of this frustration involved compliance issues as discussed earlier 
in this thesis: pharmaceutical companies and some medical professionals push 
drug compliance hard, iterating that the underlying disease is the greater problem, 
not the drug(s) used to treat it, a view that is challenged by many of these 
experienced users. 
My GP tells me I need to be on medications for life. I truly believe a 
lot of my prior failed attempts to be AD free were actually severe 
withdrawal. (Currently withdrawing) 
 
I became a different person for the 18 years I was on them, always 
trying to quit and being told withdrawal was something else. I would 
                                                 
37
 See Liebert & Gavey, 2009 for a development of this theme as perceived by medical 
professionals. 
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get another antidepressant to treat it. Have been told I had 
fibromyalgia, depression, anxiety disorder. I had none of these before 
ADs, only had leg pain. I believe these drugs caused all these things. 
(Ex-user) 
 
There are probably hundreds of thousands of individual reports of AD 
withdrawal and side-effects on the internet. I’ve read a small fraction 
of them, perhaps 10-20,000. They tally with each other, and science, 
and physiology and pharmacology and p450s and the past history of 
serotonergic drugs, and half-lives, and dopamine down-regulation, and 
dependence, and stimulant drugs, and hyper-stimulative states. 
Unfunnily, doctors still disagree with them. (Ex-user) 
 
I had multiple serious on-drug side-effects which were ignored, being 
told it was “the disease and not the drug.” The AD doses were upped, 
and benzos were added for the drug-induced insomnia… (Ex-user) 
 
My psychiatrist said he had never heard of anyone being so sensitive 
to the medication and basically accused me of lying or exaggerating. 
(Currently withdrawing) 
 
Lack of awareness on the part of doctors, according to one participant, can be 
compounded by lack of awareness in the patient: 
The thing is, you are too subsumed and destroyed by the adverse 
effects TO BE ABLE TO RECOGNISE WHAT IS HAPPENING TO 
YOU. That’s a key point of which doctors are still unaware. Their 
patient may be so cognitively-crippled by the drug that their body’s 
twitching and rattling, lethargy, eyesight changes, skeletal pain, etc. 
simply doesn’t REGISTER. …Doctors MUST know the true side-
effects profile and be able to competently work though each of the 
standard categories of side-effects with their patients. This is most 
emphatically NOT HAPPENING. (Ex-user) 
 
In a similar vein, another participant expressed concern that drug impairment 
affects patient-doctor communication: 
Due to the fact the drugs can affect cognition in a negative way it 
becomes difficult to get the understanding of the medical 
community… Many of my doctor’s appointments may have gone 
differently had I been able to properly communicate what was 
happening. That doctors regularly refused to help me when I reported 
akathesia nearly cost me my life. (Ex-user) 
 
Several participants indicated a concern that antidepressants are over-
prescribed: 
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It seems like you just have to say you are “sad” to be put on a pill. 
(Current user) 
 
When my doctor prescribed me antidepressants and I was reluctant, 
she said she was prescribing about 10 of her patients a day with them. I 
think this is shocking… (Current user) 
 
Many participants advocated more research into antidepressants and their 
effects, as well as improved education of doctors, nurses and patients regarding 
drug-related side effects, withdrawal, and long-term risks.  
Gained about 25 pounds since taking Paxil… Quit Paxil slowly over 
the last 3 weeks…symptoms of zaps, roaring in ears and dizziness with 
turning head. Absolutely miserable today… I am an RN! They didn’t 
teach us this in school… (Currently withdrawing) 
 
I think there needs to be much more research done on antidepressants 
and the long term effects they have on not only the brain but on other 
parts of the body as well. (Ex-user) 
 
Not enough education is given to GPs on the constant side effects and 
the awful withdrawal symptoms (Current user) 
 
 
Regret 
  In their comments, several participants expressed regret over their use of 
antidepressants:  
If I knew the things I know now when I was first prescribed the meds, 
I wouldn’t have taken them (Currently withdrawing) 
 
I wish I had been given a chance at learning how to live when I was 19 
instead of being put on this medication and left on it for 12.5 years. As 
I try to withdraw for the fourth time, I am finding it very difficult to 
know who I am or what I stand for. (Currently withdrawing) 
 
Many participants reported being worse off now than before they started 
taking antidepressants, which they perceived as a burden in their lives. An initial 
attempt to quantify this general observation was abandoned because of the 
difficulty in deciding, based on an undirected comment, whether a given 
participant necessarily felt that way or not, but many examples are explicit: 
 100
I regret ever taking an ssri as now I am addicted to them and they are 
EXTREMELY difficult to get off of. (Current user) 
 
I cannot get off Effexor. I have tried but the withdrawals are too severe 
and frightening. I also believe that Effexor has caused my weight gain, 
body pain, fuzzy thinking, etc. I feel like a prisoner to this medicine. 
(Current user) 
 
One day I hope to be able to walk away from all this medication and 
have some normality in my life.  (Current user) 
 
Many ex-users expressed regret that their antidepressant drug use had 
damaged their lives, leaving them in a sort of limbo: 
I took Paxil for an anxiety condition but was happy with other aspects 
of my life. I worked, had a good social life and was generally happy. I 
never felt that the pills helped, but every time I stopped I felt worse. I 
thought and was told that this was my original condition worsening. I 
believe it now to have been caused by the meds themselves. I now 
have much more severe mental problems that I didn’t have before as a 
direct result of taking these pills. I can no longer work, rarely socialise 
or leave the house and feel these pills have destroyed my life due to 
the effects that they have had on my body and mind. (Ex-user) 
 
It’s really hard to find my place in the world again. Who am I? What 
are my goals in life? I feel like a totally different person compared 
with pre-and during Paxil…the meds make you stand still, no 
emotional development, not learning to live with your problems… 
(Ex-user) 
 
I feel effexor has ruined my health. (Ex-user) 
 
I feel considerably diminished physically and mentally. All in all, 
medication made me worse. (Ex-user) 
 
I now have amnesia, the beginnings of tardive dyskinesia, severe hair 
loss, severe acne, trouble with balance, trouble with eyesight, loss of 
imagination and creativity… I have lost many friends, have alienated 
my family, lost my apartment and job… I feel very strongly that these 
drugs do not belong on the market. (ex-user) 
 
Only one person expressed regret about not being prescribed antidepressants 
earlier, and implied possible support for paediatric prescribing: 
I would have liked to have been prescribed it years earlier. Children at 
school should be taught to be mindful of depressive symptoms before 
they lose insight into their condition. (Ex-user) 
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The role of the internet 
This survey was only available on-line, so it is not surprising that many 
participants appeared to be savvy users of the internet. Lacking satisfactory 
information from their medical advisors, many accessed information and found 
support from internet sources, in some cases acting on that information. Others 
simply advocated the internet as an accessible and appropriate source of 
information about antidepressants that they felt was superior to standard medical 
advice. No one expressed concerns about inappropriate advice retrieved from the 
internet. 
I have spent a fortune on tests and doctors trying to find out what’s 
wrong with me and I had to find out on the net through paxilprogress 
and drugs.com that my symptoms are common on SSRIs and in 
withdrawal…so I decided to wean off the drug after reading info on 
both those sites. (Currently withdrawing) 
 
A few hours internet searching can provide families/partners with 
answers to their loved one’s deterioration/death/emotional blunting/ 
twitching/anger/mania/shopping sprees/ insomnia/obesity etc., nearly 
all of which will be subsequently denied by their doctors. (Ex-user) 
 
 
 
Comments on the survey itself  
Some participants expressed thanks for the survey, expressing a hope that 
results might find their way to medical authorities.  
The dependence is awful and very few members of the medical 
community are aware of this important and vital fact. It’s just 
scandalous. Thank you for participating in spreading this vital 
information. (Ex-user) 
 
Others found doing the survey itself therapeutic. 
Thank you for letting me voice my thoughts and feelings. (Current 
user) 
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Good survey! I work in mental health myself and found these useful 
questions. (Current user) 
 
Subsidiary issues and the “never used” group 
There were two other subsidiary issues (besides long-term and sequential 
use discussed earlier) raised by participants in their comments. Although 
participants were not asked at what age they began taking antidepressants, several 
reported being recipients of paediatric prescriptions. 
My experience with harmful, addictive drugs goes back to age 10½ (I 
will be 58 this month) when my mother took me to a doctor who gave 
her a prescription for me for amphetamines… (Ex-user) 
 
I was 13 when I first went on antidepressants, and I’m 22 now, so 
maybe worth bearing in mind that during the 8 plus years I used them I 
was also going through extreme hormonal changes related to puberty. 
(Ex-user) 
 
My parents put me on anti-depressants at age 11. I took lots of 
different ones. Many made me very queasy and dizzy. I stopped at 
about age 20, when I saw a psychologist instead of a psychiatrist. I 
haven’t been depressed for years. I believe I probably never was. (Ex-
user) 
 
Children and adolescents are particularly vulnerable patients because their 
prescribed drug use is involuntary, based on decisions made by their parents and 
doctors. As discussed in Chapter 3, only one antidepressant is approved for 
paediatric use in the U.S. (fluoxetine), none are approved for use in New Zealand, 
and virtually nothing is known about the long-term consequences of antidepressant 
use in maturing bodies. 
 Suicidality is the second subsidiary issue, of interest because of the 
controversy over attribution of underlying disease or drugs as the inciting cause. 
Antidepressant-induced suicidality was the primary focus of only one participant’s 
comments, but suicidality was mentioned by several participants: 
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Recently, one night while I had drank over 12 beers, I tried to commit 
suicide by taking a lot of Tylenal. I have never had suicidal thoughts, 
nor had I ever tried to commit suicide before, and I truly believe it was 
because my Paxil had been increased to 30 mg. (Current user) 
 
I have attempted to come off paroxetine several time without success. 
The last time I tried was 5 years ago and I was hospitalised for 4 weeks 
due to being extremely suicidal. This was so unusual for me… 
(Current user) 
 
Fluoxetine tended to make me feel numb, unable to cry, and suicidal. 
(Current user) 
 
Those initial three weeks…were, by a large margin, the worse days of 
my life… I considered suicide every day and for a large part of the 
day38. (Ex-user, describing withdrawal experience) 
 
 None of the participant groups showed a significantly greater level of 
suicidality than any other in the quantitative section of this study, but there is 
evidence in the comments that several participants had suicidal experiences that 
they believed were antidepressant-related either as a result of drug use, or during 
drug withdrawal at some point in the past.  
There were just 10 comments from the never-used group. Most justified why 
antidepressants hadn’t been tried, some were observational of others’ experiences, 
and they ranged from the philosophical to the practical, sometimes in a single 
comment: 
Several years ago I was having difficulty with my life and was 
recommended to see a social worker about my mental health. It was 
suggested that I try antidepressants. I declined, and my situation 
gradually improved through other means. (Never used) 
 
I’ve seen quite a few friends go through times of taking 
antidepressants, and also had a friend who was clinically depressed 
and suicidal. All she got out of the help she received was a dependency 
on pills. NO THANKS. (Never used) 
 
Friends I have known on them solve initial problems…but don’t 
resolve the issues. If stressed or getting low, I escape by going fishing. 
(Never used) 
                                                 
38
 See extended comment, p. 94, for other withdrawal symptoms reported by this participant 
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The concept of the antidepressant experience being a journey of sorts makes 
sense in the context of the comments. Some incident or problem in a person’s life 
leads to an antidepressant prescription, embarking that person upon a journey 
through drug use that may then lead to a withdrawal and post-drug experience and 
at any given point within this journey results in increased awareness, a change of 
perspective, or some other transformational change (physical, mental, and/or 
emotional). 
Nobody knows what is happening, how long it will last and how it will 
affect you. It is this uncertainty and lack of knowledge by the medical 
profession which makes this journey as difficult as it can be. (Ex-user) 
 
For me, anti-depressants were a part of learning to cope… (Ex-user) 
If I knew the things I know now when I was first prescribed the meds, 
I wouldn’t have taken them. (Currently withdrawing) 
 
Several participants sent me personal emails wanting to know where they 
could find out more about the antidepressant they were taking or asking for advice 
regarding withdrawal. I replied briefly, directing them—apropos to their query—to 
official medication information posted on pharmaceutical websites, relevant books 
and research papers, and www.paxilprogress.org, and suggested they consult their 
doctor. 
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Chapter 9 
Discussion, Conclusions and Future Directions 
This is a subjective study of self-selected participants, based on the 
personal responses of 465 individuals with antidepressant experience, and 44 
individuals with no personal experience of antidepressant use but perhaps some 
awareness or observation of others’ experiences (as noted in their comments). 
Each participant will have approached the survey differently, a reflection not only 
of their own antidepressant experience, but also their interpretation of that 
experience within the context of their lives at the time they were taking the drug(s) 
and the time they were taking the survey. A statistical analysis of their survey 
responses allows us to give some sort of operational validity to the sum total of 
those responses—enough to make broad empirical observations about the 
groups—but it is, of course, subject to the limitations of the survey design and 
questions and influenced by researcher decisions regarding data analysis. These 
“empirical” responses are supported by the thematic analysis of comments, which 
is even more subjective:  not only have participants been given free rein to 
comment in any way about their experience—or any other topic for that matter—
but my interpretation and analysis has allowed me to subjectively pick and choose 
what I think are key themes and representative or useful examples, omitting others 
for a myriad of reasons (e.g., tangential issue, only one example to support it, 
example too long or too complicated, etc.)  
And of course these participant groups are not “clean”—there are a host of 
concurrent medications, the effect of which has not been factored into responses 
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and, indeed, cannot easily be factored in given their sporadic use and inherent 
variety. Furthermore, antidepressants are mood modifiers, but so is life in all its 
messy glory: relationships begin, end, and change; jobs come and go; people are 
born and die; economic situations alter; seasons come and go. We all make 
decisions and have to live with the consequences. All of these affect moods and 
are part of the human condition; each participant has responses affected and 
compromised by these life factors which may carry more weight than the effects of 
the antidepressants themselves. Never-the-less, as far as I am aware, this study is 
unique because it presents a valuable portrait of those most affected by 
antidepressant use, as opposed to the more familiar treatises by medical 
practitioners, reports from short-term clinical trials, and analyses of broad 
statistical trends. There is huge inherent value in understanding what the end-user 
thinks.  
 
A brief summary of the results 
 When antidepressant users, those withdrawing from their drug(s), ex-users, 
and never-used participants were asked about their attitudes towards 
antidepressants, those currently taking them were the most enthusiastic about 
antidepressants in general, and about their personal use, calling them “helpful” 
(median response). Those withdrawing and non-users were less enthusiastic (“a bit 
helpful,” median response), and ex-users were quite negative, calling them 
“harmful” (median response). To some extent, these are not surprising results. It 
seems logical that participants currently taking antidepressants are likely to find 
them useful—one would think that if they did not, they would quit taking them 
(withdrawal issues aside)—and those who did not find them useful, or who found 
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the side effects draining, are most likely to have ceased their use. However, when 
it comes to self-rated mood on the WHO well-being index, users, those 
withdrawing, and ex-users all fell below the “13” demarcation line suggesting 
depression risk (based on mean responses). Only the never-used group sat 
comfortably above the 13 at a mean of 15, although ex-users who did not report a 
prolonged withdrawal reaction squeaked over the critical 13 with a mean of 13.21.  
Whether or not the majority of the participants in treatment groups would 
have had a mean below 13 prior to treatment—and we have no way of knowing 
that, but given that these individuals chose to be treated with antidepressants, it is 
not an unreasonable supposition—it is clear that neither treatment, withdrawal 
from treatment, nor the post-treatment phase overall were adequate interventions 
to provide an elevation of well-being to a “normal” level, or depression remission. 
In spite of this, when participants were asked if they feel better off now than in a 
previous state (the “that was then, this is now” section of survey questions), users 
reported themselves better than before they went on the drugs, and ex-users 
reported themselves, in general, better than when they were on the drugs and 
similar to their pre-drug state. Not surprisingly, participants experiencing 
withdrawal reported feeling worse than when they were on the antidepressants. 
 It is also not surprising that the well-being levels of the three 
“experienced” groups is low considering the bevy of unpleasant side effects they 
report suffering from: increased nervousness, agitation, tremor, twitching, chest 
pain, nausea, food and/or chemical sensitivity, weakness, dizziness, fatigue, need 
for extra sleep, sweating, headaches, head or face pain, brain zaps, vision 
abnormalities, disturbing dreams, emotional flatness, panic attacks, impaired 
judgement, and decreased libido. Furthermore, many users identified large weight 
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gains of 40, 50, even 60 pounds in their comments, often over relatively short 
periods of time. This seems extraordinary: the mean frequency and severity in all 
three experienced groups reported for every single one of these symptoms is 
higher than in the control group of non-users. 
 One possible explanation for the seeming paradox of participants’ positive 
assessment of antidepressant value in spite of low levels of well-being and 
assorted side effects is suggested by Breggin (2006). Intoxication anosognosia or 
“medication spellbinding” can be induced by a variety of drugs, causing users to 
overestimate the value of the drug and underestimate or fail to recognize drug-
induced impairment. Alcohol users, for example, often overestimate their own 
social charm or ability to drive when drinking, but at least we are all aware that 
alcohol has an intoxicating effect. In the case of antidepressants, according to 
Breggin, intoxication anosognosia generally develops over a period of time (if it 
develops at all) and it is unanticipated—after all, the drugs have been approved by 
the government and prescribed by a doctor for a given condition and thus surely 
must be helping. Patients can overestimate drug benefits while underestimating or 
failing to perceive iatrogenic effects. 
. It is important to remember that this survey data was not collected by 
random sampling. Participants self-selected to participate, and some may have 
done so because of an overall dissatisfaction with their antidepressant experience, 
although as noted earlier, Moncrieff et al. (2009) found no statistical difference 
between self-selected reporting of adverse drug effects and reports obtained by 
more traditional means. Nevertheless, it seems fairly clear from these results that 
antidepressant use does not create or restore normal well-being levels, which may 
be compromised by iatrogenic side effects. 
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 The comments left by participants in general made for grim reading. 
Although a few spoke well of their antidepressant experience, the majority 
reported problems with dependency, side effects, unhelpful health professionals, 
and long-term struggles with medication use and a variety of affective disorders. 
Although official guidelines suggest that antidepressant withdrawal symptoms are 
generally “mild” and resolve “spontaneously between day 1 and 3 weeks after 
onset” (Haddad & Anderson, 2007), comments from this study’s participants 
suggest many weeks or months often elapse before cessation of withdrawal 
symptoms, a process that may be extended further if a long taper is required. The 
post-drug impairments reported by many ex-users, in some cases years after drug 
cessation, highlights an important issue that has yet to be explored by researchers, 
other than emerging awareness of the sometimes-lingering nature of sexual 
dysfunction as identified by Bahrick and Harris (2009) and Csoka and Shipko 
(2006). Many of the long-term impairments reported by ex-users in their 
comments were of a neurological nature, and heightened sensitivity to stress and 
stimulation were commonly reported by those who had been off antidepressants 
for over a year. Fewer comments were made about social fallout, another theme 
deserving of attention in future research, but some reported on the negative impact 
of their antidepressant use, and subsequent withdrawal, on jobs, school 
performance, or relationships with family and friends. Positive comments about 
increased social functioning while taking the drugs were rarer still, and often 
involved some sort of compromise, such as creativity traded off for responsible 
functionality. 
 Contrary to expectations, given its relatively high-profile prevalence as a 
controversy in the media, suicidality did not present as a significant issue or 
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symptom in any of the groups examined quantitatively except when ex-users were 
split between those reporting prolonged withdrawal symptoms in their comments 
and those who did not. Only one participant made suicidality a primary focus in 
the comments, but several participants in the drug-experienced groups commented 
in passing on suicidality experienced in the past that they attributed to 
antidepressant use or withdrawal. It seems probable that individuals currently 
experiencing an episode of suicidality would not consider participating in a 
voluntary on-line survey on antidepressant use an activity of high priority, and in 
the quantitative section of the survey, participants were asked only about 
symptoms experienced within the past two weeks. However, the significant 
reporting of suicidality among the subgroup of ex-users experiencing a prolonged 
withdrawal experience highlights a point often missed when assessing the link 
between antidepressant use and suicidality: even a significant time after complete 
discontinuation of the drug, some ex-users may remain at risk. What is unknown 
from this data is whether these individuals were at risk of suicide prior to drug 
prescription, but if not, lingering drug after-effects may be missed by medical 
professionals and coroners in any analysis of cause of suicide attempt or death.  
  
Answering the research questions and addressing hypotheses: 
 The first proposed hypothesis, that there would be some significant 
differences between the four subject groups in terms of mood, symptoms, 
behaviours has been supported by this study’s findings. As anticipated, the 
currently-withdrawing group reported experiencing the greatest health challenges 
with a significantly higher level of the mood factor agitation than the other three 
groups, and the highest level of symptom frequency and severity for most of the 
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symptoms addressed when compared with the other groups. The never-used group, 
by contrast, had the lowest symptom severity of the four groups and scored the 
lowest on the agitation mood factor.  
Also as hypothesized, current users were the most favourably disposed to 
their antidepressants, considering them, in general, “helpful”. Nevertheless, 
symptoms such as decreased libido, weight gain, fatigue and insomnia were 
commonly reported both under symptoms and in their comments, and concern 
over dependency and an inability to discontinue the drug reported in their 
comments suggest their enthusiasm is tempered by these concerns. The overall 
WHO-5 score for this group suggests their depression symptoms had not been 
ameliorated by antidepressant use, although we cannot speculate on how much 
worse they might have been if the medication had not been prescribed from this 
data. Nervousness and agitation symptoms were significantly lower for users than 
for those withdrawing, and significantly higher than levels reported by the never-
used group, but about the same as that reported by ex-users. 
The third proposed hypothesis, that some ex-users would still be 
experiencing effects from antidepressant use months after drug cessation was 
strongly supported by participant comments, although the qualitative data cannot 
be used to definitively prove a causal link; ultimately, teasing out the difference 
between the diagnosed illness, drug side effects, and withdrawal symptoms to 
determine causation based on a one-point-in-time data collection is inherently 
impossible. Never-the-less, the possibility that antidepressant drug use causes 
long-term health issues cannot be dismissed.  
My fourth hypothesis predicted particular items of note including 
suicidality, weight changes, and emotional flattening. Although the group of ex-
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users still reporting withdrawal symptoms showed a significantly higher level of 
suicidality than ex-users not reporting ongoing symptoms, there was no difference 
found between the four main survey groups on symptoms of suicidality, and none 
between drug-experienced groups on emotional flattening or weight gain, although 
the never-used group reported significantly less weight gain and emotional 
flattening than the experienced groups. No group reported significant weight loss. 
In short, results from these specific factors did not stand out in this study. 
Coming back to the specific research questions posed in this thesis, the first 
one was the obvious: do antidepressant users find the drugs helpful? Based upon 
users’ evaluations of drug effectiveness and their responses to the “now” (on 
antidepressants)” compared to “then” (before antidepressants) response, it seems 
fairly clear that the majority of users believe the drugs are helpful. Nevertheless, 
many of these users expressed concern over unwanted side effects, dependency 
issues, and long-term efficacy (poop out), and in terms of WHO-5 well-being 
results, this group as a whole is at risk of depression, so overall, a qualified “no”. 
It would appear the drugs do little to enhance the quality of life. Indeed, many 
participants in all groups expressed regret over their drug use. 
Withdrawal appears to be a significant issue to participants in all groups. 
The likely occurrence of severe or prolonged withdrawal symptoms is difficult to 
ascertain from this data, however.  Many of the current users expressed experience 
with and concern about withdrawal in their comments: many of them are 
individuals who have thus far been unable to discontinue the drugs in spite of one 
or more attempts due to a severe withdrawal reaction. Many of those actively 
withdrawing hinted in their comments that they weren’t sure they would succeed 
in quitting the drug this time, having not succeeded with previous attempts. Of 
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those ex-users who had succeeded in withdrawing from antidepressants, 34% were 
still experiencing fallout from their antidepressant experience months or years 
after their final dose, and in some cases symptoms were still life-invasive years 
after use. Although no actual figures can be gleaned from this, it seems clear from 
this data set at least that dependency is a greater problem than has been hitherto 
acknowledged in the literature, and there is a significant long-term post-
withdrawal impact for some users that so far no one has examined in any depth. 
Does antidepressant use alter perception of the value and effectiveness of 
the drugs? The specific questions about perceived value of the drugs and 
comments made at the end of the survey make it clear that those currently using 
the drugs have a more positive assessment of their value than those who no longer 
use them or those who have never used them. Those who are withdrawing from 
the drugs are less enthusiastic than users, and ex-users in general expressed a 
belief that any value the drugs may have is compromised by the discomfort of side 
effects and risk of dependency. Drug use and withdrawal, in other words, 
significantly eroded the perceived value of the medication. 
 
Future directions 
 Further opportunities for psychological and social researchers to examine 
the impact of antidepressant drug use on individuals and social groups should be 
apparent. This study did not examine, for example, the social fallout that may 
come with personality changes brought on by the medication or withdrawal from it. 
In his book, Whitaker (2010) suggests antidepressant use has lead to the current 
bipolar boom and a worsening of the bipolar disorder with increased rapid cycling. 
The role of antidepressants in cases of violence and suicide has been examined in 
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a few papers (e.g., Breggin, 2003/2004, 2004) but little attention has been paid to 
the withdrawal and post-drug phase when iatrogenic akathesia and hypomanic 
states might also elicit violent or self-harm behaviours, or socially-inappropriate 
activities that is not so readily attributable to antidepressant use. The fundamental 
assumption that inappropriate thoughts or behaviours post-drug, even if those 
thoughts or behaviours did not exist pre-drug, indicate a need for continued drug 
treatment and support drug effectiveness remains to be critically examined in this 
light. 
 Another area ripe for future research involves looking at useful strategies 
for assisting those undertaking antidepressant withdrawal. It is generally assumed, 
for example, that a slow taper is better and safer than abrupt withdrawal, although 
a long taper may extend the withdrawal process much like pulling a sticky band-
aid off slowly extends but—presumably—lessens the overall pain experience at 
any given time. A very quick check of data from this survey suggested no 
correlation between length of taper and frequency/severity of symptoms 
experienced, which is to be expected since health professionals and 
pharmaceutical manufacturers recommend resuming the original dose if 
withdrawal symptoms become unmanageable and a slower taper commenced if 
desired (Glenmullen, 2005; Lilly, 2006)—thus, it is often the severest withdrawal 
response that mandates the slowest taper to keep symptoms manageable39. It 
seems likely (but is untested here) that patients quit or taper as quickly as they can 
comfortably handle. Given the limited supervision inherent with outpatient 
withdrawal, a prolonged tapering makes sense if withdrawal symptoms are severe, 
but illicit drugs—notorious for difficult withdrawal--are often discontinued much 
                                                 
39
 And it seems unlikely that patients in the midst of an unmanageable withdrawal experience 
would volunteer to sit down at a computer and spend twenty minutes filling in a survey. 
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more quickly within a rehabilitation care facility, an option that is rarely if ever 
considered with antidepressant withdrawal. It would be interesting to examine 
longitudinally symptom severity, recovery rates and long-term residual symptoms 
in patients from the onset of the withdrawal process (initial drop, large or small, 
abrupt stop or gradual taper) to final resolution of drug and withdrawal symptoms. 
There is also opportunity for an examination of other withdrawal support 
mechanisms that have been tried and perhaps found useful: changes with diet and 
exercise, vitamin and health supplements, meditation, acupuncture, counselling, 
and similar. A closer examination of those individuals experiencing a prolonged 
withdrawal experience or what they believe is long-term iatrogenic antidepressant 
disablement through interviews would help to expand the almost non-existent 
literature on this issue that is just now coming into public awareness. 
The marginal efficacy of antidepressants and high placebo rate in clinical 
trials has only been acknowledged in the research literature in the past two or three 
years. This coupled with a growing awareness of side effects that may affect not 
only mood and emotions but physical functioning and social interactions, often in 
negative ways, along with a risk of long-term post-drug consequences, might be 
reason enough to make prescribers hesitate when considering the appropriateness 
of antidepressant treatment for a patient. The significant issues with addiction and 
dependency, and the very real possibility of long-term disablement as described by 
many of the ex-users in this study, suggest the German regulators may have been 
right all along. Perhaps these preparations truly are “totally unsuitable for the 
treatment of depression.” (internal Eli Lilly communication reported in Healy, 
2004, p. 39, as mentioned earlier in this thesis).  
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 In a very practical way, physicians today need to exercise caution when 
prescribing antidepressants, alerting patients to possible side effects and 
dependency issues, and finding ways to educate, understand and assist their 
patients in discontinuing the drugs should they wish to do so. Psychiatric 
prescribers in particular, concerned primarily with the mental health of patients, 
must recognize the effects these pharmaceuticals can exert on patients’ physical 
health, and the impact compromised physical health can have on mental well-
being. Our society places great emphasis on treatment and rehabilitation for 
individuals who are addicted to illegal drugs, alcohol, or tobacco but provides little 
education or support for those addicted to prescription medicines, even when those 
medicines are damaging to overall health and well-being.  
 
 
Conclusions 
 “Psychiatry, for me and many of my colleagues,” wrote Daniel Carlat 
(2010), “has become a process of corralling patients’ symptoms into labels and 
finding a drug to match,” a process that highlights “a glaring deficiency in much of 
modern psychiatry.” We live in a world where, when problems occur, we want 
them fixed, and we want them fixed as quickly and as cheaply and as effortlessly 
as possible. The medicalization of depression and other affective disorders has 
been the economic response to this natural and seemingly pragmatic desire. 
Pharmaceutical companies can hardly be blamed for recognizing the economic 
goldmine that a one-pill-fits-all40 antidepressant creates for themselves and their 
shareholders. After all, who wants to be depressed? And an ANTI-depressant (and 
                                                 
40
 Patients, diagnoses, and prescribers 
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the power of that prefix on our consciousness cannot be underestimated) seems a 
perfect fix. Unfortunately, this goldmine is also a landmine, for the collateral 
damage that comes from an attempt to hit the depression [anxiety/OCD/panic] 
button with a marginally-effective chemical agent may well cause more harm for 
the overall organism and community than can be gleaned in patient benefit. 
 Understanding the history, development, and promotion of assorted mental 
illnesses and their treatment with antidepressants and other mood-changing drugs 
provides a solid foundation for recognizing the powerful appeal of these drugs and 
their role in modern society. The reality, however, is less stellar than the vision, 
and the quick (and probably ineffective) fix for each user comes with the 
substantial risk of unpleasant side effects and dependency, and a potential for 
residual post-drug fallout.  
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Appendix A: Online Survey Used in this Study 
The online survey used in this study is reproduced below. An attempt to 
copy and paste from the www.surveymonkey.com website has altered the format 
somewhat: what appears on a computer screen does not easily fit on an A4 page, 
and Word’s automatic mechanism has adjusted text and survey items to fit the 
page width. In addition, response boxes and circles did not reproduce as full 
geometric shapes. The survey itself was all on a two-shade “peach sherbet” 
coloured background which did not pick up and transfer in all cases. However, it 
was felt that this method of presenting the survey questions in this appendix would 
more closely approximate the participant experience than recreation of a new 
reformatted survey with smaller typefaces and altered design specific for an A4 
page. 
 Following the first default page, the survey divided into four separate 
surveys depending upon participant response on the default page. These four 
surveys are printed one after the other on the following pages. Introductory 
questions vary from survey to survey, mood and symptom pages do not vary, and 
the “that was then, this is now” section likewise varies. All participants were 
invited to leave comments.  
 In the symptoms section, each of the drop down boxes offered five choices. 
For frequency, the five choices were never, sometimes, often, most of the time, and 
all of the time. For severity, the five choices were very minor, mild, moderate 
(affects daily routine), severe and very severe. 
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DEFAULT SECTION 
 
1. The surveys that follow are designed to collect comparative data 
between groups of people currently using antidepressants, people 
withdrawing from antidepressants, people who used to take 
antidepressants but who don’t take them anymore, and people who 
have never used antidepressants. Information collected here will be 
used for a research study conducted at Victoria University of 
Wellington, New Zealand. The surveys have been approved by the 
Victoria University of Wellington Ethics Committee. All participation 
is voluntary and completely anonymous. It will take approximately 20-
25 minutes to complete a survey.  
 
If you wish to participate, click on the appropriate button for your 
survey. 
 
I am currently taking one or more antidepressants 
I am currently withdrawing from antidepressants, or ceased taking 
them less than 2 months ago 
I have taken antidepressants in the past, but I do not take them now, 
and I have not taken them for at least two months 
I have never taken antidepressants or other prescribed psychiatric 
medication 
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2. Introductory questions 
 
 
This survey is for participants who are CURRENTLY taking one or more 
antidepressants (and not currently in the process of antidepressant 
withdrawal). If this does not describe you, please use the back browser at 
the bottom of this page and select another survey. 
 
1. Please indicate your gender 
Male Female 
 
2. My current age is... 
Under 20 20-39 40-59 60+ 
 
3. Country of residence 
 
 
4. Antidepressant(s) that you are currently taking and current 
dose(s)(e.g., Prozac, 20 mg.) 
Antidepressant(s) 
 
Dose(s) 
 
 
5. What other prescription medicines are you currently taking? 
 
 
6. Why were you prescribed an antidepressant? (If you don't know, 
please state "don't know".) 
 
 
7. How long have you been taking antidepressants? 
Less than 
3 months 
3-12 
months 
1-3 years 3-8 years More than 
8 years 
 
8. Have you changed your antidepressant or dose in the past three 
months? 
No 
Yes, dose has gone up 
Yes, dose has gone down 
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Yes, I've changed antidepressants 
 
9. If you've changed antidepressants, what did you used to take? 
 
 
 
10. Please tick the appropriate option. There are no right or wrong answers. 
  
Very 
helpfulHelpful
a bit 
helpful
not at 
all 
helpful
Harmful Very harmful
I believe that 
antidepressants in 
general are...        
For me, the 
antidepressant(s) I am 
taking is/are...        
 
 
 
 
 
3. Mood 
 
1. The following statements deal with mood. Please tick the most appropriate box 
to match how you have been feeling during the past two weeks regardless of the 
reason. 
  
  
All of the 
time 
Most of 
the 
time 
Often Sometimes Rarely At no time 
I feel cheerful 
and in good 
spirits       
I feel 
unusually 
self-confident 
      
I feel restless 
      
I feel calm 
and relaxed       
I feel anxious 
      
I feel 
subdued and 
slowed down 
      
I feel very 
angry       
I feel active 
and vigorous       
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All of the 
time 
Most of 
the 
time 
Often Sometimes Rarely At no time 
I feel that life 
isn't worth 
living         
I feel sad 
        
I wake up 
feeling fresh 
and rested 
      
I feel agitated 
      
I have 
difficulty 
concentrating       
I feel full of 
energy       
I feel like 
harming 
myself 
      
I feel like I 
want to harm 
someone else 
      
My life is 
filled with 
things that 
interest me 
      
I feel like my 
mind is 
racing        
I have mood 
swings       
I feel 
fantastic       
I feel 
reluctant to 
leave the 
house 
      
 
 
4. Symptoms 
1. Have you experiened any of the following symptoms during the 
past two weeks (regardless of the reason)? If you have experienced a 
symptom, please indicate how severe you would rate that symptom. If 
you don't know what a symptom is (for example "brain zaps"), leave it 
blank. 
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  Frequency Severity 
Nervousness 
  
Agitation 
  
Tremor 
  
Twitching 
  
Uncontrollabl
e or 
"restless" leg 
or arm 
movements 
  
Chest pain 
  
Body pain 
  
Abdominal 
pain 
  
Nausea 
  
Vomiting 
  
Diarrhoea 
  
Constipation 
  
Decreased 
appetite 
  
Increased 
appetite 
  
Food or 
chemical 
sensitivity 
  
Weakness 
  
Dizziness 
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  Frequency Severity 
Fatigue 
  
Insomnia 
  
Increased 
need for sleep 
  
Sweating 
  
Thirst 
  
Rash 
  
Headache 
  
Head or facial 
pain 
  
Brain "zaps" 
  
Blurred or 
abnormal 
vision 
  
Tinnitus 
(ringing or 
buzzing in 
ears) 
  
Dry mouth 
  
Disturbing 
dreams 
  
Emotional 
flattening 
  
Felt suicidal 
  
Panic attacks 
  
Impaired 
judgement 
  
Urinary or 
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  Frequency Severity 
bladder 
problems 
  
Increased 
libido 
  
Decreased 
libido 
  
  
 
5. Comparing then and now 
 Since being on antidepressants, I have been...  
 Much more 
likely to 
More 
likely to 
About the 
same 
Less likely 
to 
Much less 
likely to 
     
Show 
affection      
Remember 
things      
Act 
impulsively      
Enjoy social 
events      
Care about 
others      
Feel good 
about 
myself       
Worry about 
things      
Keep a tidy 
environment      
Succeed at 
work or 
school 
     
Spend time 
with my 
family      
Lose my 
temper      
Feel 
depressed      
Feel 
motivated      
Cry 
     
Laugh 
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 Much more 
likely to 
More 
likely to 
About the 
same 
Less likely 
to 
Much less 
likely to 
     
Drink 
alcohol      
Be creative 
     
Crave "junk 
food" or 
sweets 
     
Think 
clearly      
Have dental 
problems      
Find 
something 
positive in a 
difficult 
situation 
     
Feel happy 
     
Gamble 
     
 
 
 
 
 
 
 
6. Comments 
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 1. If there is anything else you would like to add about your 
antidepressant experience, or about this survey, please share your 
comments in the box below.  
 
  
7. Thank you 
 Thank you very much for your participation in this survey.  
 
If you would like to be notified of any publications utilizing data collected 
from this survey please send us a separate email (to 
susan.thrasher@vuw.ac.nz) which cannot be linked to your responses. 
 
If you would like to share more about your antidepressant experience, we'd 
like to hear from you. Again, feel free to contact us via email at 
susan.thrasher@vuw.ac.nz 
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8. Survey 2 Introductory Questions 
 
 
This survey is for participants who are currently withdrawing from one or 
more antidepressants, including individuals who ceased taking 
antidepressants within the last 2 months. If you ceased taking 
antidepressants more than 2 months ago, even if you are still experiencing 
withdrawal symptoms, please use the back browser link at the bottom of 
this page and complete the survey for participants who used to take an 
antidepressant. 
  
1. Please indicate your gender 
Male Female 
 2. My current age is... 
Under 20 20-39 40-59 Over 60 
 3. Country of residence 
 
 4. Antidepressant(s) that you are currently taking (or were taking)and 
dose(s), e.g. Prozac, was 20 mg, now 5 mg. 
Antidepressant(s) 
 
Dose(s) 
 
 5. What other prescription medication(s) are your currently taking? 
 
 6. Why were you prescribed antidepressants? (If you don't know, 
please put "don't know".) 
 
 7. How long have you been taking antidepressants? 
Less than 
3 months 
3-12 
months 
1-3 years 3-8 years More than 
8 years 
 8. How long have you been tapering off the drug(s) or, if you are now 
at zero, how long did it take you to taper off your drug(s)? 
Abrupt 
discontinuation 
(cold turkey) 
less than 3 
months 
3-6 
months 
6-12 
months 
More than 
a year 
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 9. Is this your first attempt to discontinue taking your antidepressant? 
If not, how many times have you tried to quit? 
This is the first time I've tried to quit 1-3 
times before 
I've tried to quit 4+ 
times before this time 
 10. Please tick the appropriate box. There are no right or wrong 
answers. 
  
Very 
helpful Helpful 
A bit 
helpful 
Not at 
all 
helpful 
Harmful Very harmful 
I believe 
antidepressants 
in general are...    
 l 
  
For me, the 
antidepressant(s) 
I am/was taking 
is(are)... 
      
  
[Author’s note—mood and symptom surveys are identical between groups. See 
Survey 1.] 
11. Survey 2: Comparing Then and Now  
1. Compared to when I was taking antidepressants, now that I am 
withdrawing, I am... 
  
Much 
more likely 
to 
More likely 
to 
About the 
same 
Less likely 
to 
Much less 
likely to 
Show 
affection      
Remember 
things      
Act 
impulsively      
Enjoy social 
events      
Care about 
others      
Feel good 
about myself      
Worry about 
things      
Keep a tidy 
environment      
Succeed at 
work or 
school 
     
 130
  
Much 
more likely 
to 
More likely 
to 
About the 
same 
Less likely 
to 
Much less 
likely to 
Spend time 
with my 
family 
     
Lose my 
temper        
Feel 
depressed      
Feel 
motivated      
Cry 
     
Laugh 
     
Drink alcohol 
     
Be creative 
     
Crave "junk 
food" or 
sweets 
     
Think clearly 
     
Have dental 
problems      
Find 
something 
positive in a 
difficult 
situation 
     
Feel happy 
     
Gamble 
     
 
[Author’s note: The invitation for comments and Thank you page were the same 
for all groups. See Survey 1.] 
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14. Survey 3: Introductory Questions 
 
 
This survey is for participants who used to taken an antidepressant but do 
not do so now (and haven't taken one for at least 2 months). If you ceased 
taking an antidepressant less than two months ago, please use the back 
browser button at the bottom of the page and fill out the survey for 
"currently withdrawing from antidepressants". 
  
1. What is your gender? 
Male Female 
 2. What is your age? 
Under 20 20-39 40-59 60+ 
3. What is your country of residence? 
 
 4. Antidepressant(s) that you used to take and maximum dose (e.g., 
Prozac, 20 mg) 
Antidepressant(s) 
 
Dose 
 
 5. What other prescription medications were you taking when you 
were taking antidepressants (if any)? 
 
 6. What prescription medications are you taking now (if any)? 
 
 7. Why were you prescribed antidepressants? (If you don't know, 
please put "don't know".) 
 
 8. How long did you take antidepressants? 
Less than 
3 months 
3-12 
months 
1-3 years 3-8 years more than 
8 years 
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 9. How long did you spend withdrawing from your antidepressant 
(reducing doses)? 
Abrupt 
discontinuation 
(cold turkey) 
less than 3 
months 
3-6 
months 
6-12 
months 
1+ years 
 10. How long ago did you quit taking antidepressants? 
Less than a 
year ago 
1-3 years ago 3-5 years ago More than 5 
years ago 
 11. How many times did you attempt to quit taking your 
antidepressant (including the most recent successful withdrawal)? 
Once 2-4 times 5+ times 
 12. Please tick the appropriate answer. There are no right or wrong 
answers. 
  
Very 
helpful Helpful 
A bit 
helpful 
Not at 
all 
helpful 
Harmful Very harmful 
I believe that 
antidepressants 
in general are...       
For me, the 
antidepressant I 
was taking 
was... 
      
  
[Author’s note—mood and symptom surveys are identical between groups. See 
Survey 1.] 
17. Survey 3: Then and Now 
 
1. Compared to WHEN I was taking antidepressants, NOW I am... 
  
Much 
more likely 
to 
more likely 
to 
About the 
same 
less likely 
to 
Much less 
likely to 
Show 
affection      
Remember 
things      
Act 
impulsively      
Enjoy social 
events       
Care about 
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Much 
more likely 
to 
more likely 
to 
About the 
same 
less likely 
to 
Much less 
likely to 
others 
Feel good 
about myself      
Worry about 
things      
Keep a tidy 
environment        
Succeed at 
work or 
school 
     
Spend time 
with my 
family 
     
Lose my 
temper      
Feel 
depressed      
Feel 
motivated      
Cry 
     
Laugh 
     
Drink alcohol 
     
Be creative 
     
Crave "junk 
food" or 
sweets 
     
Think clearly 
     
Have dental 
problems      
Find 
something 
positive in a 
difficult 
situation 
     
Feel happy 
     
Gamble 
     
 
 
17. Survey 3: Then and Now 
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1. Compared to BEFORE I was taking antidepressants, NOW I am... 
  
Much 
more likely 
to 
more likely 
to 
About the 
same 
less likely 
to 
Much less 
likely to 
Show 
affection      
Remember 
things      
Act 
impulsively      
Enjoy social 
events       
Care about 
others       
Feel good 
about myself      
Worry about 
things      
Keep a tidy 
environment        
Succeed at 
work or 
school 
     
Spend time 
with my 
family      
Lose my 
temper      
Feel 
depressed      
Feel 
motivated      
Cry 
     
Laugh 
     
Drink alcohol 
     
Be creative 
     
Crave "junk 
food" or 
sweets 
     
Think clearly 
     
Have dental 
problems      
Find 
something 
positive in a 
difficult 
situation 
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Feel happy 
     
Gamble 
     
 
[Author’s note: The invitation for comments and thank you page were the same for 
all groups. See Survey 1.] 
 
!0. Survey 4: Introductory Questions--Never taken an AD 
 
 
This survey is for participants who have NEVER taken an antidepressant. 
If you have taken an antidepressant before, please click on the back 
browser button on the bottom of the page and choose another survey. 
 
1. What is your gender? 
Male Female 
2. What is your age? 
Under 20 20-39 40-59 60+ 
3. What is your country of residence? 
 
4. What prescription medications are you currently taking? 
 
5. I believe that antidepressants in general are... 
Very 
helpful 
Helpful A bit 
helpful 
Not at 
all helpful 
Harmful Very 
harmful 
 
[Author’s note—mood and symptom surveys are identical between groups. See  
 
Survey 1.] 
 
1. in the past two weeks, how often have you done the following? 
  
I've done 
this every 
day 
I've done 
this often 
I've done 
this 
sometimes 
I've done 
this rarely 
I haven't 
done this 
Shown 
affection      
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I've done 
this every 
day 
I've done 
this often 
I've done 
this 
sometimes 
I've done 
this rarely 
I haven't 
done this 
Forgot 
things      
Acted 
impulsively       
Enjoyed 
social events      
Cared about 
others       
Felt good 
about 
yourself 
          
Worried 
about things      
Kept a tidy 
environment      
Succeeded 
at work or 
school 
     
Spent time 
with your 
family 
     
Lost your 
temper      
Felt 
depressed      
Felt 
motivated      
Cried 
     
Laughed 
     
Drunk 
alcohol      
Been 
creative      
Craved "junk 
food" or 
sweets 
     
Thought 
clearly      
Had dental 
problems      
Found 
something 
positive in a 
difficult 
situation 
     
Felt happy 
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I've done 
this every 
day 
I've done 
this often 
I've done 
this 
sometimes 
I've done 
this rarely 
I haven't 
done this 
Gambled 
     
felt anxious 
     
Felt irritable 
     
Felt tired 
     
 
[Author’s note: The invitation for comments and thank you page were the same for 
all groups. See Survey 1.] 
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